# ::snt Function , expression and localization of annexin A7 in platelets and red blood cells : Insights derived from an annexin A7 mutant mouse .
# ::tok Function , expression and localization of annexin A7 in platelets and red blood cells : Insights derived from an annexin A7 mutant mouse .
# ::alignments 22-23|0.2.0.0.0 21-22|0.2.0.0 16-17|0.2.0.0.0.0 15-16|0.2.0.0.0.0.0 13-14|0.2.0.1 12-13|0.2.0.1.0 11-12|0.2.0.1.1 10-11|0.0.0 9-10|0.0 7-8|0.1 6-7|0.1.0 4-5|0.2.1 3-4|0.2 2-3|0 0-1|0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:02.105
(e / express-01 
      :ARG0 (p / platelet 
            :op1-of (a / and)) 
      :ARG1 (a2 / A7 
            :mod (a3 / annexin)) 
      :op2-of (a4 / and 
            :op1 (f / function-01 
                  :ARG0 (m2 / mutant 
                        :mod-of (m / mouse 
                              :ARG2-of (d / derive-01 
                                    :ARG1 (i / insight)))) 
                  :ARG1 (c / cell 
                        :mod (b / blood) 
                        :mod (r / red))) 
            :op3 (l / localization)))

# ::snt Annexin A7 is a Ca2 + - and phospholipid-binding protein expressed as a 47 and 51 kDa isoform , which is thought to be involved in membrane fusion processes .
# ::tok Annexin A7 is a Ca2 + - and phospholipid-binding protein expressed as a 47 and 51 kDa isoform , which is thought to be involved in membrane fusion processes .
# ::alignments 28-29|0.2.0.1 27-28|0.2.0.1.1 26-27|0.2.0.1.2 24-25|0.2.0 21-22|0.2.0.0 17-18|0.0.0 16-17|0.0.0.0 15-16|0.0.0.0.1 14-15|0.0.0.0.0 13-14|0.2.0.1.0 10-11|0.0 9-10|0 8-9|0.2.1 7-8|0.2 0-2|0.1.0.1+0.1.0.0+0.1.0+0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:07.012
(p2 / protein 
      :ARG1-of (e / express-01 
            :ARG2 (i2 / isoform 
                  :mod (k / kDa 
                        :op1-of (a / and) 
                        :value 51))) 
      :domain (t2 / thing 
            :name (n / name 
                  :op1 (a3 / Annexin) 
                  :op2 (a4 / A7))) 
      :op2-of (a2 / and 
            :ARG1-of (i / involve-01 
                  :ARG1-of (t / think-01) 
                  :ARG2 (p / process-02 
                        :ARG0 47 
                        :ARG1 (f / fusion) 
                        :mod (m / membrane))) 
            :op1 (p3 / phospholipid-bind)))

# ::snt Recently the 47 kDa isoform has been identified in erythrocytes where it was proposed to be a key component in the process of the Ca2 + - dependent vesicle release , a process with which red blood cells might protect themselves against an attack by for example complement components .
# ::tok Recently the 47 kDa isoform has been identified in erythrocytes where it was proposed to be a key component in the process of the Ca2 + - dependent vesicle release , a process with which red blood cells might protect themselves against an attack by for example complement components .
# ::alignments 48-49|0.1.1.1.0.0.0.0.1 47-48|0.1.1.1.0.0.0.0 46-47|0.1.1.1.0.0.0.0.0 43-44|0.1.0.2 39-40|0.1.0 38-39|0.1.0.1 37-38|0.1.0.0 36-37|0.1.0.0.0 35-36|0.1.0.0.1 32-33|0.1 29-30|0.1.1.1.0.0.0 28-29|0.0 27-28|0 21-22|0.1.0.2.0 18-19|0.1.1.1.0 17-18|0.1.1.1.0.0 13-14|0.1.1.1 9-10|0.1.1.2 7-8|0.1.1 4-5|0.1.1.0 3-4|0.1.1.0.0 2-3|0.1.1.0.1 0-1|0.1.1.3 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:11.788
(d / depend-01 
      :ARG1 (v / vesicle) 
      :ARG1-of (p3 / process-02 
            :ARG1-of (p / protect-01 
                  :ARG0 (c3 / cell 
                        :mod (b / blood) 
                        :mod (r / red)) 
                  :ARG1-of (p2 / possible-01) 
                  :ARG2 (a / attack-01 
                        :ARG1-of (p4 / process-02))) 
            :ARG1-of (i / identify-01 
                  :ARG0 (i2 / isoform 
                        :mod (k2 / kDa) 
                        :quant 47) 
                  :ARG2 (p5 / propose-01 
                        :ARG1 (c4 / component 
                              :ARG1-of (k / key-02 
                                    :ARG0 (r2 / release-01 
                                          :ARG1 (c2 / complement-01 
                                                :ARG0 (e / example) 
                                                :ARG1 (c / component)))))) 
                  :manner (e2 / erythrocyt) 
                  :time (r3 / recent))))

# ::snt The role of annexin A7 in red blood cells was addressed in erythrocytes from anxA7 - / - mice .
# ::tok The role of annexin A7 in red blood cells was addressed in erythrocytes from anxA7 - / - mice .
# ::alignments 18-19|0.2 16-17|0.0 12-13|0.3 10-11|0 8-9|0.1.0.0 7-8|0.1.0.0.0 6-7|0.1.0.0.1 4-5|0.1.0 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:12.576
(a / address-02 
      :ARG0 (s / slash) 
      :ARG1 (r2 / role 
            :poss (a2 / A7 
                  :location (c / cell 
                        :mod (b / blood) 
                        :mod (r / red)))) 
      :ARG3 (m / mouse) 
      :location (e / erythrocyt))

# ::snt Interestingly , the Ca2 + - mediated vesiculation process was not impaired .
# ::tok Interestingly , the Ca2 + - mediated vesiculation process was not impaired .
# ::alignments 11-12|0.1.0.0 10-11|0.1.0.0.0 8-9|0.1.0 7-8|0.1 6-7|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:12.707
(m / mediate-01 
      :ARG0 (i2 / interesting) 
      :ARG1 (v / vesiculation 
            :ARG1-of (p / process-02 
                  :ARG1-of (i / impair-01 
                        :polarity -))))

# ::snt Also , the membrane organization appeared not to be disturbed as assessed using gradient fractionation studies .
# ::tok Also , the membrane organization appeared not to be disturbed as assessed using gradient fractionation studies .
# ::alignments 15-16|0.0.1.0 14-15|0.0.1.0.0 13-14|0.0.1.0.1 12-13|0.0.1 11-12|0.0.1.1 9-10|0.0 6-7|0.0.2 5-6|0 4-5|0.0.0 3-4|0.0.0.0 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:12.908
(a2 / appear-01 
      :ARG1 (d / disturb-01 
            :ARG0 (o / organization 
                  :mod (m / membrane)) 
            :ARG1 (u / use-01 
                  :ARG1 (s / study-01 
                        :ARG1 (f / fractionation) 
                        :mod (g / gradient)) 
                  :manner (a / assess-01)) 
            :polarity -) 
      :mod (a3 / also))

# ::snt Instead , lack of annexin A7 led to an altered cell shape and increased osmotic resistance of red blood cells .
# ::tok Instead , lack of annexin A7 led to an altered cell shape and increased osmotic resistance of red blood cells .
# ::alignments 19-20|0.1.0.0 18-19|0.1.0.0.0 17-18|0.1.0.0.1 15-16|0.1.0 14-15|0.1.0.1 13-14|0.1 12-13|0 11-12|0.0.2 10-11|0.0.2.0 9-10|0.0.2.1 6-7|0.0 5-6|0.0.0.0 2-3|0.0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:13.214
(a / and 
      :op1 (l / lead-02 
            :ARG0 (l2 / lack-01 
                  :ARG1 (a3 / A7)) 
            :ARG1-of (i2 / instead-of-91) 
            :ARG2 (s / shape-01 
                  :ARG1 (c2 / cell) 
                  :ARG1-of (a2 / alter-01))) 
      :op2 (i / increase-01 
            :ARG1 (r2 / resist-01 
                  :ARG1 (c / cell 
                        :mod (b / blood) 
                        :mod (r / red)) 
                  :mod (o / osmotic))))

# ::snt Annexin A7 was also identified in platelets .
# ::tok Annexin A7 was also identified in platelets .
# ::alignments 6-7|0.1 4-5|0 3-4|0.2 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:13.284
(i / identify-01 
      :ARG1 (a2 / A7 
            :mod (a3 / Annexin)) 
      :ARG2 (p / platelet) 
      :mod (a / also))

# ::snt In these cells its loss led to a slightly slower aggregation velocity which seems to be compensated by an increased number of platelets .
# ::tok In these cells its loss led to a slightly slower aggregation velocity which seems to be compensated by an increased number of platelets .
# ::alignments 22-23|0.0.1 20-21|0.0 19-20|0 16-17|0.0.0 13-14|0.0.0.1 11-12|0.0.0.0 10-11|0.0.0.0.1 9-10|0.0.0.0.2 8-9|0.0.0.0.2.0 5-6|0.0.0.0.0 4-5|0.0.0.0.0.0 2-3|0.0.0.0.0.1 1-2|0.0.0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:13.975
(i / increase-01 
      :ARG1 (n / number 
            :ARG0-of (c / compensate-01 
                  :ARG1 (v / velocity 
                        :ARG1-of (l / lead-02 
                              :ARG0 (l2 / loss) 
                              :ARG2 (c2 / cell 
                                    :mod (t / this))) 
                        :mod (a / aggregation) 
                        :mod (s2 / slow 
                              :degree (s3 / slight))) 
                  :ARG1-of (s / seem-01)) 
            :quant-of (p / platelet)))

# ::snt The results appear to rule out an important role of annexin A7 in membrane fusion processes occurring in red blood cells .
# ::tok The results appear to rule out an important role of annexin A7 in membrane fusion processes occurring in red blood cells .
# ::alignments 20-21|0.0.2.1.0 19-20|0.0.2.1.0.0 18-19|0.0.2.1.0.1 16-17|0.0.2.1 15-16|0.0.2 14-15|0.0.2.0 13-14|0.0.2.2 10-11|0.0.1.1 8-9|0.0.1 7-8|0.0.1.0 4-5|0.0 2-3|0 1-2|0.0.0.0+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:14.955
(a2 / appear-02 
      :ARG1 (r3 / rule-03 
            :ARG0 (t / thing 
                  :ARG2-of (r4 / result-01)) 
            :ARG1 (r2 / role 
                  :mod (i / important) 
                  :poss (a / annexin)) 
            :time (p / process-02 
                  :ARG1 (f / fusion) 
                  :ARG1-of (o / occur-01 
                        :ARG0 (c / cell 
                              :mod (b / blood) 
                              :mod (r / red))) 
                  :mod (m / membrane))))

# ::snt Instead the protein might be involved in the organization of the membrane cytoskeleton .
# ::tok Instead the protein might be involved in the organization of the membrane cytoskeleton .
# ::alignments 12-13|0.1.0 11-12|0.1.0.0 8-9|0.0.1 5-6|0.0 3-4|0 2-3|0.0.0 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:16.515
(p / possible-01 
      :ARG1 (i / involve-01 
            :ARG1 (p2 / protein) 
            :ARG2 (o / organization)) 
      :ARG1-of (i2 / instead-of-91 
            :ARG0 (c / cytoskeleton 
                  :mod (m / membrane))))

# ::snt Red blood cells may represent an appropriate model to study the role of annexin A7 in cellular processes .
# ::tok Red blood cells may represent an appropriate model to study the role of annexin A7 in cellular processes .
# ::alignments 17-18|0.0.1.0 16-17|0.0.1.0.0 14-15|0.0.0.0.0.0 11-12|0.0.0.0.0 9-10|0.0.0.0 7-8|0.0.1 6-7|0.0.1.1 4-5|0.0 3-4|0 2-3|0.0.0 1-2|0.0.0.1 0-1|0.0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:17.206
(p2 / possible-01 
      :ARG1 (r2 / represent-01 
            :ARG0 (c2 / cell 
                  :ARG0-of (s / study-01 
                        :ARG1 (r / role 
                              :poss (a / A7))) 
                  :mod (b / blood) 
                  :mod (r3 / red)) 
            :ARG1 (m / model 
                  :ARG0-of (p / process-02 
                        :ARG1 (c / cell)) 
                  :ARG1-of (a2 / appropriate-02))))

# ::snt We have demonstrated the presence of both annexin A7 isoforms in red blood cells and the presence of the small isoform in platelets .
# ::tok We have demonstrated the presence of both annexin A7 isoforms in red blood cells and the presence of the small isoform in platelets .
# ::alignments 22-23|0.1.0.2.0.0 20-21|0.1.0.2.0.1 19-20|0.1.0.2.0.1.0 16-17|0.1.0.2.0 14-15|0.1.0.2 13-14|0.1.0 12-13|0.1.0.0 11-12|0.1.0.1 9-10|0.1.1 6-7|0.1.1.0 4-5|0.1 2-3|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:18.165
(d / demonstrate-01 
      :ARG0 (w / we) 
      :ARG1 (p3 / presence 
            :location (c / cell 
                  :mod (b / blood) 
                  :mod (r / red) 
                  :op1-of (a / and 
                        :op2 (p2 / presence 
                              :location (p / platelet) 
                              :poss (i / isoform 
                                    :mod (s / small))))) 
            :quant-of (i2 / isoform 
                  :mod (b2 / both))))

# ::snt In both cell types the loss of annexin A7 impairs cellular functions .
# ::tok In both cell types the loss of annexin A7 impairs cellular functions .
# ::alignments 11-12|0.0.0 10-11|0.0.0.0 9-10|0.0 8-9|0.1 7-8|0.1.0 5-6|0 3-4|0.0.1 2-3|0.0.1.0 1-2|0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:18.717
(l / loss 
      :ARG0-of (i / impair-01 
            :ARG1 (f / function-01 
                  :ARG1 (c / cell)) 
            :location (t / type 
                  :mod (c2 / cell) 
                  :mod (b / both))) 
      :mod (a / A7 
            :mod (a2 / annexin)))

# ::snt The defects observed are however not compatible with a crucial role for annexin A7 in membrane fusion processes in these cell types .
# ::tok The defects observed are however not compatible with a crucial role for annexin A7 in membrane fusion processes in these cell types .
# ::alignments 21-22|0.0.2.0 20-21|0.0.2 19-20|0.0.0.1 17-18|0.0 16-17|0.0.1 15-16|0 13-14|0.0.3 10-11|0.0.3.0 9-10|0.0.3.0.0 6-7|0.0.0.0.0 5-6|0.0.0.0.0.0 2-3|0.0.0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:19.634
(m / membrane 
      :mod-of (p / process-02 
            :ARG0 (d / defect-01 
                  :ARG0-of (o / observe-01 
                        :ARG1 (c3 / compatible 
                              :polarity -)) 
                  :ARG1 (t2 / this)) 
            :ARG1 (f / fusion) 
            :ARG2 (c / cell 
                  :mod-of (t / type)) 
            :purpose-of (a / A7 
                  :beneficiary-of (r / role 
                        :mod (c2 / crucial)))))

# ::snt Annexin A7 is a Ca2 + - and phospholipid-binding protein , which was isolated as the agent that mediated aggregation of chromaffin granules and fusion of phospholipid membranes in the presence of Ca2 + .
# ::tok Annexin A7 is a Ca2 + - and phospholipid-binding protein , which was isolated as the agent that mediated aggregation of chromaffin granules and fusion of phospholipid membranes in the presence of Ca2 + .
# ::alignments 30-31|0.0.0.0.1.0.1.0 27-28|0.0.0.0.1.0.1 26-27|0.0.0.0.1.0.1.1 24-25|0.0.0.0.1.1 23-24|0.0.0.0.1 22-23|0.0.0.0.1.0 21-22|0.0.0.0.1.0.0 19-20|0.0.0.0.0 18-19|0.0.0.0 16-17|0.0.0 13-14|0.0 9-10|0 8-9|0.2.0 7-8|0.2 0-2|0.1.0.1+0.1.0.0+0.1.0+0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:23.411
(p3 / protein 
      :ARG1-of (i / isolate-01 
            :ARG2 (a3 / agent 
                  :ARG0-of (m2 / mediate-01 
                        :ARG1 (a2 / aggregation) 
                        :purpose (a / and 
                              :op1 (g / granul 
                                    :mod (c / chromaffin) 
                                    :poss (m / membran 
                                          :location (p / presence) 
                                          :mod (p2 / phospholipid))) 
                              :op2 (f / fusion))))) 
      :domain (t / thing 
            :name (n / name 
                  :op1 (a5 / Annexin) 
                  :op2 (a6 / A7))) 
      :op2-of (a4 / and 
            :op1 (p4 / phospholipid-bind)))

# ::snt This activity led to the proposal of annexin A7 's involvement in the exocytotic secretion of catecholamines [ 1 ] .
# ::tok This activity led to the proposal of annexin A7 's involvement in the exocytotic secretion of catecholamines [ 1 ] .
# ::alignments 18-19|0.0.0.0.0.0.1.0 16-17|0.0.0.0.0.0.0 14-15|0.0.0.0.1 10-11|0.0.0.0 7-9|0+0.0.1+0.0+0.0.0 5-6|0.0.0.0.0 2-3|0.0.0.0.0.0 1-2|0.0.0.0.0.0.1 0-1|0.0.0.0.0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:24.102
(a2 / A7 
      :op2-of (n / name 
            :name-of (t / thing 
                  :ARG1-of (i / involve-01 
                        :ARG1-of (p / propose-01 
                              :ARG2-of (l / lead-02 
                                    :ARG0 (c / catecholamin) 
                                    :ARG1 (a3 / activity-06 
                                          :ARG1 1 
                                          :mod (t2 / this)))) 
                        :ARG2 (s / secretion))) 
            :op1 (a / annexin)))

# ::snt The protein belongs to a family of evolutionarily conserved proteins of a bipartite structure with a variable N-terminal and a conserved C-terminal domain .
# ::tok The protein belongs to a family of evolutionarily conserved proteins of a bipartite structure with a variable N-terminal and a conserved C-terminal domain .
# ::alignments 22-23|0.2 20-21|0.2.0 18-19|0 16-17|0.1 13-14|0.0 12-13|0.0.1 9-10|0.0.0 8-9|0.0.0.0 7-8|0.0.0.1 5-6|0.0.0.2 2-3|0.0.0.2.0 1-2|0.0.0.2.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:24.518
(a / and 
      :domain-of (s / structure 
            :consist (p / protein 
                  :ARG1-of (c2 / conserve-01) 
                  :mod (e / evolutionarily) 
                  :poss-of (f / family 
                        :ARG1-of (b2 / belong-01 
                              :ARG0 (p2 / protein)))) 
            :mod (b / bipartite)) 
      :mod (v / variable) 
      :op1 (d / domain 
            :ARG1-of (c / conserve-01)))

# ::snt The C-terminal domain is responsible for the Ca2 + - and phospholipid-binding , the N-terminal domain appears to confer functional diversity [ 2-4 ] .
# ::tok The C-terminal domain is responsible for the Ca2 + - and phospholipid-binding , the N-terminal domain appears to confer functional diversity [ 2-4 ] .
# ::alignments 20-21|0.1.1 19-20|0.1.1.0 18-19|0.1 16-17|0 15-16|0.1.0 11-12|0.0 10-11|0.0.0 7-8|0.0.0.0.1 4-5|0.0.0.0 2-3|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:26.726
(a / appear-02 
      :ARG0 (p / phospholipid-bind 
            :op1-of (a2 / and 
                  :compared-to-of (r / responsible-01 
                        :ARG0 (d3 / domain) 
                        :ARG1 (c2 / Ca2)))) 
      :ARG1 (c / confer-01 
            :ARG0 (d2 / domain) 
            :ARG1 (d / diversity 
                  :mod (f / functional))))

# ::snt The binding to negatively charged phospholipids is thought to be mediated by Ca2 + ions .
# ::tok The binding to negatively charged phospholipids is thought to be mediated by Ca2 + ions .
# ::alignments 14-15|0.1.0.0 10-11|0.1.0 7-8|0.1.0.1 5-6|0.0 4-5|0 3-4|0.2 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:27.242
(c / charge-05 
      :ARG1 (p / phospholipid) 
      :ARG1-of (b / binding-07 
            :ARG0-of (m / mediate-01 
                  :ARG1 (i / ion) 
                  :ARG1-of (t / think-01))) 
      :mod (n / negatively))

# ::snt Annexin A7 is unique in that it carries an extraordinarily long and hydrophobic amino terminus with more than 100 amino acids .
# ::tok Annexin A7 is unique in that it carries an extraordinarily long and hydrophobic amino terminus with more than 100 amino acids .
# ::alignments 20-21|0.0.0.0 19-20|0.0.0.0.0 18-19|0.0.0 16-17|0.0.0.0.1 14-15|0.2 13-14|0.0.1 12-13|0.1 11-12|0 10-11|0.0 9-10|0.0.2 7-8|0.2.0 3-4|0.2.0.0.0 0-2|0.2.0.0.1.1+0.2.0.0.1.0+0.2.0.0.1+0.2.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:28.249
(a4 / and 
      :op1 (l / long-03 
            :ARG0 (1 / 100 
                  :quant-of (a / acid 
                        :mod (a2 / amino) 
                        :quant (m / more))) 
            :ARG1 (a3 / amino) 
            :degree (e / extraordinary)) 
      :op2 (h / hydrophobic) 
      :op3 (t / terminu 
            :ARG1-of (c / carry-out-03 
                  :ARG0 (t2 / thing 
                        :domain-of (u / unique) 
                        :name (n / name 
                              :op1 (a5 / Annexin) 
                              :op2 (a6 / A7))))))

# ::snt Alternative splicing gives rise to two isoforms of 47 and 51 kDa .
# ::tok Alternative splicing gives rise to two isoforms of 47 and 51 kDa .
# ::alignments 11-12|0.0.1.0.0 10-11|0.0.1.0.0.0 9-10|0 8-9|0.0.0.0 6-7|0.0.1.0 5-6|0.0.1.0.1 3-4|0.0.1 2-3|0.0 1-2|0.0.0 0-1|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:28.508
(a / and 
      :ARG2-of (g / give-01 
            :ARG0 (s / splice-01 
                  :ARG0 47 
                  :ARG1 (a2 / alternative)) 
            :ARG1 (r / rise-01 
                  :ARG1 (i / isoform 
                        :mod (k / kDa 
                              :quant 51) 
                        :quant 2))))

# ::snt Both isoforms differ by an additional cassette exon located in the first third of the N-terminal domain .
# ::tok Both isoforms differ by an additional cassette exon located in the first third of the N-terminal domain .
# ::alignments 16-17|0.0.0.0 8-9|0.0.0 7-8|0.0 6-7|0.0.1.0 5-6|0.0.1 2-3|0 1-2|0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:28.752
(d2 / differ-02 
      :ARG0 (e / exon 
            :ARG1-of (l / locate-01 
                  :ARG0 (d / domain)) 
            :mod (a / additional 
                  :mod-of (c / cassette))) 
      :ARG1 (i / isoform 
            :mod (b / both)))

# ::snt Most tissues harbor only the 47 kDa isoform , both forms are found in brain and heart , while the large isoform is exclusively expressed in mature skeletal muscle .
# ::tok Most tissues harbor only the 47 kDa isoform , both forms are found in brain and heart , while the large isoform is exclusively expressed in mature skeletal muscle .
# ::alignments 28-29|0.3.0 27-28|0.3.0.1 26-27|0.3.0.0 24-25|0.3 23-24|0.3.1 20-21|0.3.0.0.0.0 16-17|0.2.1 15-16|0.2 14-15|0.2.0 12-13|0 10-11|0.1 9-10|0.1.0 7-8|0.0 5-6|0.3.0.0.0 3-4|0.3.1.0 2-3|0.0.0 1-2|0.0.0.0 0-1|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:32.813
(f / find-01 
      :ARG0 (i / isoform 
            :ARG1-of (h2 / harbor-01 
                  :ARG0 (t / tissue 
                        :mod (m3 / most)))) 
      :ARG1 (f2 / form 
            :mod (b2 / both)) 
      :location (a / and 
            :op1 (b / brain) 
            :op2 (h / heart)) 
      :time (e / express-01 
            :ARG1 (m / muscle-01 
                  :ARG1-of (m2 / mature-02 
                        :ARG0 (4 / 47 
                              :quant-of (l / large))) 
                  :mod (s / skeletal)) 
            :manner (e2 / exclusive-02 
                  :ARG0 (o / only))))

# ::snt At the cellular level annexin A7 can be detected in the cytosol , at the plasma membrane , around the nucleus , at vesicular structures including adrenal chromaffin granules , and at the t-tubule system [ 5,6 ] .
# ::tok At the cellular level annexin A7 can be detected in the cytosol , at the plasma membrane , around the nucleus , at vesicular structures including adrenal chromaffin granules , and at the t-tubule system [ 5,6 ] .
# ::alignments 34-35|0.1.0.2 30-31|0.1 28-29|0.1.0 27-28|0.1.0.0 26-27|0.1.0.1 24-25|0.0.0 23-24|0.0.0.0 20-21|0.0.2.0.0 18-19|0.0.2.0 16-17|0.0.0.0.0.0 15-16|0.0.0.0.0 11-12|0.0.2 8-9|0.0 6-7|0 5-6|0.0.1 4-5|0.0.1.0 3-4|0.0.3 2-3|0.0.3.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:35.792
(p2 / possible-01 
      :ARG1 (d / detect-01 
            :ARG0 (s2 / structure 
                  :mod (v / vesicular 
                        :name (p / plasma 
                              :mod-of (m / membrane)))) 
            :ARG1 (a4 / A7 
                  :mod (a5 / annexin)) 
            :ARG2 (c2 / cytosol 
                  :op1-of (a3 / around 
                        :op2 (n / nucleus))) 
            :location (l / level 
                  :mod (c3 / cell))) 
      :op1-of (a / and 
            :op2 (g / granul 
                  :mod (c / chromaffin) 
                  :mod (a2 / adrenal) 
                  :mod-of (s / system))))

# ::snt Annexin A7 translocates to membranes in a Ca2 + - dependent fashion and , when intracellular Ca2 + levels rise , sequentially redistributes to the plasma and the nuclear membrane as well as to intracellular vesicles .
# ::tok Annexin A7 translocates to membranes in a Ca2 + - dependent fashion and , when intracellular Ca2 + levels rise , sequentially redistributes to the plasma and the nuclear membrane as well as to intracellular vesicles .
# ::alignments 35-36|0.0.2.0.1.0 34-35|0.0.2.0.1 29-30|0.0.2.1 28-29|0.0.2.1.0 26-27|0.0.2 25-26|0.0.3 22-23|0.0 21-22|0.0.0 19-20|0.0.4 18-19|0.0.4.1 15-16|0.0.4.1.0 12-13|0 11-12|0.0.2.0.0 10-11|0.0.2.0 4-5|0.0.4.0 0-2|0.0.1.0.1+0.0.1.0.0+0.0.1.0+0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:37.752
(a2 / and 
      :op1 (r / redistribute-01 
            :ARG0 (s / sequentially) 
            :ARG1 (t / thing 
                  :name (n2 / name 
                        :op1 (a3 / Annexin) 
                        :op2 (a4 / A7))) 
            :ARG2 (a / and 
                  :ARG0-of (d / depend-01 
                        :ARG1 (f / fashion) 
                        :ARG2 (i / intracellular 
                              :mod-of (v / vesicl))) 
                  :op1 (m / membrane 
                        :mod (n / nucleus))) 
            :ARG4 (p / plasma) 
            :condition (r2 / rise-01 
                  :ARG0 (m2 / membran) 
                  :ARG1 (l / level 
                        :mod (i2 / intracellular)))))

# ::snt Furthermore , annexin A7 associates with lipid rafts [ 7 ] .
# ::tok Furthermore , annexin A7 associates with lipid rafts [ 7 ] .
# ::alignments 9-10|0.0.0.0 7-8|0 6-7|0.0.0 4-5|0.0 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:37.842
(r / raft-01 
      :ARG1 (a / associate-01 
            :ARG1 (l / lipid 
                  :op1 7)) 
      :manner (f / furthermore))

# ::snt Lipid rafts play a key role in membrane budding and in vesiculation processes such as endo - and exocytosis [ 8-10 ] .
# ::tok Lipid rafts play a key role in membrane budding and in vesiculation processes such as endo - and exocytosis [ 8-10 ] .
# ::alignments 18-19|0.0 17-18|0 13-14|0.1.1.0 12-13|0.1.1 11-12|0.1.1.1 9-10|0.1 8-9|0.1.0.2.0 7-8|0.1.0.2 5-6|0.1.0.1 4-5|0.1.0.1.0 2-3|0.1.0 1-2|0.1.0.0 0-1|0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:38.672
(a / and 
      :op1 (e / exocytosi) 
      :op2-of (a2 / and 
            :ARG2-of (p2 / play-01 
                  :ARG0 (r2 / raft-01 
                        :mod (l / lipid)) 
                  :ARG1 (r / role 
                        :ARG1-of (k / key-02)) 
                  :location (m / membrane 
                        :ARG1-of (b / bud-01))) 
            :op1 (p / process-02 
                  :ARG1 (s / such) 
                  :mod (v / vesiculation))))

# ::snt Two binding partners of annexin A7 have been identified , sorcin and galectin-3 [ 11-13 ] .
# ::tok Two binding partners of annexin A7 have been identified , sorcin and galectin-3 [ 11-13 ] .
# ::alignments 11-12|0.0 10-11|0.0.0 8-9|0 2-3|0.0.0.0 1-2|0.0.0.0.0 0-1|0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:38.876
(i / identify-01 
      :ARG1 (a / and 
            :op1 (s / sorcin 
                  :domain (p / partner-01 
                        :ARG1-of (b / binding-07) 
                        :quant 2))))

# ::snt Sorcin is a Ca2 + - binding protein and belongs to the penta EF-hand protein family [ 14 ] .
# ::tok Sorcin is a Ca2 + - binding protein and belongs to the penta EF-hand protein family [ 14 ] .
# ::alignments 17-18|0.0.0.0.0.0.0 15-16|0.0 14-15|0 13-14|0.0.0.1.0.0.0+0.0.0.1.0.0+0.0.0.1.0 9-10|0.0.0 8-9|0.0.0.1 7-8|0.0.0.0.0 6-7|0.0.0.0.0.0 0-1|0.0.0.0.1.0+0.0.0.0.1+0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:39.422
(p / protein 
      :mod-of (f / family 
            :ARG1-of (b / belong-01 
                  :ARG0 (c / country 
                        :domain-of (p2 / protein 
                              :ARG0-of (b2 / binding-07 
                                    :ARG2 14)) 
                        :name (n2 / name 
                              :op1 "Sorcin")) 
                  :op1-of (a / and 
                        :op2 (t / thing 
                              :name (n / name 
                                    :op1 "EF-hand"))))))

# ::snt Like annexin A7 it binds to membranes in a Ca2 + - dependent manner .
# ::tok Like annexin A7 it binds to membranes in a Ca2 + - dependent manner .
# ::alignments 13-14|0.1 12-13|0 9-10|0.0 4-5|0.2.0 2-3|0.2.0.0 1-2|0.2.0.0.0 0-1|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:39.619
(d / depend-01 
      :ARG0 (c / Ca2) 
      :ARG1 (m / manner) 
      :ARG2-of (r / resemble-01 
            :ARG1 (b / bind-01 
                  :ARG1 (a / A7 
                        :mod (a2 / annexin)))))

# ::snt Sorcin also has been described as interaction partner of the ryanodine receptor , and appears to modulate its function [ 15 ] .
# ::tok Sorcin also has been described as interaction partner of the ryanodine receptor , and appears to modulate its function [ 15 ] .
# ::alignments 20-21|0.0.1.1.0 18-19|0.1.0.0 16-17|0.1.0 14-15|0.1 13-14|0 11-12|0.0.1.0 10-11|0.0.1.0.0 7-8|0.0.1 6-7|0.0.1.1 4-5|0.0 1-2|0.0.2 0-1|0.0.0.0.0+0.0.0.0+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:40.496
(a2 / and 
      :op1 (d / describe-01 
            :ARG1 (c / country 
                  :name (n / name 
                        :op1 "Sorcin")) 
            :ARG2 (p / partner-01 
                  :ARG1 (r / receptor 
                        :mod (r2 / ryanodine)) 
                  :ARG1-of (i / interact-01 
                        :ARG0 15)) 
            :mod (a3 / also)) 
      :op2 (a / appear-02 
            :ARG1 (m / modulate-01 
                  :ARG1 (f / function-01))))

# ::snt The influence of the sorcin/annexin A7 interaction on the ryanodine receptor is unknown .
# ::tok The influence of the sorcin/annexin A7 interaction on the ryanodine receptor is unknown .
# ::alignments 12-13|0.1+0 10-11|0.0.0.0 9-10|0.0.0.0.0 6-7|0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:40.629
(k / know-01 
      :ARG1 (i2 / influence-01 
            :ARG1 (i / interact-01 
                  :ARG1 (r / receptor 
                        :mod (r2 / ryanodine)))) 
      :polarity -)

# ::snt Sorcin and annexin A7 are coexpressed in all tissues examined so far [ 11 ] .
# ::tok Sorcin and annexin A7 are coexpressed in all tissues examined so far [ 11 ] .
# ::alignments 13-14|0.0.0.1.0 11-12|0.0.0.1.2 9-10|0.0.0.1 8-9|0.0.0.1.1 7-8|0.0.0.1.1.0 3-4|0.0 2-3|0 1-2|0.0.0 0-1|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:41.015
(a3 / annexin 
      :mod-of (a2 / A7 
            :op2-of (a4 / and 
                  :op1 (c / country 
                        :name (n / name 
                              :op1 "Sorcin")) 
                  :op3 (e / examine-01 
                        :ARG0 11 
                        :ARG1 (t / tissue 
                              :quant (a / all)) 
                        :ARG2 (f / far)))))

# ::snt The binding of annexin A7 and sorcin is Ca2 + - dependent and occurs at micromolar Ca2 + concentrations .
# ::tok The binding of annexin A7 and sorcin is Ca2 + - dependent and occurs at micromolar Ca2 + concentrations .
# ::alignments 18-19|0.1.0.1.0 13-14|0.1.0.1 12-13|0.1.0 11-12|0.1.0.0 6-7|0.2 5-6|0 4-5|0.1 3-4|0.1.1 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:41.437
(a2 / and 
      :ARG2-of (b / binding-07) 
      :op1 (a3 / A7 
            :domain-of (a / and 
                  :op1 (d / depend-01) 
                  :op2 (o / occur-01 
                        :ARG1 (c / concentration))) 
            :mod (a4 / annexin)) 
      :op2 (s / sorcin))

# ::snt The binding sites have been localised to the amino terminal GGYY and GYGG motifs in sorcin and to the GYPP motif in the amino terminus of annexin A7 .
# ::tok The binding sites have been localised to the amino terminal GGYY and GYGG motifs in sorcin and to the GYPP motif in the amino terminus of annexin A7 .
# ::alignments 27-28|0.2.0.0.0.0 26-27|0.2.0.0.0 24-25|0.2.0.0.0.0.0 23-24|0.2.0.0.0.0.0.0 20-21|0.1 16-17|0 15-16|0.0 13-14|0.2.1 12-13|0.2.1.0.0.0+0.2.1.0.0+0.2.1.0 11-12|0.2 10-11|0.2.0.2.0+0.2.0.2+0.2.0 9-10|0.2.0.1 8-9|0.2.0.0.1.0.0 5-6|0.2.0.0 2-3|0.2.0.0.1 1-2|0.2.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:42.549
(a4 / and 
      :op1 (s / sorcin) 
      :op2 (m / motif) 
      :op3-of (a5 / and 
            :op1 (o2 / organization 
                  :ARG2-of (l / localize-01 
                        :ARG0 (a2 / annexin 
                              :mod-of (a / A7 
                                    :mod-of (t / terminu 
                                          :mod (a3 / amino)))) 
                        :ARG1 (s2 / site 
                              :ARG1-of (b / binding-07 
                                    :ARG2 (a6 / amino)))) 
                  :mod (t2 / terminal) 
                  :name (n2 / name 
                        :op1 "GGYY")) 
            :op2 (m2 / motif 
                  :mod (o / organization 
                        :name (n / name 
                              :op1 "GYGG")))))

# ::snt The proteins bind to each other with a stoichiometry of two sorcin molecules per annexin A7 molecule [ 12 ] .
# ::tok The proteins bind to each other with a stoichiometry of two sorcin molecules per annexin A7 molecule [ 12 ] .
# ::alignments 18-19|0.1.0.3.0.0 16-17|0.1 15-16|0 14-15|0.0 12-13|0.1.0.0.0 11-12|0.1.0.0.0.0 10-11|0.1.0.0 8-9|0.1.0.2 5-6|0.1.0.3 4-5|0.1.0.3.0 2-3|0.1.0 1-2|0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:44.214
(a / A7 
      :mod (a2 / annexin) 
      :mod-of (m / molecule 
            :op1 (b / bind-01 
                  :ARG0 (2 / 2 
                        :quant-of (m2 / molecule 
                              :mod (s / sorcin))) 
                  :ARG1 (p / protein) 
                  :ARG2 (s2 / stoichiometry) 
                  :prep-to (o / other 
                        :mod (e / each 
                              :mod-of 12)))))

# ::snt Galectin-3 is a multifunctional oncogenic protein with an anti-apoptotic activity found in the extracellular space , in the nucleus and cytoplasm and in mitochondria .
# ::tok Galectin-3 is a multifunctional oncogenic protein with an anti-apoptotic activity found in the extracellular space , in the nucleus and cytoplasm and in mitochondria .
# ::alignments 23-24|0.0.1.1.1 21-22|0.0.1.1 20-21|0.0.1.0 19-20|0.0.1 18-19|0.0.1.1.0 14-15|0.0.0.0 13-14|0.0.0.0.0 10-11|0.0.0 9-10|0.0 5-6|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:44.701
(p / protein 
      :ARG1-of (a3 / activity-06 
            :ARG1-of (f / find-01 
                  :location (s / space 
                        :mod (e / extracellular))) 
            :location (a2 / and 
                  :op1 (c / cytoplasm) 
                  :op2 (a / and 
                        :op1 (n / nucleus) 
                        :op2 (m / mitochondrion)))))

# ::snt Cytoplasmic galectin-3 correlates with tumor progression and protects mitochondrial integrity .
# ::tok Cytoplasmic galectin-3 correlates with tumor progression and protects mitochondrial integrity .
# ::alignments 9-10|0.1.0 7-8|0.1 6-7|0 5-6|0.0.0 4-5|0.0.0.0 2-3|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:44.819
(a / and 
      :op1 (c / correlate-01 
            :ARG1 (p2 / progress-01 
                  :ARG1 (t / tumor))) 
      :op2 (p / protect-01 
            :ARG1 (i / integrity)))

# ::snt Down regulation of annexin A7 prevents galectin-3 translocation to the perinuclear membrane and increases galectin-3 secretion .
# ::tok Down regulation of annexin A7 prevents galectin-3 translocation to the perinuclear membrane and increases galectin-3 secretion .
# ::alignments 15-16|0.2.0 13-14|0.2 12-13|0 11-12|0.1 10-11|0.1.0 7-8|0.0.1 5-6|0.0 4-5|0.0.0.1 3-4|0.0.0.1.0 1-2|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:45.755
(a / and 
      :op1 (p2 / prevent-01 
            :ARG0 (r / regulate-01 
                  :ARG0 (d / down-01) 
                  :ARG1 (a2 / A7 
                        :mod (a3 / annexin))) 
            :ARG1 (t / translocation)) 
      :op2 (m / membrane 
            :mod (p / perinuclear)) 
      :op3 (i / increase-01 
            :ARG1 (s / secretion)))

# ::snt For annexin A7 a role for galectin-3 trafficking , apoptosis regulation , and mitochondrial integrity was proposed [ 13 ] .
# ::tok For annexin A7 a role for galectin-3 trafficking , apoptosis regulation , and mitochondrial integrity was proposed [ 13 ] .
# ::alignments 18-19|0.0.1.2.0 16-17|0.0.1.0 14-15|0.0.1.3 12-13|0.0.1 10-11|0.0 9-10|0 7-8|0.0.1.2 4-5|0.0.1.1 2-3|0.0.0 1-2|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:46.318
(a2 / apoptosi 
      :ARG0-of (r / regulate-01 
            :ARG1 (a3 / A7 
                  :mod (a4 / annexin)) 
            :op3-of (a / and 
                  :ARG1-of (p / propose-01) 
                  :op1 (r2 / role) 
                  :op2 (t / traffic-01 
                        :ARG1 13) 
                  :op4 (i / integrity))))

# ::snt The cellular role of annexin A7 is not well understood .
# ::tok The cellular role of annexin A7 is not well understood .
# ::alignments 9-10|0 7-8|0.1 5-6|0.0.1 2-3|0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:46.514
(u / understand-01 
      :ARG1 (r / role 
            :mod (c / cell) 
            :poss (a / A7)) 
      :polarity -)

# ::snt It is thought to regulate and stabilize membrane domains and to have a role in Ca2 + homeostasis and Ca2 + - dependent signaling pathways .
# ::tok It is thought to regulate and stabilize membrane domains and to have a role in Ca2 + homeostasis and Ca2 + - dependent signaling pathways .
# ::alignments 24-25|0.0.1.0.0.0.1 23-24|0.0.1.0.0.0.1.0 22-23|0.0.1.0.0.0.1.1 18-19|0.0.1.0.0.0 17-18|0.0.1.0.0.0.0 13-14|0.0.1.0.0 9-10|0.0.1.0 8-9|0.0.0.1 7-8|0.0.0.1.0 6-7|0.0.1 5-6|0.0 4-5|0.0.0 2-3|0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:47.675
(t / think-01 
      :ARG1 (a3 / and 
            :op1 (r2 / regulate-01 
                  :ARG0 (i / it) 
                  :ARG1 (d2 / domain 
                        :mod (m / membrane))) 
            :op2 (s2 / stabilize-01 
                  :op1-of (a2 / and 
                        :op2 (r / role 
                              :op1-of (a / and 
                                    :op2 (h / homeostasi) 
                                    :op3 (p / pathway 
                                          :ARG1-of (s / signal-01) 
                                          :ARG1-of (d / depend-01))))))))

# ::snt These proposals are supported by data obtained from analysis of annexin A7 deficient mouse mutants .
# ::tok These proposals are supported by data obtained from analysis of annexin A7 deficient mouse mutants .
# ::alignments 14-15|0.0 13-14|0.0.1 12-13|0 8-9|0.0.0 6-7|0.0.0.0 5-6|0.0.0.0.0 3-4|0.0.0.0.0.0 1-2|0.0.0.0.0.0.0.0+0.0.0.0.0.0.0 0-1|0.0.0.0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:48.011
(d / deficient 
      :mod-of (m / mutant 
            :ARG1-of (a / analyze-01 
                  :manner-of (o / obtain-01 
                        :ARG1 (d2 / data 
                              :ARG0-of (s / support-01 
                                    :ARG1 (t / thing 
                                          :ARG1-of (p / propose-01) 
                                          :mod (t2 / this)))))) 
            :mod (m2 / mouse)))

# ::snt Two annexin A7 129Sv null mice strains were generated independently using a different strategy .
# ::tok Two annexin A7 129Sv null mice strains were generated independently using a different strategy .
# ::alignments 13-14|0.1.1 12-13|0.1.1.0 10-11|0.1 9-10|0.1.2 8-9|0 6-7|0.0 5-6|0.0.1 4-5|0.0.0 0-3|0.1.0.0.2+0.1.0.0.1+0.1.0.0.0+0.1.0.0+0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:49.888
(g / generate-01 
      :ARG0 (s2 / strain 
            :ARG1-of (n / null-02) 
            :mod (m / mouse)) 
      :ARG1 (u / use-01 
            :ARG0 (t / thing 
                  :name (n2 / name 
                        :op1 (t2 / Two) 
                        :op2 (a / annexin) 
                        :op3 (a2 / A7))) 
            :ARG1 (s / strategy 
                  :ARG1-of (d / differ-02)) 
            :manner (i / independent)))

# ::snt The one of Srivastava et al. [ 16 ] is lethal .
# ::tok The one of Srivastava et al. [ 16 ] is lethal .
# ::alignments 10-11|0 7-8|0.0.0 3-6|0.0.1.2+0.0.1.1+0.0.1.0+0.0.1+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:50.082
(l / lethal 
      :op1-of (t / thing 
            :mod 16 
            :name (n / name 
                  :op1 "Srivastava" 
                  :op2 "et" 
                  :op3 "al.")))

# ::snt Heterozygous mice exhibit an insulin secretion defect and tumor phenotypes .
# ::tok Heterozygous mice exhibit an insulin secretion defect and tumor phenotypes .
# ::alignments 9-10|0.1.0 8-9|0.1.0.0 7-8|0.1 6-7|0.2 5-6|0.2.0 4-5|0.2.0.0 2-3|0 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:51.484
(e / exhibit-01 
      :ARG0 (m / mouse 
            :mod (h / heterozygou)) 
      :ARG1 (a / and 
            :op1 (p / phenotyp 
                  :mod (t / tumor))) 
      :ARG2 (d / defect-01 
            :ARG1 (s / secretion 
                  :mod (i / insulin))))

# ::snt The null strain reported by Herr et al. [ 17 ] is viable , healthy , and shows no insulin secretion defect or other obvious defects .
# ::tok The null strain reported by Herr et al. [ 17 ] is viable , healthy , and shows no insulin secretion defect or other obvious defects .
# ::alignments 25-26|0.2 24-25|0.2.1 23-24|0.2.2 22-23|0 21-22|0.1 20-21|0.1.0 19-20|0.1.0.0 18-19|0.2.1.0 17-18|0.0 16-17|0.0.0 14-15|0.0.0.0 12-13|0.0.0.0.0.1 9-10|0.2.0 5-8|0.0.0.0.0.0.0.0.2+0.0.0.0.0.0.0.0.1+0.0.0.0.0.0.0.0.0+0.0.0.0.0.0.0.0+0.0.0.0.0.0.0 3-4|0.0.0.0.0.0 2-3|0.0.0.0.0.3+0.0.0.0.0 1-2|0.0.0.0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:53.081
(o3 / or 
      :ARG1-of (s2 / show-01 
            :op2-of (a / and 
                  :op1 (h / healthy 
                        :domain (s3 / strain 
                              :ARG1-of (r / report-01 
                                    :ARG0 (t / thing 
                                          :name (n / name 
                                                :op1 "Herr" 
                                                :op2 "et" 
                                                :op3 "al."))) 
                              :domain-of (v / viable) 
                              :mod (n2 / null-02) 
                              :wiki "Influenza_A_virus_subtype_H5N1")))) 
      :op1 (d2 / defect-01 
            :ARG1 (s / secretion 
                  :mod (i / insulin))) 
      :op2 (d / defect-01 
            :ARG1 17 
            :ARG1-of (o / obvious-01 
                  :polarity -) 
            :mod (o2 / other)))

# ::snt However , in isolated cardiomyocytes the frequency-induced shortening is disturbed .
# ::tok However , in isolated cardiomyocytes the frequency-induced shortening is disturbed .
# ::alignments 9-10|0 7-8|0.0 6-7|0.0.0 4-5|0.1 3-4|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:53.158
(d / disturb-01 
      :ARG1 (s / shorten-01 
            :mod (f / frequency-induc)) 
      :time (c / cardiomyocyt 
            :ARG1-of (i / isolate-01)))

# ::snt Here we have focused on the analysis of red blood cells and platelets of the anxA7 - / - mutant .
# ::tok Here we have focused on the analysis of red blood cells and platelets of the anxA7 - / - mutant .
# ::alignments 19-20|0 17-18|0.0.1.0 12-13|0.0.1.2.0 11-12|0.0.1.2 10-11|0.0.1.1 9-10|0.0.1.1.0 8-9|0.0.1.1.1 6-7|0.0.1 3-4|0.0 1-2|0.0.0 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:53.554
(m / mutant 
      :ARG1-of (f / focus-01 
            :ARG0 (w / we) 
            :ARG2 (a2 / analyze-01 
                  :ARG0 (s / slash) 
                  :ARG1 (c / cell 
                        :mod (b / blood) 
                        :mod (r / red)) 
                  :op1-of (a / and 
                        :op2 (p / platelet))) 
            :op1-of (h / here)))

# ::snt Generally , red blood cells and platelets were thought not to contain annexin A7 and only recently the 47 kDa isoform has been reported as component of red blood cells [ 7 ] .
# ::tok Generally , red blood cells and platelets were thought not to contain annexin A7 and only recently the 47 kDa isoform has been reported as component of red blood cells [ 7 ] .
# ::alignments 31-32|0.0 29-30|0.3.0.0.0 28-29|0.3.0.0.0.0 27-28|0.3.0.0.0.1 25-26|0.3.0.0 23-24|0.3.0 20-21|0.3.0.1 19-20|0.3.0.1.0 18-19|0.3.0.1.1 16-17|0.3.1 15-16|0.3.1.0 14-15|0.3 13-14|0.2.1 12-13|0.2.1.0 11-12|0.2 9-10|0.2.2 8-9|0 6-7|0.1.0 5-6|0.1 4-5|0.2.0 3-4|0.2.0.0 2-3|0.2.0.1 0-1|0.3.0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:05:59.912
(t / think-01 
      :ARG0 7 
      :ARG1 (a4 / and 
            :op1 (p / platelet)) 
      :ARG2 (c3 / contain-01 
            :ARG0 (c4 / cell 
                  :mod (b2 / blood) 
                  :mod (r4 / red)) 
            :ARG1 (a2 / A7 
                  :mod (a3 / annexin)) 
            :polarity -) 
      :op1-of (a / and 
            :op2 (r2 / report-01 
                  :ARG0 (c2 / component 
                        :mod (c / cell 
                              :mod (b / blood) 
                              :mod (r / red 
                                    :ARG1-of (g / general-02)))) 
                  :ARG1 (i / isoform 
                        :mod (k / kDa) 
                        :quant 47)) 
            :time (r3 / recent 
                  :mod (o / only))))

# ::snt Red blood cells undergo various biochemical or morphological changes that appear to be Ca2 + - dependent processes [ 18,19 ] .
# ::tok Red blood cells undergo various biochemical or morphological changes that appear to be Ca2 + - dependent processes [ 18,19 ] .
# ::alignments 17-18|0.0 16-17|0 10-11|0.1 8-9|0.1.0 7-8|0.1.0.2.1 6-7|0.1.0.2 5-6|0.1.0.2.0 4-5|0.1.0.1 3-4|0.1.0.0 2-3|0.1.0.0.0 1-2|0.1.0.0.0.0 0-1|0.1.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:00.875
(d / depend-01 
      :ARG1 (p / process-02) 
      :condition (a / appear-02 
            :ARG0 (c / change-01 
                  :ARG2-of (u / undergo-28 
                        :ARG1 (c2 / cell 
                              :mod (b2 / blood) 
                              :mod (r / red))) 
                  :mod (v / various) 
                  :op3-of (o / or 
                        :op1 (b / biochemical) 
                        :op2 (m / morphological)))))

# ::snt One of them is the release of hemoglobin-containing exovesicles occurring in vivo as well as in vitro [ 7,20 ] .
# ::tok One of them is the release of hemoglobin-containing exovesicles occurring in vivo as well as in vitro [ 7,20 ] .
# ::alignments 11-12|0.1.0.0 9-10|0.1.0 8-9|0.1 7-8|0.1.1 5-6|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:01.802
(r / release-01 
      :ARG0 1 
      :ARG1 (e / exovesicl 
            :ARG0-of (o / occur-01 
                  :ARG1 (v / vivo)) 
            :mod (h / hemoglobin-contain)))

# ::snt This process is thought to represent a protective method of the red blood cell against an attack by for example complement components .
# ::tok This process is thought to represent a protective method of the red blood cell against an attack by for example complement components .
# ::alignments 21-22|0.0.0.1.1 20-21|0.0.0.1 19-20|0.0.0.1.0 16-17|0.0.0.0 13-14|0.0.1.0 12-13|0.0.1.0.0 11-12|0.0.1.0.1 8-9|0.0.1 7-8|0.0.1.1 5-6|0.0 3-4|0 1-2|0.0.0 0-1|0.0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:04.169
(t / think-01 
      :ARG1 (r2 / represent-01 
            :ARG0 (p2 / process-02 
                  :ARG1-of (a / attack-01) 
                  :ARG2-of (c2 / complement-01 
                        :ARG0 (e / example) 
                        :ARG1 (c / component)) 
                  :mod (t2 / this)) 
            :ARG1 (m / method 
                  :domain (c3 / cell 
                        :mod (b / blood) 
                        :mod (r / red)) 
                  :mod (p / protect-01))))

# ::snt Red blood cells which lack the ability to vesiculate cause a disease with red blood cell destruction and haemoglobinuria [ 21 ] .
# ::tok Red blood cells which lack the ability to vesiculate cause a disease with red blood cell destruction and haemoglobinuria [ 21 ] .
# ::alignments 20-21|0.2 18-19|0.3.0 17-18|0.3 16-17|0.1.0 15-16|0.1.0.1 14-15|0.1.0.0 13-14|0.1.0.2 11-12|0.1 9-10|0 6-7|0.0 4-5|0.0.0 2-3|0.0.0.0 1-2|0.0.0.0.0 0-1|0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:05.161
(c2 / cause-01 
      :ARG0 (a2 / ability 
            :ARG1-of (l / lack-01 
                  :ARG0 (c3 / cell 
                        :mod (b2 / blood) 
                        :mod (r2 / red)))) 
      :ARG1 (d2 / disease 
            :purpose (d / destroy-01 
                  :ARG1 (b / blood) 
                  :mod (c / cell) 
                  :mod (r / red))) 
      :op1-of 21 
      :op1-of (a / and 
            :op2 (h / haemoglobinuria)))

# ::snt There exist two types of vesicles , micro - and nanovesicles with a size of 180 nm and 60 nm , respectively .
# ::tok There exist two types of vesicles , micro - and nanovesicles with a size of 180 nm and 60 nm , respectively .
# ::alignments 21-22|0.2.0 18-19|0.0.1 17-18|0.2 16-17|0.2.1 15-16|0.0.2 13-14|0.2.1.0 10-11|0.2.1.0.0 9-10|0 7-8|0.1 5-6|0.0.0 3-4|0.0.0.0 2-3|0.0.0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:05.605
(a2 / and 
      :ARG0-of (e / exist-01 
            :ARG1 (v / vesicl 
                  :mod (t / type 
                        :quant 2)) 
            :ARG2 60 
            :op1-of 180) 
      :op1 (m / micro) 
      :op1-of (a / and 
            :mod (r / respective) 
            :op2 (n / nm 
                  :poss-of (s / size 
                        :location-of (n2 / nanovesicl)))))

# ::snt They are enriched in cholesterol and sphingolipid rich lipid raft domains that are associated with proteins like acetylcholinesterase , cell surface proteins including a complement receptor , and the lipid raft proteins stomatin and flotillin , but they lack any cytoskeletal protein [ 7 ] .
# ::tok They are enriched in cholesterol and sphingolipid rich lipid raft domains that are associated with proteins like acetylcholinesterase , cell surface proteins including a complement receptor , and the lipid raft proteins stomatin and flotillin , but they lack any cytoskeletal protein [ 7 ] .
# ::alignments 43-44|0.1.3.3.0.0 41-42|0.1.1 39-40|0.1.1.0 38-39|0.1 37-38|0.1.0 36-37|0 34-35|0.1.3.2 33-34|0.1.3 32-33|0.1.3.1 31-32|0.1.3.1.0 30-31|0.1.3.3.2 29-30|0.1.3.3.2.0 27-28|0.1.3.3 25-26|0.0.0 24-25|0.0 21-22|0.1.3.3.1 20-21|0.1.3.3.1.0 19-20|0.1.3.3.1.0.0 17-18|0.1.3.0 16-17|0.1.3.3.0 15-16|0.1.3.3.0.1 13-14|0.1.3.3.0.1.0 10-11|0.1.3.3.0.1.0.0 9-10|0.1.3.3.0.1.0.0.0 8-9|0.1.3.3.0.1.0.0.0.0 7-8|0.1.3.3.0.1.0.0.1 5-6|0.1.2 4-5|0.1.2.0.1 2-3|0.1.2.0 0-1|0.1.2.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:07.994
(c / contrast-01 
      :ARG1 (c2 / complement-01 
            :ARG1 (r2 / receptor)) 
      :ARG2 (l / lack-01 
            :ARG0 (t / they) 
            :ARG1 (p / protein 
                  :mod (a / any)) 
            :op2-of (a6 / and 
                  :op1 (e / enrich-01 
                        :ARG1 (t2 / they) 
                        :ARG2 (c4 / cholesterol))) 
            :op4-of (a2 / and 
                  :op1 (a4 / acetylcholinesterase) 
                  :op2 (s / stomatin 
                        :mod (p2 / protein)) 
                  :op3 (f / flotillin) 
                  :op3-of (a3 / and 
                        :ARG2-of (r3 / resemble-01 
                              :ARG0 7 
                              :ARG1 (p4 / protein 
                                    :ARG2-of (a5 / associate-01 
                                          :ARG1 (d / domain 
                                                :ARG0-of (r4 / raft-01 
                                                      :ARG1 (l3 / lipid)) 
                                                :mod (r5 / rich))))) 
                        :op1 (p3 / protein 
                              :mod (s2 / surface 
                                    :mod (c3 / cell))) 
                        :op2 (r / raft-01 
                              :ARG1 (l2 / lipid))))))

# ::snt Furthermore , they contain sorcin and annexin A7 attached to the lipid rafts .
# ::tok Furthermore , they contain sorcin and annexin A7 attached to the lipid rafts .
# ::alignments 12-13|0.0.0.1 11-12|0.0.0.1.1 8-9|0.0.0 6-7|0.0.0.0 5-6|0.2 4-5|0.1 3-4|0 2-3|0.0 0-1|0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:08.450
(c / contain-01 
      :ARG0 (t / they 
            :ARG0-of (a / attach-01 
                  :ARG1 (a2 / annexin) 
                  :ARG2 (r / raft-01 
                        :ARG0 (f / furthermore) 
                        :ARG1 (l / lipid)))) 
      :ARG1 (s / sorcin) 
      :op1-of (a3 / and))

# ::snt Both proteins are more abundant in nanovesicles .
# ::tok Both proteins are more abundant in nanovesicles .
# ::alignments 6-7|0.2 4-5|0 3-4|0.0 1-2|0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:08.534
(a / abundance 
      :degree (m / more) 
      :domain (p / protein 
            :mod (b / both)) 
      :location (n / nanovesicl))

# ::snt The vesicle formation goes along with several other changes in the red blood cell like cytoskeletal rearrangements and changes in the phospholipid orientation in the cellular membrane .
# ::tok The vesicle formation goes along with several other changes in the red blood cell like cytoskeletal rearrangements and changes in the phospholipid orientation in the cellular membrane .
# ::alignments 26-27|0.0.3 25-26|0.0.0.0.0 22-23|0.0.0.2.0 21-22|0.0.0.2.0.0 18-19|0.0.0.2 17-18|0.0.0 16-17|0.0.0.1 14-15|0.0.0.0 13-14|0.0.1 12-13|0.0.1.0 11-12|0.0.1.1 8-9|0.0 7-8|0.0.2 6-7|0.0.4 4-5|0.2 3-4|0 2-3|0.1 1-2|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:09.329
(g / go-01 
      :ARG0 (c4 / change-01 
            :ARG0 (a / and 
                  :ARG2-of (r2 / resemble-01 
                        :ARG1 (c / cell)) 
                  :op1 (r / rearrangement) 
                  :op2 (c2 / change-01 
                        :ARG1 (o / orientation 
                              :mod (p / phospholipid)))) 
            :ARG1 (c3 / cell 
                  :mod (b / blood) 
                  :mod (r3 / red)) 
            :mod (o2 / other) 
            :op1-of (m / membrane) 
            :quant (s / several)) 
      :ARG1 (f / form-01 
            :mod (v / vesicle)) 
      :manner (a2 / along))

# ::snt Annexin A7 expression in red blood cells , red blood cell derived exovesicles and in platelets .
# ::tok Annexin A7 expression in red blood cells , red blood cell derived exovesicles and in platelets .
# ::alignments 15-16|0.0.2 13-14|0 12-13|0.0.1 11-12|0.0 10-11|0.0.0 9-10|0.0.1.1 8-9|0.0.0.0 6-7|0.0.1.0.0 5-6|0.0.1.0 4-5|0.0.1.0.0.1 2-3|0.0.1.0.0.0 0-2|0.0.1.0.0.0.0.0.1+0.0.1.0.0.0.0.0.0+0.0.1.0.0.0.0.0+0.0.1.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:11.566
(a / and 
      :op1 (d / derive-01 
            :ARG0 (c / cell 
                  :mod (r / red)) 
            :ARG1 (e / exovesicl 
                  :mod (b2 / blood 
                        :mod-of (c2 / cell 
                              :ARG1-of (e2 / express-01 
                                    :ARG0 (t / thing 
                                          :name (n / name 
                                                :op1 (a2 / Annexin) 
                                                :op2 (a3 / A7)))) 
                              :mod (r2 / red))) 
                  :poss-of (b / blood)) 
            :ARG2 (p / platelet)))

# ::snt Salzer et al. recently reported the presence of the 47 kDa isoform of annexin A7 and its partner sorcin in micro - and nanovesicles derived from red blood cells where they are located in the lumen and are also enriched in membrane rafts [ 7 ] .
# ::tok Salzer et al. recently reported the presence of the 47 kDa isoform of annexin A7 and its partner sorcin in micro - and nanovesicles derived from red blood cells where they are located in the lumen and are also enriched in membrane rafts [ 7 ] .
# ::alignments 44-45|0.1.0.0.0.0.0.2.2.0.0 42-43|0.1.1 41-42|0.1.1.1 39-40|0.1 38-39|0.1.2 36-37|0 35-36|0.0.1 32-33|0.0 30-31|0.0.0 28-29|0.1.0 27-28|0.1.0.1 26-27|0.1.0.2 24-25|0.1.0.0 23-24|0.1.0.0.0 22-23|0.1.0.0.0.0 20-21|0.1.1.0 18-19|0.1.0.0.0.0.0.2.2 17-18|0.1.0.0.0.0.0.2.2.0 15-16|0.1.0.0.0.0.0.2 14-15|0.1.0.0.0.0.0.2.1 13-14|0.1.0.0.0.0.0.2.1.0 11-12|0.1.0.0.0.0.0.2.0 10-11|0.1.0.0.0.0.0.2.0.0 9-10|0.1.0.0.0.0.0.2.2.1 6-7|0.1.0.0.0.0.0.1 4-5|0.1.0.0.0.0.0 3-4|0.1.0.0.0.0.0.3 0-3|0.1.0.0.0.0.0.0.0.2+0.1.0.0.0.0.0.0.0.1+0.1.0.0.0.0.0.0.0.0+0.1.0.0.0.0.0.0.0+0.1.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:18.509
(a2 / and 
      :op1 (l2 / locate-01 
            :ARG1 (t / they) 
            :location (l / lumen)) 
      :op2 (e / enrich-01 
            :ARG1 (c / cell 
                  :ARG2-of (d / derive-01 
                        :ARG1 (n / nanovesicl 
                              :op2-of (a3 / and 
                                    :op1 (r3 / report-01 
                                          :ARG0 (t2 / thing 
                                                :name (n2 / name 
                                                      :op1 "Salzer" 
                                                      :op2 "et" 
                                                      :op3 "al.")) 
                                          :ARG1 (p2 / presence) 
                                          :op1-of (a4 / and 
                                                :op2 (i / isoform 
                                                      :mod (k / kDa)) 
                                                :op3 (a5 / A7 
                                                      :mod (a6 / annexin)) 
                                                :op4 (s / sorcin 
                                                      :ARG1-of (p / partner-01 
                                                            :ARG0 7) 
                                                      :quant 47)) 
                                          :time (r4 / recent))))) 
                  :mod (b / blood) 
                  :mod (r2 / red)) 
            :ARG2 (r / raft-01 
                  :ARG1 (m2 / micro) 
                  :mod (m / membrane)) 
            :mod (a / also)))

# ::snt We have now extended these findings and show here that the 51 kDa isoform is present as well .
# ::tok We have now extended these findings and show here that the 51 kDa isoform is present as well .
# ::alignments 15-16|0.1.1 13-14|0.1.1.0 12-13|0.1.1.0.0 11-12|0.1.0 8-9|0.1.2 7-8|0.1 6-7|0 5-6|0.0.1.0+0.0.1 4-5|0.0.1.1 3-4|0.0 2-3|0.2 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:19.000
(a / and 
      :op1 (e / extend-01 
            :ARG0 (w / we) 
            :ARG1 (t / thing 
                  :ARG1-of (f / find-01) 
                  :mod (t2 / this))) 
      :op2 (s / show-01 
            :ARG0 51 
            :ARG1 (p / present 
                  :domain (i / isoform 
                        :mod (k / kDa))) 
            :location (h / here)) 
      :time (n / now))

# ::snt In western blots of human red blood cells the 47 and 51 kDa isoforms were detected using mAb 203 -- 217 ( Fig. 1 ) .
# ::tok In western blots of human red blood cells the 47 and 51 kDa isoforms were detected using mAb 203 -- 217 ( Fig. 1 ) .
# ::alignments 23-24|0.0.1.0.0.1.0 22-23|0.0.0.0+0.0.0+0.0 17-18|0.0.1.0 16-17|0.0.1.0.0 15-16|0.0.1.0.0.1 13-14|0.0.1.0.0.0 12-13|0.0.1.0.0.0.0 11-12|0.0.1.3 10-11|0 9-10|0.0.1.0.0.0.1 7-8|0.0.1.1 6-7|0.0.1.1.0 5-6|0.0.1.1.1 4-5|0.0.1.1.0.0 2-3|0.0.1 1-2|0.0.1.2.1+0.0.1.2.0.0+0.0.1.2.0+0.0.1.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:23.943
(a / and 
      :op1 (c / country 
            :name (n / name 
                  :op1 "Fig.") 
            :op1 (b2 / blot-01 
                  :ARG0 (m / mAb 
                        :ARG1-of (u / use-01 
                              :ARG0 (i / isoform 
                                    :mod (k / kDa) 
                                    :quant 47) 
                              :ARG1-of (d / detect-01 
                                    :ARG0 1))) 
                  :ARG1 (c2 / cell 
                        :mod (b / blood 
                              :mod (h / human)) 
                        :mod (r / red)) 
                  :mod (w / world-region 
                        :name (n2 / name 
                              :op1 "West") 
                        :wiki "Western_world") 
                  :op1-of 51)))

# ::snt The 47 kDa isoform was detected in silver stained gels and its identity with annexin A7 confirmed by peptide mass fingerprinting ( data not shown ) .
# ::tok The 47 kDa isoform was detected in silver stained gels and its identity with annexin A7 confirmed by peptide mass fingerprinting ( data not shown ) .
# ::alignments 24-25|0 23-24|0.2 22-23|0.1 20-21|0.0.0.0.0.0 19-20|0.0.0.0.0.1 18-19|0.0.0.0.0.2 16-17|0.0.0.0.0.0.0 15-16|0.0.0.0.0.0.0.0 14-15|0.0.0.0.0.0.0.0.0 12-13|0.0.1 10-11|0.0 9-10|0.0.1.0 8-9|0.0.1.0.0 7-8|0.0.1.0.1 5-6|0.0.0 3-4|0.0.0.0 2-3|0.0.0.0.0 1-2|0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:25.153
(s / show-01 
      :ARG0 (a3 / and 
            :ARG0-of (d2 / detect-01 
                  :ARG1 (i2 / isoform 
                        :mod (k / kDa 
                              :poss-of (f / fingerprint 
                                    :ARG0-of (c / confirm-01 
                                          :ARG1 (a / A7 
                                                :mod (a2 / annexin)))) 
                              :poss-of (m / mass) 
                              :poss-of (p / peptide)) 
                        :quant 47)) 
            :op1 (i / identity 
                  :poss (g / gel 
                        :ARG1-of (s2 / stain-01) 
                        :mod (s3 / silver)))) 
      :ARG1 (d / data) 
      :polarity -)

# ::snt The 51 kDa isoform was only detected in western blots .
# ::tok The 51 kDa isoform was only detected in western blots .
# ::alignments 9-10|0.1 8-9|0.1.0.1+0.1.0.0.0+0.1.0.0+0.1.0 6-7|0 5-6|0.2 3-4|0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:25.410
(d / detect-01 
      :ARG1 (i / isoform 
            :mod 51) 
      :ARG2 (b / blot-01 
            :ARG1 (w / world-region 
                  :name (n / name 
                        :op1 "West") 
                  :wiki "Western_world")) 
      :mod (o / only))

# ::snt Expression of annexin A7 in human red blood cells ( 1 ) and human platelets ( 2 ) .
# ::tok Expression of annexin A7 in human red blood cells ( 1 ) and human platelets ( 2 ) .
# ::alignments 16-17|0.0.0.0.0.0 14-15|0.0.0.2.0 13-14|0.0.0.2.0.0 12-13|0.0.0.2 10-11|0.1 8-9|0.0.0 7-8|0.0.0.0 6-7|0.0.0.1 5-6|0.0.0.0.0 3-4|0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:25.773
(e / expression 
      :mod (a2 / A7 
            :mod (c / cell 
                  :mod (b / blood 
                        :mod (h2 / human 
                              :poss-of 2)) 
                  :mod (r / red) 
                  :op1-of (a / and 
                        :op2 (p / platelet 
                              :mod (h / human))))) 
      :mod 1)

# ::snt Protein homogenates were separated by SDS-PAGE ( 12 % acrylamide ) .
# ::tok Protein homogenates were separated by SDS-PAGE ( 12 % acrylamide ) .
# ::alignments 9-10|0.0.0.1 8-9|0.0.0.1.0 7-8|0.0.0.1.0.0 5-6|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 3-4|0.0.0 1-2|0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:26.187
(p3 / protein 
      :mod-of (h / homogenat 
            :ARG1-of (s / separate-01 
                  :ARG0 (p2 / person 
                        :name (n / name 
                              :op1 "SDS-PAGE")) 
                  :ARG2 (a / acrylamide 
                        :degree (p / percentage-entity 
                              :value 12)))))

# ::snt The resulting western blot was probed with mAb 203 -- 217 , visualization was by a secondary peroxidase coupled antibody followed by ECL .
# ::tok The resulting western blot was probed with mAb 203 -- 217 , visualization was by a secondary peroxidase coupled antibody followed by ECL .
# ::alignments 22-23|0.1.1.0.0.1.0.0.0.0+0.1.1.0.0.1.0.0.0+0.1.1.0.0.1.0.0 20-21|0.1.1.0.0.1.0 19-20|0.1.1.0.0.1 18-19|0.1.1.0.0 17-18|0.1.1.0.0.0 16-17|0.0 12-13|0.1.1.0 5-6|0.1.1 3-4|0.1 2-3|0.1.0.1+0.1.0.0.0+0.1.0.0+0.1.0 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:27.302
(r / result-01 
      :ARG0 (s / secondary) 
      :ARG1 (b / blot-01 
            :ARG1 (w / world-region 
                  :name (n2 / name 
                        :op1 "West") 
                  :wiki "Western_world") 
            :ARG1-of (p2 / probe-01 
                  :ARG0 (v / visualization 
                        :ARG2-of (c / couple-01 
                              :ARG0 (p / peroxidase) 
                              :ARG1 (a / antibody 
                                    :ARG1-of (f / follow-01 
                                          :ARG0 (o / organization 
                                                :name (n / name 
                                                      :op1 "ECL")))))))))

# ::snt Both isoforms are detected in red blood cells , in platelets only the small isoform is present .
# ::tok Both isoforms are detected in red blood cells , in platelets only the small isoform is present .
# ::alignments 16-17|0.0 14-15|0.0.0 13-14|0.0.0.1 11-12|0.0.0.2 10-11|0 7-8|0.0.0.0.1 6-7|0.0.0.0.1.0 5-6|0.0.0.0.1.1 3-4|0.0.0.0 1-2|0.0.0.0.0 0-1|0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:27.866
(p2 / platelet 
      :time-of (p / present 
            :domain (i / isoform 
                  :ARG0-of (d / detect-01 
                        :ARG1 (i2 / isoform 
                              :mod (b2 / both)) 
                        :time (c / cell 
                              :mod (b / blood) 
                              :mod (r / red))) 
                  :mod (s / small) 
                  :mod (o / only))))

# ::snt Its presence in vesicles led to the suggestion , that , along with raft domains , annexin A7 plays a role in membrane organization and the vesiculation process .
# ::tok Its presence in vesicles led to the suggestion , that , along with raft domains , annexin A7 plays a role in membrane organization and the vesiculation process .
# ::alignments 27-28|0.1 26-27|0.1.0 24-25|0 23-24|0.0.1 22-23|0.0.1.1 20-21|0.0 18-19|0.0.0 16-18|0.0.0.0.0.1+0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 14-15|0.0.1.0.1.1.0 13-14|0.0.1.0.1.1 11-12|0.0.1.0.1.1.1 7-8|0.0.1.0.1.0+0.0.1.0.1 4-5|0.0.1.0 3-4|0.0.1.0.0.0 1-2|0.0.1.0.0 0-1|0.0.1.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:28.845
(a / and 
      :op1 (r / role 
            :ARG1-of (p2 / play-02 
                  :ARG0 (t / thing 
                        :name (n / name 
                              :op1 (a2 / annexin) 
                              :op2 (a3 / A7)))) 
            :mod (o / organization 
                  :ARG1-of (l / lead-02 
                        :ARG0 (p3 / presence 
                              :location (v2 / vesicl) 
                              :poss (i / it)) 
                        :ARG2 (t2 / thing 
                              :ARG1-of (s / suggest-01) 
                              :ARG1-of (r2 / raft-01 
                                    :ARG0 (d / domain) 
                                    :op1-of (a4 / along)))) 
                  :mod (m / membrane))) 
      :op2 (p / process-02 
            :ARG1 (v / vesiculation)))

# ::snt To examine this , we analysed the ability of red blood cells derived from the annexin A7 knock out mice ( anxA7 - / - ) to form exovesicles .
# ::tok To examine this , we analysed the ability of red blood cells derived from the annexin A7 knock out mice ( anxA7 - / - ) to form exovesicles .
# ::alignments 28-29|0.0.1.2.0.1.1 27-28|0.0.1.2.0.1 23-24|0.0.0 19-20|0.0.1.2.0.0 17-18|0.0.1.2.0 16-17|0 12-13|0.0 11-12|0.0.1 10-11|0.0.1.0 9-10|0.0.1.1 7-8|0.0.1.2 4-5|0.0.1.2.0.1.0 2-3|0.0.1.2.0.1.0.0.0 1-2|0.0.1.2.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:29.641
(a / A7 
      :ARG2-of (d / derive-01 
            :ARG0 (s / slash) 
            :ARG1 (c / cell 
                  :mod (b / blood) 
                  :mod (r / red) 
                  :mod-of (a2 / ability 
                        :ARG0-of (k / knock-01 
                              :ARG1 (m / mouse) 
                              :purpose (f / form-01 
                                    :ARG0 (w / we 
                                          :ARG0-of (e2 / examine-01 
                                                :ARG1 (t / this))) 
                                    :ARG1 (e / exovesicl)))))))

# ::snt Because of better accessibility and larger available amounts that led to clear results , we included our data obtained with human blood .
# ::tok Because of better accessibility and larger available amounts that led to clear results , we included our data obtained with human blood .
# ::alignments 21-22|0.0.1.0.0.0.1.0.0 20-21|0.0.1.0.0.0.1.0.0.0 18-19|0.0.1.0.0.0.1.0 17-18|0.0.1.0.0.0.1 16-17|0.0.1.0.0.0.1.1 15-16|0.0.1.0.0.0 14-15|0.0.1.0.0.0.0 12-13|0+0.0 11-12|0.0.0 9-10|0.0.1 7-8|0.0.1.0 6-7|0.0.1.0.1 5-6|0.0.1.0.0.0.2.0.0 4-5|0.0.1.0.0.0.2 3-4|0.0.1.0.0.0.2.0 2-3|0.0.1.0.0.0.2.0.1 0-1|0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:30.592
(r / result-01 
      :ARG2 (t / thing 
            :ARG1-of (c / clear-06) 
            :ARG2-of (l / lead-02 
                  :ARG0 (a / amount 
                        :ARG0-of (c2 / cause-01 
                              :ARG1 (i / include-01 
                                    :ARG0 (w2 / we) 
                                    :ARG1 (d / data 
                                          :ARG1-of (o / obtain-01 
                                                :ARG2 (b / blood 
                                                      :mod (h / human))) 
                                          :poss (w / we)) 
                                    :op2-of (a3 / and 
                                          :op1 (a4 / access-01 
                                                :ARG1 (l2 / large) 
                                                :degree (g / good))))) 
                        :ARG1-of (a2 / available-02)))))

# ::snt Independent of the presence of annexin A7 both types of exovesicles , micro - and nanovesicles , were released after Ca2 + / ionophore treatment as determined by acetylcholine esterase activity and microscopic examination .
# ::tok Independent of the presence of annexin A7 both types of exovesicles , micro - and nanovesicles , were released after Ca2 + / ionophore treatment as determined by acetylcholine esterase activity and microscopic examination .
# ::alignments 33-34|0.0.2 32-33|0.0.2.0 31-32|0.0 30-31|0.1 29-30|0.1.0 28-29|0.1.1 26-27|0 24-25|0.2 23-24|0.2.0 22-23|0.2.1 19-20|0.0.0.0.0.1 18-19|0.0.0.0.0 15-16|0.0.1.1 14-15|0.0.1 12-13|0.0.1.0 10-11|0.0.0.0.1 8-9|0.0.0.0 7-8|0.0.0 6-7|0.0.0.0.0.0.1.0 5-6|0.0.0.0.0.0.1.0.0 3-4|0.0.0.0.0.0.1 0-1|0.0.0.0.0.0.0.0+0.0.0.0.0.0.0+0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:32.477
(d / determined-02 
      :ARG0 (a / and 
            :mod (b / both 
                  :mod-of (t2 / type 
                        :ARG1-of (r / release-01 
                              :ARG0 (p2 / political-party 
                                    :name (n2 / name 
                                          :op1 "Independent") 
                                    :poss (p / presence 
                                          :mod (a6 / A7 
                                                :mod (a7 / annexin)))) 
                              :time (a4 / after)) 
                        :mod-of (e3 / exovesicl))) 
            :op1 (a5 / and 
                  :op1 (m2 / micro) 
                  :op2 (n / nanovesicl)) 
            :op2 (e / examine-01 
                  :ARG0 (m / microscopic))) 
      :ARG1 (a2 / activity-06 
            :ARG1 (e2 / esterase) 
            :mod (a3 / acetylcholine)) 
      :ARG1-of (t / treat-03 
            :ARG2 (i / ionophore) 
            :op1-of (s / slash)))

# ::snt Annexin A7 is present in both vesicle types where it is more enriched in nanovesicles ( Fig. 2 ) .
# ::tok Annexin A7 is present in both vesicle types where it is more enriched in nanovesicles ( Fig. 2 ) .
# ::alignments 17-18|0.0.0.0.1 16-17|0.0.1.0.0+0.0.1.0+0.0.1 14-15|0 12-13|0.0 11-12|0.0.2 7-8|0.0.0.1 6-7|0.0.0.1.1 5-6|0.0.0.1.0 3-4|0.0.0 0-2|0.0.0.0.0.1+0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:32.657
(n2 / nanovesicl 
      :ARG2-of (e / enrich-01 
            :ARG0 (p / present 
                  :domain (t2 / thing 
                        :name (n3 / name 
                              :op1 (a / Annexin) 
                              :op2 (a2 / A7)) 
                        :quant 2) 
                  :domain (t / type 
                        :mod (b / both) 
                        :mod (v / vesicle))) 
            :ARG1 (c / country 
                  :name (n / name 
                        :op1 "Fig.")) 
            :degree (m / more)))

# ::snt The 51 kDa isoform is only detectable in nanovesicles .
# ::tok The 51 kDa isoform is only detectable in nanovesicles .
# ::alignments 8-9|0.1 6-7|0 5-6|0.2 3-4|0.0 2-3|0.0.0 1-2|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:32.688
(d / detectable 
      :domain (i / isoform 
            :mod (k / kDa) 
            :quant 51) 
      :location (n / nanovesicl) 
      :mod (o / only))

# ::snt The quantity of both vesicle types did not differ between wild type and knock out red blood cell vesicles as determined by the AChE-values ( A405 nanovesicles : ~ 0.18 ; A405 microvesicles : ~ 0.9 ; both , for wt and ko ) .
# ::tok The quantity of both vesicle types did not differ between wild type and knock out red blood cell vesicles as determined by the AChE-values ( A405 nanovesicles : ~ 0.18 ; A405 microvesicles : ~ 0.9 ; both , for wt and ko ) .
# ::alignments 42-43|0.1 41-42|0 37-38|0.2.0 32-33|0.2.1.0 30-31|0.2.2 29-30|0.2.2.0 26-27|0.0 25-26|0.0.0 23-24|0.2.3.0.0.0+0.2.3.0.0+0.2.3.0 20-21|0.2.3.1.0 18-19|0.2.3.1 17-18|0.2.3.1.1 16-17|0.2.3.1.1.0 15-16|0.2.3.1.2 13-14|0.2.3 12-13|0.2 11-12|0.2.3.1.0.0.0 10-11|0.2.3.1.0.0 8-9|0.2.1 7-8|0.2.1.2 5-6|0.2.1.1.0 4-5|0.2.1.1.0.1 3-4|0.2.1.1.0.0 1-2|0.2.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:34.002
(a / and 
      :consist (n / nanovesicl 
            :mod (a3 / A405)) 
      :op1 (k / ko) 
      :op3-of (a4 / and 
            :mod (b / both) 
            :op1 (d2 / differ-02 
                  :ARG0 (m / microvesicl) 
                  :ARG1 (q / quantity 
                        :quant-of (t3 / type 
                              :mod (b3 / both) 
                              :mod (v2 / vesicle))) 
                  :polarity -) 
            :op1-of (a2 / and 
                  :op2 0.18) 
            :op2 (k2 / knock-01 
                  :ARG0 (t / thing 
                        :name (n2 / name 
                              :op1 "AChE-values")) 
                  :ARG1 (v / vesicl 
                        :ARG1-of (d / determined-02 
                              :ARG0 (w / wild 
                                    :mod-of (t2 / type))) 
                        :mod (c / cell 
                              :mod (b2 / blood)) 
                        :mod (r / red)))))

# ::snt It appears that annexin A7 , although it has been described to fuse membranes , is not a key component in the process of the formation of red blood cell exovesicles .
# ::tok It appears that annexin A7 , although it has been described to fuse membranes , is not a key component in the process of the formation of red blood cell exovesicles .
# ::alignments 30-31|0.1.1.0.0 29-30|0.1.1.0 28-29|0.1.1 27-28|0.1.1.0.0.1 25-26|0.1.1.0.0.0 22-23|0.1.1.0.0.0.1 19-20|0.1 18-19|0.1.0 16-17|0.1.1.0.0.0.1.0.0 13-14|0.1.1.0.0.0.1.0.1 12-13|0.1.1.0.0.0.1.0.2 10-11|0.1.1.0.0.0.1.0 4-5|0.1.1.0.0.0.0 3-4|0.1.1.0.0.0.0.0 1-2|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:35.054
(a3 / appear-02 
      :ARG0 (i / it) 
      :ARG1 (c2 / component 
            :ARG1-of (k / key-02) 
            :location (b / blood 
                  :mod-of (c / cell 
                        :mod-of (e / exovesicl 
                              :ARG1-of (f / form-01 
                                    :ARG0 (a / A7 
                                          :mod (a2 / annexin)) 
                                    :ARG1-of (p / process-02 
                                          :manner-of (d / describe-01 
                                                :ARG1 - 
                                                :ARG2 (m / membran) 
                                                :purpose (f2 / fuse-01)))) 
                              :mod (r / red))))))

# ::snt When we probed for the presence of sorcin in wild type and mutant vesicles we found that the sorcin levels were reduced in the mutant nanovesicles ( Fig. 2 ) .
# ::tok When we probed for the presence of sorcin in wild type and mutant vesicles we found that the sorcin levels were reduced in the mutant nanovesicles ( Fig. 2 ) .
# ::alignments 28-29|0.0.0.1.2 27-28|0.0.0.1.1.2.0.0+0.0.0.1.1.2.0+0.0.0.1.1.2 25-26|0.0.0.1.0.0.1 24-25|0.0.0.1.0.0.1.0 21-22|0.0.0.1.0.0 19-20|0.0.0.1.0.0.0 15-16|0.0.0 14-15|0.0.0.0 13-14|0.0 12-13|0 11-12|0.0.0.1.1.0 10-11|0.0.0.1.1.0.0 9-10|0.0.0.1.1.0.0.0 7-8|0.0.0.1.1.1 5-6|0.0.0.1.1 2-3|0.0.0.1 1-2|0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:37.748
(m2 / mutant 
      :mod-of (v / vesicl 
            :ARG1-of (f / find-01 
                  :ARG0 (w / we) 
                  :time (p2 / probe-01 
                        :ARG0 (w3 / we 
                              :ARG0-of (r / reduce-01 
                                    :ARG1 (l / level) 
                                    :ARG2 (n2 / nanovesicl 
                                          :mod (m / mutant)))) 
                        :ARG1 (p / presence 
                              :location (a / and 
                                    :op1 (t / type 
                                          :mod (w2 / wild))) 
                              :mod (s / sorcin) 
                              :poss (c / country 
                                    :name (n / name 
                                          :op1 "Fig."))) 
                        :ARG2 2))))

# ::snt Enrichment of annexin A7 and sorcin in exovesicles derived from red blood cells .
# ::tok Enrichment of annexin A7 and sorcin in exovesicles derived from red blood cells .
# ::alignments 12-13|0.0.1.0.0.1 11-12|0.0.1.0.0.1.0 10-11|0.0.1.0.0.1.1 8-9|0.0.1.0.0 7-8|0.0.1.0.0.0 5-6|0.0.1.0 4-5|0.0.1 3-4|0.0 2-3|0.0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:38.309
(e2 / enrichment 
      :topic (a2 / A7 
            :mod (a3 / annexin) 
            :op1-of (a / and 
                  :op2 (s / sorcin 
                        :ARG0-of (d / derive-01 
                              :ARG1 (e / exovesicl) 
                              :ARG2 (c / cell 
                                    :mod (b / blood) 
                                    :mod (r / red)))))))

# ::snt Vesicles from wild type ( wt ) and anxA7 - / - mutant ( ko ) were generated with Ca2 + / ionophore treatment , isolated by differential centrifugation and analysed by immunoblotting with mAb 203 -- 217 and a sorcin polyclonal antibody .
# ::tok Vesicles from wild type ( wt ) and anxA7 - / - mutant ( ko ) were generated with Ca2 + / ionophore treatment , isolated by differential centrifugation and analysed by immunoblotting with mAb 203 -- 217 and a sorcin polyclonal antibody .
# ::alignments 42-43|0.0.3.1.1.0.1.0.0 41-42|0.0.3.1.1.0.1.0 40-41|0.0.3.1.1.0.1 38-39|0 34-35|0.0.3.1.1.0.0 29-30|0.0.3 28-29|0.0.3.1.0 27-28|0.0.3.1.0.0 25-26|0.0.3.1 23-24|0.0.3.0 21-22|0.0.3.0.1 17-18|0.0.3.1.1.0 14-15|0.0.3.0.0 12-13|0.0.2 10-11|0.0.3.1.1 8-9|0.0.1 7-8|0.0 3-4|0.0.0 2-3|0.0.0.0 0-1|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:40.549
(a2 / and 
      :op5-of (a5 / and 
            :op1 (t2 / type 
                  :mod (w / wild) 
                  :source-of (v / vesicl)) 
            :op2 (a4 / anxA7) 
            :op3 (m2 / mutant) 
            :op4 (a3 / and 
                  :ARG1-of (t / treat-03 
                        :ARG0 (k / ko) 
                        :op1-of (s2 / slash)) 
                  :op1 (i / isolate-01 
                        :ARG0 (c / centrifugation 
                              :mod (d / differential)) 
                        :ARG1 (s3 / slash 
                              :ARG1-of (g / generate-01 
                                    :ARG0 (m / mAb) 
                                    :ARG2 (s / sorcin 
                                          :mod-of (p / polyclonal 
                                                :mod-of (a / antibody)))))))))

# ::snt In general , annexin A7 and sorcin are more abundant in nanovesicles .
# ::tok In general , annexin A7 and sorcin are more abundant in nanovesicles .
# ::alignments 11-12|0.3 9-10|0 8-9|0.1 6-7|0.2.1 5-6|0.2 4-5|0.2.0 3-4|0.2.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:40.777
(a / abundance 
      :ARG1-of (g / general-02) 
      :degree (m / more) 
      :domain (a2 / and 
            :op1 (a3 / A7 
                  :mod (a4 / annexin)) 
            :op2 (s / sorcin)) 
      :location (n / nanovesicl))

# ::snt The 51 kDa isoform of annexin A7 ( arrows ) is only observed in nanovesicles .
# ::tok The 51 kDa isoform of annexin A7 ( arrows ) is only observed in nanovesicles .
# ::alignments 14-15|0.0.1 12-13|0.0 11-12|0.0.2 8-9|0 6-7|0.0.0.1 5-6|0.0.0.1.0 3-4|0.0.0 2-3|0.0.0.0 1-2|0.0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:41.740
(a / arrow 
      :ARG0-of (o / observe-01 
            :ARG1 (i / isoform 
                  :mod (k / kDa) 
                  :mod (a2 / A7 
                        :mod (a3 / annexin)) 
                  :quant 51) 
            :location (n / nanovesicl) 
            :mod (o2 / only)))

# ::snt Samples of both vesicles types were normalized according to their acetylcholine esterase activity .
# ::tok Samples of both vesicles types were normalized according to their acetylcholine esterase activity .
# ::alignments 12-13|0.0.1.0 11-12|0.0.1.0.0 10-11|0.0.1.1 7-8|0.0.1 6-7|0 4-5|0.0.0 3-4|0.0.0.1 2-3|0.0.0.0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:42.442
(n / normalize-01 
      :ARG1 (s2 / sample-01 
            :ARG1 (t / type 
                  :mod (b / both) 
                  :mod (v / vesicl)) 
            :ARG1-of (s / say-01 
                  :ARG0 (a / activity-06 
                        :ARG1 (e / esterase)) 
                  :ARG2 (a2 / acetylcholine))))

# ::snt Human red blood cells ( co ) were used for control and normalized independently .
# ::tok Human red blood cells ( co ) were used for control and normalized independently .
# ::alignments 13-14|0.2 12-13|0.1.1 11-12|0.1 10-11|0.1.0 8-9|0 3-4|0.0 2-3|0.0.0 1-2|0.0.1 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:43.175
(u / use-01 
      :ARG1 (c2 / cell 
            :mod (b / blood 
                  :mod (h / human)) 
            :mod (r / red)) 
      :ARG2 (a / and 
            :op1 (c / control-01) 
            :op2 (n / normalize-01)) 
      :manner (i / independent))

# ::snt To study the distribution of annexin A7 in red blood cells we used self forming iodixanol density gradients .
# ::tok To study the distribution of annexin A7 in red blood cells we used self forming iodixanol density gradients .
# ::alignments 17-18|0.1 16-17|0.1.0 14-15|0.0.1 13-14|0.0.1.0 12-13|0 11-12|0.0 10-11|0.0.0.0.0 9-10|0.0.0.0.0.0 8-9|0.0.0.0.0.1 3-4|0.0.0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:43.476
(u / use-01 
      :ARG0 (w / we 
            :ARG0-of (s2 / study-01 
                  :ARG1 (d2 / distribute-01 
                        :ARG1 (c / cell 
                              :mod (b / blood) 
                              :mod (r / red)))) 
            :ARG0-of (f / form-01 
                  :ARG1 (s / self))) 
      :ARG1 (g / gradient 
            :mod (d / density)))

# ::snt Both isoforms were present in the soluble fraction as well as in the gradient fractions where they are assumed to be associated with membranes .
# ::tok Both isoforms were present in the soluble fraction as well as in the gradient fractions where they are assumed to be associated with membranes .
# ::alignments 23-24|0 21-22|0.0 18-19|0.0.2 16-17|0.0.0 14-15|0.0.2.0 13-14|0.0.2.0.1 7-8|0.0.2.0.0.0.0 6-7|0.0.2.0.0.0.0.0 3-4|0.0.2.0.0.0 1-2|0.0.2.0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:44.922
(m / membran 
      :ARG2-of (a / associate-01 
            :ARG0 (t / they) 
            :ARG1 (b / both) 
            :ARG2-of (a2 / assume-02 
                  :ARG1 (f / fraction-01 
                        :ARG0 (i / isoform 
                              :domain-of (p / present 
                                    :domain (f2 / fraction 
                                          :mod (s / soluble)))) 
                        :ARG1 (g / gradient)))))

# ::snt These membranes are exclusively plasma membranes as red blood cells are free of any organelles .
# ::tok These membranes are exclusively plasma membranes as red blood cells are free of any organelles .
# ::alignments 14-15|0 13-14|0.1 11-12|0.0 9-10|0.0.1 8-9|0.0.1.0 7-8|0.0.1.1 5-6|0.0.0.0 4-5|0.0.0.0.1 3-4|0.0.0.0.0 1-2|0.0.0 0-1|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:45.956
(o / organell 
      :ARG2-of (f / free-04 
            :ARG0 (m2 / membran 
                  :domain-of (m / membran 
                        :ARG1-of (e / exclusive-02) 
                        :mod (p / plasma)) 
                  :mod (t / this)) 
            :ARG1 (c / cell 
                  :mod (b / blood) 
                  :mod (r / red))) 
      :mod (a / any))

# ::snt The distribution was however not homogeneous throughout the gradient .
# ::tok The distribution was however not homogeneous throughout the gradient .
# ::alignments 8-9|0 6-7|0.0 4-5|0.0.0 1-2|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:46.057
(g / gradient 
      :op1-of (t / throughout 
            :mod-of - 
            :time-of (d / distribute-01)))

# ::snt This could reflect the binding of annexin A7 to membrane subdomains that have different lipid or lipid/protein composition as discussed by Salzer et al. [ 7 ] .
# ::tok This could reflect the binding of annexin A7 to membrane subdomains that have different lipid or lipid/protein composition as discussed by Salzer et al. [ 7 ] .
# ::alignments 25-26|0.0.0.0.0.1.0.0 21-24|0.0.0.0.0.3.0.2+0.0.0.0.0.3.0.1+0.0.0.0.0.3.0.0+0.0.0.0.0.3.0+0.0.0.0.0.3 19-20|0.0.0 17-18|0 15-16|0.0 14-15|0.0.2 13-14|0.0.1 10-11|0.0.0.0 9-10|0.0.0.0.1 7-8|0.0.0.0.0.1 6-7|0.0.0.0.0.1.1 4-5|0.0.0.0.0.1.0 2-3|0.0.0.0.0 1-2|0.0.0.0.0.2 0-1|0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:48.632
(c / compose-01 
      :op2-of (o / or 
            :ARG0-of (d / discuss-01 
                  :ARG1 (s / subdomain 
                        :ARG3-of (r / reflect-01 
                              :ARG0 (t2 / this) 
                              :ARG1 (a / A7 
                                    :ARG1-of (b / binding-07 
                                          :ARG0 7) 
                                    :mod (a2 / annexin)) 
                              :ARG1-of (p / possible-01) 
                              :ARG2 (t / thing 
                                    :name (n / name 
                                          :op1 "Salzer" 
                                          :op2 "et" 
                                          :op3 "al."))) 
                        :mod (m / membrane))) 
            :ARG1-of (d2 / differ-02) 
            :op1 (l / lipid)))

# ::snt Likewise , sorcin does not exhibit a homogeneous distribution in the gradient .
# ::tok Likewise , sorcin does not exhibit a homogeneous distribution in the gradient .
# ::alignments 11-12|0.1.0 8-9|0.1 7-8|0.1.1 5-6|0 4-5|0.2 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:48.749
(e / exhibit-01 
      :ARG0 (l / likewise) 
      :ARG1 (d / distribute-01 
            :ARG1 (g / gradient) 
            :ARG2 (h / homogeneou)) 
      :polarity -)

# ::snt Moreover , it segregates into vesicles which are not associated with annexin A7 ( Fig. 3 ) .
# ::tok Moreover , it segregates into vesicles which are not associated with annexin A7 ( Fig. 3 ) .
# ::alignments 15-16|0.0 14-15|0.1.0.0+0.1.0+0.1 12-13|0.2.0.0 11-12|0.2.0.0.0 9-10|0.2.0 8-9|0.2.0.1 5-6|0.2 3-4|0 0-1|0.3 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:50.313
(s / segregate-01 
      :ARG0 3 
      :ARG1 (c / country 
            :name (n / name 
                  :op1 "Fig.")) 
      :ARG2 (v / vesicl 
            :ARG1-of (a3 / associate-01 
                  :ARG2 (a / A7 
                        :mod (a2 / annexin)) 
                  :polarity -)) 
      :manner (m / moreover))

# ::snt We also tested platelets for annexin A7 expression and detected the 47 kDa isoform ( Fig. 1 ) .
# ::tok We also tested platelets for annexin A7 expression and detected the 47 kDa isoform ( Fig. 1 ) .
# ::alignments 16-17|0.0.2.0 15-16|0.0.2.1.0.0+0.0.2.1.0+0.0.2.1 13-14|0.1.0 12-13|0.1.0.0 11-12|0.1.0.1 9-10|0.1 8-9|0 7-8|0.0.2 3-4|0.0.1 2-3|0.0 1-2|0.0.3 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:51.944
(a / and 
      :op1 (t / test-01 
            :ARG0 (w / we) 
            :ARG1 (p / platelet) 
            :ARG3 (e / express-01 
                  :ARG0 1 
                  :ARG1 (c / country 
                        :name (n / name 
                              :op1 "Fig."))) 
            :mod (a2 / also)) 
      :op2 (d / detect-01 
            :ARG1 (i / isoform 
                  :mod (k / kDa) 
                  :quant 47)))

# ::snt Association of annexin A7 and sorcin with distinct red blood cell plasma membrane fractions .
# ::tok Association of annexin A7 and sorcin with distinct red blood cell plasma membrane fractions .
# ::alignments 13-14|0.0.0.0 12-13|0.0.0.0.0 11-12|0 10-11|0.0 9-10|0.0.0 8-9|0.0.0.0.2 7-8|0.0.0.0.1 5-6|0.0.0.0.3 4-5|0.0.0.0.3.0 0-4|0.0.0.0.3.0.0.0.3+0.0.0.0.3.0.0.0.2+0.0.0.0.3.0.0.0.1+0.0.0.0.3.0.0.0.0+0.0.0.0.3.0.0.0+0.0.0.0.3.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:52.752
(p / plasma 
      :mod (c / cell 
            :mod (b / blood 
                  :ARG1-of (f / fraction-01 
                        :ARG0 (m / membrane) 
                        :mod (d / distinct) 
                        :mod (r / red) 
                        :topic-of (s / sorcin 
                              :op2-of (a / and 
                                    :op1 (o / organization 
                                          :name (n / name 
                                                :op1 "Association" 
                                                :op2 "of" 
                                                :op3 "annexin" 
                                                :op4 "A7"))))))))

# ::snt Lysed human red blood cells were added to a self forming iodixanol density gradient .
# ::tok Lysed human red blood cells were added to a self forming iodixanol density gradient .
# ::alignments 13-14|0.1.0.0 12-13|0.1.0.0.0 10-11|0.1.0 9-10|0.1 6-7|0 4-5|0.0 3-4|0.0.0 2-3|0.0.1 1-2|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:52.969
(a / add-01 
      :ARG0 (c / cell 
            :mod (b / blood 
                  :mod (h / human)) 
            :mod (r / red)) 
      :ARG2 (s / self 
            :ARG1-of (f / form-01 
                  :ARG0 (g / gradient 
                        :mod (d / density)))))

# ::snt The density of the gradient increases from left ( 1.06 g/ml ) to right ( 1.20 g/ml ) .
# ::tok The density of the gradient increases from left ( 1.06 g/ml ) to right ( 1.20 g/ml ) .
# ::alignments 13-14|0.2 7-8|0.1 5-6|0 4-5|0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:53.075
(i / increase-01 
      :ARG0 (d / density 
            :poss (g / gradient)) 
      :ARG1 (l / left) 
      :ARG3 (r / right-05))

# ::snt Fractions were analysed by immunoblotting using mAb 203 -- 217 and the sorcin polyclonal antibody .
# ::tok Fractions were analysed by immunoblotting using mAb 203 -- 217 and the sorcin polyclonal antibody .
# ::alignments 14-15|0.0.0 10-11|0 6-7|0.0.1.1 5-6|0.0.1 4-5|0.0.1.0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:53.212
(a2 / and 
      :ARG1-of (f / fraction-01 
            :ARG0 (a / antibody) 
            :ARG2-of (u / use-01 
                  :ARG0 (i / immunoblott) 
                  :ARG1 (m / mAb))))

# ::snt The lack of annexin A7 changes red blood cell morphology and osmotic resistance .
# ::tok The lack of annexin A7 changes red blood cell morphology and osmotic resistance .
# ::alignments 12-13|0.1.1 11-12|0.1.1.0 10-11|0.1 9-10|0.1.0 8-9|0.1.0.0 7-8|0.1.0.0.0 6-7|0.1.0.1 5-6|0 4-5|0.0.0 3-4|0.0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:54.005
(c2 / change-01 
      :ARG0 (l / lack-01 
            :ARG1 (a2 / A7 
                  :mod (a3 / annexin))) 
      :ARG1 (a / and 
            :op1 (m / morphology 
                  :mod (c / cell 
                        :mod (b / blood)) 
                  :mod (r2 / red)) 
            :op2 (r / resist-01 
                  :mod (o / osmotic))))

# ::snt As annexin A7 is a component of red blood cell vesicles we studied the consequences of the loss of the protein in the anxA7 - / - mouse for red blood cell morphology and osmotic resistance .
# ::tok As annexin A7 is a component of red blood cell vesicles we studied the consequences of the loss of the protein in the anxA7 - / - mouse for red blood cell morphology and osmotic resistance .
# ::alignments 35-36|0 34-35|0.2 33-34|0.3 32-33|0.3.1 31-32|0.3.1.0 30-31|0.3.1.0.0 29-30|0.3.1.1 27-28|0.1 25-26|0.0 20-21|0.3.0.1.0.0 17-18|0.3.0.1.0 14-15|0.3.0.1 12-13|0.3.0 11-12|0.3.0.0 10-11|0.3.0.2 9-10|0.3.0.2.0 8-9|0.3.0.2.0.0 7-8|0.3.0.2.1 5-6|0.3.0.2.2 2-3|0.3.0.2.2.0 1-2|0.3.0.2.2.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:55.213
(r / resist-01 
      :ARG0 (s / slash) 
      :ARG1 (m2 / mouse) 
      :mod (o / osmotic) 
      :op3-of (a / and 
            :op1 (s2 / study-01 
                  :ARG0 (w / we) 
                  :ARG1 (c2 / consequence 
                        :mod (l / loss 
                              :poss (p / protein))) 
                  :ARG2 (v / vesicl 
                        :mod (c3 / cell 
                              :mod (b2 / blood)) 
                        :mod (r3 / red) 
                        :mod-of (c4 / component 
                              :domain (a2 / A7 
                                    :mod (a3 / annexin))))) 
            :op2 (m / morphology 
                  :mod (c / cell 
                        :mod (b / blood)) 
                  :mod (r2 / red))))

# ::snt In a standard ` blood smear ' we did not note a deformation of the cells , however dark field microscopy revealed changes in shape and diameter of the anxA7 - / - red blood cells .
# ::tok In a standard ` blood smear ' we did not note a deformation of the cells , however dark field microscopy revealed changes in shape and diameter of the anxA7 - / - red blood cells .
# ::alignments 35-36|0.0.0.0.0 34-35|0.0.0.0.0.0 33-34|0.0.0.0.0.1 31-32|0.1.0.1.2 29-30|0.1.0.0 26-27|0.1.0.1.1 25-26|0.1.0.1 24-25|0.1.0 22-23|0.1 21-22|0 20-21|0.0 19-20|0.0.0 18-19|0.0.0.0 15-16|0.1.0.1.0.1.0 12-13|0.1.0.1.0.1 10-11|0.1.0.1.0 9-10|0.1.0.1.0.3 7-8|0.1.0.1.0.0 5-6|0.1.0.1.0.2 4-5|0.1.0.1.0.2.1 2-3|0.1.0.1.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:06:57.592
(r2 / reveal-01 
      :ARG0 (m / microscopy 
            :mod (f / field 
                  :ARG1-of (d2 / dark-02 
                        :ARG0 (c / cell 
                              :mod (b / blood) 
                              :mod (r / red))))) 
      :ARG1 (c2 / change-01 
            :ARG1 (s2 / shape-01 
                  :ARG1 (a / anxA7) 
                  :op2-of (a2 / and 
                        :op1 (n / note-01 
                              :ARG0 (w / we) 
                              :ARG1 (d3 / deformation 
                                    :domain (c3 / cell)) 
                              :ARG2 (s3 / smear 
                                    :ARG1-of (s4 / standard-02) 
                                    :mod (b2 / blood)) 
                              :polarity -) 
                        :op3 (d / diameter) 
                        :op4 (s / slash)))))

# ::snt They had a statistically significant larger cell diameter of 6.0 m compared to wild type with 5.7 m ( p = 0.015 , n = 40 ) , a remarkably lower emphasized central impression and a more flat shape ( Fig. 4 ) .
# ::tok They had a statistically significant larger cell diameter of 6.0 m compared to wild type with 5.7 m ( p = 0.015 , n = 40 ) , a remarkably lower emphasized central impression and a more flat shape ( Fig. 4 ) .
# ::alignments 41-42|0.4.0.0 38-39|0.4.0 37-38|0.2.1.0 36-37|0.2.1 34-35|0.4 33-34|0 32-33|0.3 31-32|0.1 30-31|0.2 29-30|0.2.2 25-26|0.0.1.0.0 19-20|0.2.2.0 14-15|0.0.2 13-14|0.0.2.0 11-12|0.0 10-11|0.0.0 9-10|0.2.0 7-8|0.0.1 6-7|0.0.1.1 5-6|0.0.1.2 4-5|0.0.1.0 3-4|0.0.1.0.1 0-1|0.0.1.3 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:00.352
(i / impression-03 
      :ARG1 (c2 / compare-01 
            :ARG0 (m2 / m) 
            :ARG1 (d / diameter 
                  :ARG1-of (s2 / significant-02 
                        :ARG0 40 
                        :mod (s3 / statistics)) 
                  :mod (c3 / cell) 
                  :mod (l2 / large) 
                  :poss (t2 / they)) 
            :ARG2 (t / type 
                  :mod (w / wild))) 
      :ARG1-of (e / emphasize-01) 
      :ARG2 (l / low-04 
            :ARG0 6.0 
            :ARG1 (m / more 
                  :degree-of (f / flat)) 
            :ARG1-of (r / remarkable-02 
                  :ARG0 (p / p))) 
      :mod (c / central) 
      :op1-of (a / and 
            :op2 (s / shape-01 
                  :ARG1 4)))

# ::snt No significant change in the mean corpuscular volume ( MCV ) was measured with the ADVIA 120 cell counter .
# ::tok No significant change in the mean corpuscular volume ( MCV ) was measured with the ADVIA 120 cell counter .
# ::alignments 18-19|0.0.1 17-18|0.0.1.2 16-17|0.0.1.3 15-16|0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 12-13|0 9-10|0.0.1.1.0.0+0.0.1.1.0+0.0.1.1 7-8|0.0.0 6-7|0.0.0.0.0 5-6|0.0.0.0 2-3|0.0 1-2|0.0.2 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:01.864
(m / measure-01 
      :ARG1 (c4 / change-01 
            :ARG1 (v / volume 
                  :ARG2-of (m2 / mean-01 
                        :ARG1 (c3 / corpuscular))) 
            :ARG1-of (c / counter-01 
                  :ARG0 (o / organization 
                        :name (n / name 
                              :op1 "ADVIA")) 
                  :ARG2 (o2 / organization 
                        :name (n2 / name 
                              :op1 "MCV")) 
                  :mod (c2 / cell) 
                  :quant 120) 
            :ARG1-of (s / significant-02)) 
      :polarity -)

# ::snt Dark field microscopy of red blood cells from anxA7 - / - mutant ( B ) and wild type mice ( A ) .
# ::tok Dark field microscopy of red blood cells from anxA7 - / - mutant ( B ) and wild type mice ( A ) .
# ::alignments 19-20|0.0.1 18-19|0.0.1.0 17-18|0.0.1.1 16-17|0.0 14-15|0.2.1.0.1+0.2.1.0.0.0+0.2.1.0.0+0.2.1.0 12-13|0.0.0 10-11|0.2.2.0 8-9|0.2.2 6-7|0.2 5-6|0.2.0 4-5|0.2.1 2-3|0 1-2|0.1 0-1|0.3 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:02.289
(m3 / microscopy 
      :domain (a / and 
            :op1 (m2 / mutant) 
            :op2 (m / mouse 
                  :mod (t / type) 
                  :mod (w / wild))) 
      :mod (f / field) 
      :mod (c / cell 
            :mod (b / blood) 
            :mod (r / red 
                  :mod-of (l / location 
                        :name (n / name 
                              :op1 "B") 
                        :wiki -)) 
            :source (a2 / anxA7 
                  :mod-of (s / slash))) 
      :mod (d / dark))

# ::snt The mean cellular diameters are 6.0 m and 5.7 m , respectively .
# ::tok The mean cellular diameters are 6.0 m and 5.7 m , respectively .
# ::alignments 11-12|0.1 7-8|0 6-7|0.2 5-6|0.2.0 3-4|0.0 2-3|0.0.1 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:02.622
(a / and 
      :domain (d / diameter 
            :ARG1-of (m2 / mean-01) 
            :mod (c / cell)) 
      :mod (r / respective) 
      :op1 (m / m 
            :quant 6.0))

# ::snt The size differences are statistically significant ( p = 0.015 ; n = 40 ) .
# ::tok The size differences are statistically significant ( p = 0.015 ; n = 40 ) .
# ::alignments 13-14|0.0.0.0 11-12|0.1 10-11|0 5-6|0.0 4-5|0.0.1 2-3|0.0.0 1-2|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:02.851
(a / and 
      :ARG0-of (s / significant-02 
            :ARG1 (d / differ-01 
                  :ARG0 40 
                  :ARG1 (s3 / size)) 
            :mod (s2 / statistics)) 
      :op1 (n / n))

# ::snt Bar , 3 m .
# ::tok Bar , 3 m .
# ::alignments 3-4|0.0.0 2-3|0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:02.888
(b / bar-01 
      :ARG1 (3 / 3 
            :quant-of (m / m)))

# ::snt Shape and MCV of a red blood cell essentially influence its function and capillary passage .
# ::tok Shape and MCV of a red blood cell essentially influence its function and capillary passage .
# ::alignments 14-15|0.0.1 13-14|0.0.1.0 12-13|0.1 11-12|0.2 9-10|0 8-9|0.3 7-8|0.2.0 6-7|0.2.0.1 5-6|0.2.0.2 2-3|0.0.0.0.0+0.0.0.0+0.0.0 1-2|0.0 0-1|0.2.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:03.667
(i / influence-01 
      :ARG0 (a2 / and 
            :op1 (o / organization 
                  :name (n / name 
                        :op1 "MCV")) 
            :op2 (p / pass-01 
                  :ARG1 (c / capillary))) 
      :ARG1 (a / and) 
      :ARG2 (f / function-01 
            :ARG1 (c2 / cell 
                  :ARG1-of (s / shape-01) 
                  :mod (b / blood) 
                  :mod (r / red))) 
      :manner (e / essential))

# ::snt The typical biconcave form depends on various influences including the membrane lipid composition and the submembranous cytoskeleton [ 32 ] where annexin A7 might play a role .
# ::tok The typical biconcave form depends on various influences including the membrane lipid composition and the submembranous cytoskeleton [ 32 ] where annexin A7 might play a role .
# ::alignments 26-27|0.0.1 24-25|0.0 23-24|0 21-23|0.0.0.0.1+0.0.0.0.0+0.0.0.0+0.0.0 18-19|0.1.0.0.0 16-17|0.2.1 15-16|0.2.1.0 13-14|0.2 12-13|0.2.0 11-12|0.2.0.0 10-11|0.2.0.1 7-8|0.1.1 6-7|0.1.1.0 4-5|0.1 3-4|0.1.0 2-3|0.1.0.1 1-2|0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:08.741
(p2 / possible-01 
      :ARG1 (p / play-01 
            :ARG0 (t / thing 
                  :name (n / name 
                        :op1 (a / annexin) 
                        :op2 (a2 / A7))) 
            :ARG1 (r / role)) 
      :condition (d / depend-01 
            :ARG0 (f / form 
                  :ARG1-of (t2 / typical-02 
                        :ARG0 32) 
                  :mod (b / biconcave)) 
            :ARG1 (i / influence 
                  :mod (v / various))) 
      :op3-of (a3 / and 
            :op1 (c2 / compose-01 
                  :ARG1 (l / lipid) 
                  :mod (m / membrane)) 
            :op2 (c / cytoskeleton 
                  :mod (s / submembranou))))

# ::snt The osmotic resistance , which is the resistance towards changes in the extracellular ionic strength , is a convenient assay for analysis of the red blood cell integrity .
# ::tok The osmotic resistance , which is the resistance towards changes in the extracellular ionic strength , is a convenient assay for analysis of the red blood cell integrity .
# ::alignments 27-28|0.0.1.0.0.0 26-27|0.0.1.0.0.0.0 25-26|0.0.1.0.0.0.0.0 24-25|0.0.1.0.0.0.1 21-22|0.0.1.0.0 19-20|0.0.1.0.0.1 18-19|0.0.1.0.0.1.0 14-15|0.0.0 13-14|0.0.0.0 12-13|0.0.0.1 9-10|0.0 7-8|0 2-3|0.0.1 1-2|0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:09.912
(r2 / resist-01 
      :ARG2 (c3 / change-01 
            :ARG1 (s / strength 
                  :mod (i2 / ionic) 
                  :mod (e / extracellular)) 
            :ARG1-of (r3 / resist-01 
                  :mod (o / osmotic 
                        :ARG0-of (a / analyze-01 
                              :ARG1 (i / integrity 
                                    :mod (c / cell 
                                          :mod (b / blood)) 
                                    :mod (r / red)) 
                              :purpose-of (a2 / assay 
                                    :mod (c2 / convenient)))))))

# ::snt It is measured as the sodium chloride concentration at which cellular lysis starts ( minimal resistance ) up to a complete lysis ( maximal resistance ) of the cells [ 33 ] .
# ::tok It is measured as the sodium chloride concentration at which cellular lysis starts ( minimal resistance ) up to a complete lysis ( maximal resistance ) of the cells [ 33 ] .
# ::alignments 30-31|0.1 28-29|0.0.0.1.0.0 24-25|0 23-24|0.2 21-22|0.0.0.1.0 20-21|0.0.0.1 15-16|0.0.0.0.1.1 14-15|0.0.0.0.1.1.0 12-13|0.0.0.0.1 11-12|0.0.0.0.1.0 10-11|0.0.0.0.1.0.0 7-8|0.0.0.0 6-7|0.0.0.0.0 5-6|0.0.0.0.0.0 2-3|0.0.0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:11.831
(r / resist-01 
      :ARG0 (i / it 
            :ARG1-of (m3 / measure-01 
                  :prep-as (c4 / concentrate-02 
                        :ARG1 (c5 / chloride 
                              :mod (s2 / sodium)) 
                        :ARG1-of (s / start-01 
                              :ARG0 (l2 / lysi 
                                    :mod (c3 / cell)) 
                              :ARG2 (r2 / resist-01 
                                    :ARG1-of (m2 / minimal-02)))) 
                  :purpose (c2 / complete-02 
                        :ARG1 (l / lysi 
                              :domain (c / cell))))) 
      :ARG1 33 
      :degree (m / maximum))

# ::snt Osmotic resistance increases with higher MCV , larger surface area and a higher degree of cellular metabolism stabilizing the intracellular ion levels .
# ::tok Osmotic resistance increases with higher MCV , larger surface area and a higher degree of cellular metabolism stabilizing the intracellular ion levels .
# ::alignments 21-22|0.0.0.0.0.2 20-21|0.0.0.0.0.2.0 19-20|0.0.0.0.0.2.0.0 17-18|0.0.0.0 16-17|0.0.0.0.0.1.1 15-16|0.0.0.0.0.1.1.0 13-14|0.0.0.0.0.1 12-13|0.0.0.0.0.1.0 10-11|0.0.0.0.0 9-10|0.0.0.0.0.0 8-9|0.0.0.0.0.0.1 7-8|0.0.0.0.0.0.0 5-6|0.0.0.2.0+0.0.0.2+0.0.0 4-5|0.0.0.1 2-3|0 1-2|0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:15.360
(i3 / increase-01 
      :ARG0 (r / resist-01 
            :ARG1 (o / organization 
                  :ARG0-of (s / stabilize-01 
                        :ARG1 (a / and 
                              :op1 (a2 / area 
                                    :mod (l2 / large) 
                                    :mod (s2 / surface)) 
                              :op2 (d / degree 
                                    :ARG1-of (h / high-02) 
                                    :mod (m / metabolism 
                                          :mod (c / cell))) 
                              :poss-of (l / level 
                                    :mod (i / ion 
                                          :mod (i2 / intracellular))))) 
                  :ARG1-of (h2 / high-02) 
                  :name (n / name 
                        :op1 "MCV")) 
            :mod (o2 / osmotic)))

# ::snt Aged red blood cells show a lowered MCV and lower osmotic resistance [ 33 ] .
# ::tok Aged red blood cells show a lowered MCV and lower osmotic resistance [ 33 ] .
# ::alignments 13-14|0.0.0.0 11-12|0.0.0.1 10-11|0.1.0 9-10|0.0.0.1.0 8-9|0.1 7-8|0.2.1.0+0.2.1+0.2 6-7|0.2.0 4-5|0 3-4|0.0 2-3|0.0.1 1-2|0.0.2 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:17.505
(s / show-01 
      :ARG0 (c / cell 
            :ARG1-of (a2 / age-01 
                  :ARG0 33 
                  :ARG1-of (r / resist-01 
                        :ARG1-of (l / low-04))) 
            :mod (b / blood) 
            :mod (r2 / red)) 
      :ARG1 (a / and 
            :op1 (o / osmotic)) 
      :ARG2 (o2 / organization 
            :ARG1-of (l2 / lower-05) 
            :name (n / name 
                  :op1 "MCV")))

# ::snt Similar properties can be observed in red blood cells with lowered membrane permeability .
# ::tok Similar properties can be observed in red blood cells with lowered membrane permeability .
# ::alignments 12-13|0.0.0.0.0 11-12|0.0.0.0.0.0 10-11|0.0.0.0 8-9|0.0.0 7-8|0.0.0.1 6-7|0.0.0.2 4-5|0.0 2-3|0 1-2|0.0.1 0-1|0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:17.838
(p2 / possible-01 
      :ARG1 (o / observe-01 
            :ARG0 (c / cell 
                  :ARG0-of (l / lower-05 
                        :ARG1 (p / permeability 
                              :mod (m / membrane))) 
                  :mod (b / blood) 
                  :mod (r / red)) 
            :ARG1 (p3 / property 
                  :ARG1-of (r2 / resemble-01))))

# ::snt The osmotic resistance of annexin A7 deficient red blood cells is significantly increased compared to wild type cells .
# ::tok The osmotic resistance of annexin A7 deficient red blood cells is significantly increased compared to wild type cells .
# ::alignments 17-18|0.0 16-17|0.0.1 15-16|0 13-14|0.0.0 12-13|0.0.0.0 11-12|0.0.0.0.1 9-10|0.0.0.0.0.0 8-9|0.0.0.0.0.0.0 7-8|0.0.0.0.0.0.1 6-7|0.0.0.0.0.0.2 2-3|0.0.0.0.0 1-2|0.0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:18.540
(w / wild 
      :mod-of (c / cell 
            :ARG2-of (c2 / compare-01 
                  :ARG0-of (i / increase-01 
                        :ARG1 (r2 / resist-01 
                              :ARG1 (c3 / cell 
                                    :mod (b / blood) 
                                    :mod (r / red) 
                                    :mod (d / deficient)) 
                              :mod (o / osmotic)) 
                        :ARG2 (s / significant-02))) 
            :mod (t / type)))

# ::snt The minimal resistance value of knock out cells is observed in a 0.60 % NaCl solution versus 0.65 % for wild type cells .
# ::tok The minimal resistance value of knock out cells is observed in a 0.60 % NaCl solution versus 0.65 % for wild type cells .
# ::alignments 22-23|0.0.0.0.0 21-22|0.0.0.0.0.0 20-21|0.0.0.0.0.1 18-19|0.0.0.0 16-17|0.0.0 15-16|0.0 13-14|0.1.2.0 9-10|0 7-8|0.1.0.0 5-6|0.1.0 3-4|0.1 2-3|0.1.2 1-2|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:19.538
(o / observe-01 
      :ARG0 (s / solution 
            :location (v / versu 
                  :op1 (p / percentage-entity 
                        :purpose (c / cell 
                              :mod (t / type) 
                              :mod (w / wild))))) 
      :ARG1 (v2 / value-01 
            :ARG1 (k / knock-01 
                  :ARG1 (c2 / cell)) 
            :ARG1-of (m / minimal-02) 
            :mod (r / resist-01 
                  :ARG1 (p2 / percentage-entity))))

# ::snt 50 % haemolysis is achieved at 0.516 % NaCl solution for knock out versus 0.564 % NaCl for wild type cells ( mean values , p = 0.00066 , n = 8 ; Fig. 5 ) .
# ::tok 50 % haemolysis is achieved at 0.516 % NaCl solution for knock out versus 0.564 % NaCl for wild type cells ( mean values , p = 0.00066 , n = 8 ; Fig. 5 ) .
# ::alignments 34-35|0.2.0.1.1 33-34|0.1.1.0.0+0.1.1.0+0.1.1 32-33|0.1 31-32|0.1.0 23-24|0.0 22-23|0 20-21|0.2.2.0 19-20|0.2.2.0.0 18-19|0.2.2 15-16|0.2.3 13-14|0.2.3.0 11-12|0.2.0.1 9-10|0.2.0 8-9|0.2.0.0 7-8|0.2.0.0.0 4-5|0.2 2-3|0.2.1 1-2|0.2.0.1.0 0-1|0.2.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:21.578
(m / mean-01 
      :ARG1 (v / value) 
      :ARG2 (a / and 
            :op1 8 
            :op2 (c / country 
                  :name (n / name 
                        :op1 "Fig."))) 
      :purpose-of (a2 / achieve-01 
            :ARG0 (s / solution 
                  :mod (n2 / NaCl 
                        :quant (p2 / percentage-entity)) 
                  :purpose (k / knock-01 
                        :ARG0 (p3 / percentage-entity 
                              :value 50) 
                        :op1-of 5)) 
            :ARG1 (h / haemolysi) 
            :op1-of (w / wild 
                  :mod-of (c2 / cell 
                        :mod (t / type))) 
            :op1-of (p / percentage-entity 
                  :op1-of (v2 / versu))))

# ::snt The resistance width of the knock out cells is slightly lower ( 0.20 % instead of 0.25 % NaCl solution ) .
# ::tok The resistance width of the knock out cells is slightly lower ( 0.20 % instead of 0.25 % NaCl solution ) .
# ::alignments 19-20|0.2 17-18|0.0 14-15|0 13-14|0.1.0.0.0 10-11|0.1.0.0 9-10|0.1.0.0.1 7-8|0.1.0.1.0 5-6|0.1.0.1 2-3|0.1.0 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:22.153
(i / instead-of-91 
      :ARG1 (p / percentage-entity) 
      :ARG1-of (r / resist-01 
            :mod-of (w / width 
                  :ARG1-of (l / low-04 
                        :ARG0 (p2 / percentage-entity) 
                        :degree (s2 / slight)) 
                  :topic (k / knock-01 
                        :ARG1 (c / cell)))) 
      :ARG2 (s / solution))

# ::snt We also performed direct measurements of the red blood cell membrane deformability , to further characterize a possible role of annexin A7 on the membrane stability .
# ::tok We also performed direct measurements of the red blood cell membrane deformability , to further characterize a possible role of annexin A7 on the membrane stability .
# ::alignments 25-26|0.0.0.2 24-25|0.0.0.2.0 21-22|0.0 20-21|0 18-19|0.0.0 17-18|0.0.0.1 15-16|0.0.0.0 14-15|0.0.0.0.1 10-11|0.0.0.0.0.0.0.0 9-10|0.0.0.0.0.0.0.0.0 8-9|0.0.0.0.0.0.0.0.0.0 7-8|0.0.0.0.0.0.0.0.1 4-5|0.0.0.0.0.0.0 3-4|0.0.0.0.0.0.0.1 2-3|0.0.0.0.0.0 1-2|0.0.0.0.0.0.1 0-1|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:22.831
(a2 / annexin 
      :mod-of (a / A7 
            :poss-of (r / role 
                  :ARG1-of (c / characterize-01 
                        :ARG0 (w / we 
                              :ARG0-of (p2 / perform-02 
                                    :ARG1 (m3 / measure-01 
                                          :ARG1 (m2 / membrane 
                                                :mod (c2 / cell 
                                                      :mod (b / blood)) 
                                                :mod (r2 / red)) 
                                          :ARG1-of (d / direct-02)) 
                                    :mod (a3 / also))) 
                        :degree (f / further)) 
                  :ARG1-of (p / possible-01) 
                  :topic (s / stability 
                        :mod (m / membrane)))))

# ::snt With micropipette experiments we tried to correlate mechanical characteristics of the red blood cells with their morphology .
# ::tok With micropipette experiments we tried to correlate mechanical characteristics of the red blood cells with their morphology .
# ::alignments 16-17|0.1.0.0.0.2 13-14|0.1.0.0.0 12-13|0.1.0.0.0.0 11-12|0.1.0.0.0.1 8-9|0.1.0.0+0.1.0 7-8|0.0.0.0 6-7|0.1 4-5|0 3-4|0.0 2-3|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:23.768
(t2 / try-01 
      :ARG0 (w / we 
            :ARG0-of (e / experiment-01 
                  :ARG1 (m2 / mechanics))) 
      :ARG1 (c3 / correlate-01 
            :ARG1 (t / thing 
                  :ARG2-of (c2 / characteristic-02 
                        :ARG1 (c / cell 
                              :mod (b / blood) 
                              :mod (r / red) 
                              :part-of (m / morphology)))) 
            :ARG0 w))

# ::snt We could not observe any statistically significant difference of values describing membrane rigidity and lysis force in these experiments ( M. Heil , B. Hoffmann and R. Merkel , unpublished results ) .
# ::tok We could not observe any statistically significant difference of values describing membrane rigidity and lysis force in these experiments ( M. Heil , B. Hoffmann and R. Merkel , unpublished results ) .
# ::alignments 30-31|0+0.0 29-30|0.0.0 26-28|0.1.1.4.0.1+0.1.1.4.0.0+0.1.1.4.0+0.1.1.4 25-26|0.1 23-25|0.1.1.3.0.1+0.1.1.3.0.0+0.1.1.3.0+0.1.1.3 20-22|0.1.0.0.1+0.1.0.0.0+0.1.0.0+0.1.0 18-19|0.1.1.0 17-18|0.1.1.0.0 15-16|0.1.1.2 14-15|0.1.1.2.0 13-14|0.1.1 12-13|0.1.1.1.1 11-12|0.1.1.1.1.0 10-11|0.1.1.1 9-10|0.1.1.1.0 7-8|0.1.1.1.0.0 6-7|0.1.1.1.0.0.1 5-6|0.1.1.1.0.0.1.0 4-5|0.1.1.1.0.0.2 3-4|0.1.1.1.0.0.0 2-3|0.1.1.1.0.0.0.1.0 1-2|0.1.1.1.0.0.0.1 0-1|0.1.1.1.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:32.095
(r / result-01 
      :ARG2 (t / thing 
            :mod (u / unpublish)) 
      :op2-of (a / and 
            :op1 (p3 / person 
                  :name (n3 / name 
                        :op1 "M." 
                        :op2 "Heil")) 
            :op3-of (a2 / and 
                  :ARG1-of (e / experiment-01 
                        :mod (t2 / this)) 
                  :ARG1-of (d / describe-01 
                        :ARG0 (v / value 
                              :ARG1-of (d2 / differ-02 
                                    :ARG1-of (o / observe-01 
                                          :ARG0 (w / we) 
                                          :ARG1-of (p4 / possible-01 
                                                :polarity -)) 
                                    :ARG1-of (s / significant-02 
                                          :mod (s2 / statistics)) 
                                    :mod (a3 / any))) 
                        :ARG2 (r2 / rigidity 
                              :mod (m / membrane))) 
                  :op1 (f / force 
                        :mod (l / lysi)) 
                  :op2 (p2 / person 
                        :name (n2 / name 
                              :op1 "B." 
                              :op2 "Hoffmann")) 
                  :op4 (p / person 
                        :name (n / name 
                              :op1 "R." 
                              :op2 "Merkel")))))

# ::snt However , the distinction observed in the osmotic resistance experiments was highly significant and reflects a mean value over a high number of different red blood cells .
# ::tok However , the distinction observed in the osmotic resistance experiments was highly significant and reflects a mean value over a high number of different red blood cells .
# ::alignments 26-27|0.0.0.1 25-26|0.0.0.1.1 24-25|0.0.0.1.2 23-24|0.0.0.1.0 21-22|0.0.0 20-21|0.0.0.0 17-18|0.0 16-17|0 14-15|0.0.1 13-14|0.0.1.1 12-13|0.0.1.0.0 11-12|0.0.1.0.0.0 9-10|0.0.1.0.1.0 8-9|0.0.1.0.1.0.0 7-8|0.0.1.0.1.0.1 4-5|0.0.1.0.1 3-4|0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:32.686
(m / mean-01 
      :ARG1 (v / value-01 
            :ARG1 (n / number 
                  :ARG1-of (h / high-02) 
                  :mod (c / cell 
                        :ARG1-of (d / differ-02) 
                        :mod (b / blood) 
                        :mod (r / red))) 
            :ARG2-of (r2 / reflect-01 
                  :ARG1 (d2 / distinguish-01 
                        :ARG1-of (s / significant-02 
                              :degree (h2 / high)) 
                        :ARG1-of (o2 / observe-01 
                              :ARG2 (e / experiment-01 
                                    :ARG1 (r3 / resist-01) 
                                    :mod (o / osmotic)))) 
                  :op1-of (a / and))))

# ::snt Osmotic resistance curves of red blood cells from wild type and anxA7 - / - mutant mice .
# ::tok Osmotic resistance curves of red blood cells from wild type and anxA7 - / - mutant mice .
# ::alignments 16-17|0.0.0 15-16|0.0 13-14|0.1 11-12|0.2.0.1 10-11|0.2.0 9-10|0.2.0.0 8-9|0.2.0.0.0 6-7|0.2.1 5-6|0.2.1.0 4-5|0.2.1.1 2-3|0.2 1-2|0 0-1|0.2.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:33.249
(r2 / resist-01 
      :ARG0 (m2 / mutant 
            :mod-of (m / mouse)) 
      :ARG1 (s / slash) 
      :mod-of (c2 / curve-01 
            :ARG0 (a2 / and 
                  :op1 (t / type 
                        :mod (w / wild)) 
                  :op2 (a / anxA7)) 
            :ARG1 (c / cell 
                  :mod (b / blood) 
                  :mod (r / red)) 
            :mod (o / osmotic)))

# ::snt The osmotic resistance towards changes in the extracellular ionic strength is a convenient assay for analysis of the red blood cell integrity .
# ::tok The osmotic resistance towards changes in the extracellular ionic strength is a convenient assay for analysis of the red blood cell integrity .
# ::alignments 21-22|0.0.0.0 20-21|0.0.0.0.0 19-20|0.0.0.0.0.0 18-19|0.0.0.0.1 15-16|0.0.0 13-14|0.0.0.1 12-13|0.0.0.1.0 9-10|0.0 8-9|0 7-8|0.0.2 4-5|0.0.1 2-3|0.0.1.0 1-2|0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:34.081
(i2 / ionic 
      :mod-of (s / strength 
            :ARG0-of (a / analyze-01 
                  :ARG1 (i / integrity 
                        :mod (c / cell 
                              :mod (b / blood)) 
                        :mod (r / red)) 
                  :purpose-of (a2 / assay 
                        :mod (c2 / convenient))) 
            :ARG1-of (c3 / change-01 
                  :ARG2-of (r2 / resist-01 
                        :mod (o / osmotic))) 
            :mod (e / extracellular)))

# ::snt It is measured as a sodium chloride concentration in which cellular lysis starts ( minimal resistance ) up to a complete lysis ( maximal resistance ) of a red blood cell .
# ::tok It is measured as a sodium chloride concentration in which cellular lysis starts ( minimal resistance ) up to a complete lysis ( maximal resistance ) of a red blood cell .
# ::alignments 30-31|0.0.0.0.1.1.1.0 29-30|0.0.0.0.1.1.1.0.0 28-29|0.0.0.0.1.1.1 24-25|0 23-24|0.1 21-22|0.0.0.0.1.1.0 20-21|0.0.0.0.1.1.0.0 15-16|0.0.0.0.1.1 14-15|0.0.0.0.1.1.2 12-13|0.0.0.0.1 11-12|0.0.0.0.1.0 10-11|0.0.0.0.1.0.0 7-8|0.0.0.0 6-7|0.0.0.0.0 5-6|0.0.0.0.0.0 2-3|0.0.0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:37.898
(r2 / resist-01 
      :ARG0 (i / it 
            :ARG1-of (m3 / measure-01 
                  :prep-as (c4 / concentrate-02 
                        :ARG1 (c5 / chloride 
                              :mod (s2 / sodium)) 
                        :ARG2-of (s / start-01 
                              :ARG0 (l2 / lysi 
                                    :mod (c3 / cell)) 
                              :ARG1 (r3 / resist-01 
                                    :ARG0 (l / lysi 
                                          :ARG1-of (c2 / complete-02)) 
                                    :ARG1 (r / red 
                                          :mod-of (c / cell 
                                                :mod (b / blood))) 
                                    :ARG1-of (m2 / minimal-02)))))) 
      :degree (m / maximum))

# ::snt The osmotic resistance of annexin A7 deficient red blood cells is significantly increased compared to the one of wild type ( p = 0.00066 ; n = 8 ) .
# ::tok The osmotic resistance of annexin A7 deficient red blood cells is significantly increased compared to the one of wild type ( p = 0.00066 ; n = 8 ) .
# ::alignments 27-28|0.0.1.0 25-26|0.1 24-25|0 19-20|0.0.2.0.0 18-19|0.0.2.0 13-14|0.0.0 12-13|0.0 11-12|0.0.2 9-10|0.0.1.1 8-9|0.0.1.1.0 7-8|0.0.0.0 6-7|0.0.0.0.0 2-3|0.0.1 1-2|0.0.1.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:38.818
(a / and 
      :op1 (i / increase-01 
            :ARG0 (c / compare-01 
                  :ARG2 (r / red 
                        :mod (d / deficient))) 
            :ARG1 (r2 / resist-01 
                  :ARG0 8 
                  :ARG1 (c2 / cell 
                        :mod (b / blood)) 
                  :mod (o / osmotic)) 
            :ARG2 (s / significant-02 
                  :ARG1 (w / wild 
                        :mod-of (t / type)))) 
      :op2 (n / n))

# ::snt These data suggest that annexin A7 contributes to the shape of red blood cells and the osmotic resistance .
# ::tok These data suggest that annexin A7 contributes to the shape of red blood cells and the osmotic resistance .
# ::alignments 17-18|0.1.1.1.0 16-17|0.1.1.1.0.0 14-15|0.1.1.1 13-14|0.1.1.0 12-13|0.1.1.0.0 11-12|0.1.1.0.1 9-10|0.1.1 6-7|0.1 5-6|0.1.0 4-5|0.1.0.0 2-3|0 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:40.157
(s2 / suggest-01 
      :ARG0 (d / data 
            :mod (t / this)) 
      :ARG1 (c2 / contribute-01 
            :ARG0 (a2 / A7 
                  :mod (a3 / annexin)) 
            :ARG2 (s / shape-01 
                  :ARG1 (c / cell 
                        :mod (b / blood) 
                        :mod (r2 / red)) 
                  :op1-of (a / and 
                        :op2 (r / resist-01 
                              :ARG1 (o / osmotic))))))

# ::snt As we have not observed a binding of annexin A7 to F-actin ( data not shown ) it could do so either by alteration of the membrane rigidity and/or by affecting the ion homeostasis .
# ::tok As we have not observed a binding of annexin A7 to F-actin ( data not shown ) it could do so either by alteration of the membrane rigidity and/or by affecting the ion homeostasis .
# ::alignments 33-34|0.0.1.0.0 32-33|0.0.1.0.0.0 30-31|0.0.1.0 27-28|0.0.1 26-27|0.0.1.1 23-24|0.0.1.0.1 21-22|0.0.0.0.1.0.0 19-20|0.0 18-19|0 15-16|0.0.0.0.1.0.1 14-15|0.0.0.0.1.0.1.1 13-14|0.0.0.0.1.0.1.0 11-12|0.0.0.0.1.1.0+0.0.0.0.1.1+0.0.0.0.1 9-10|0.0.0.0.0 8-9|0.0.0.0.0.0 6-7|0.0.0.0.1.0 4-5|0.0.0.0 3-4|0.0.0.0.2 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:43.695
(p / possible-01 
      :ARG1 (d / do-02 
            :ARG0 (w / we 
                  :ARG0-of (o / observe-01 
                        :ARG1 (a3 / A7 
                              :mod (a4 / annexin)) 
                        :ARG2 (t / thing 
                              :ARG4-of (b / binding-07 
                                    :ARG0 (e / either) 
                                    :ARG1 (s / show-01 
                                          :ARG1 (d2 / data) 
                                          :polarity -)) 
                              :name (n / name 
                                    :op1 "F-actin")) 
                        :polarity -)) 
            :ARG1 (r / rigidity 
                  :ARG0-of (a / affect-01 
                        :ARG1 (h / homeostasi 
                              :mod (i / ion)) 
                        :ARG2 (a2 / alteration)) 
                  :mod (m / membrane))))

# ::snt The lack of annexin A7 affects primary haemostasis ex vivo .
# ::tok The lack of annexin A7 affects primary haemostasis ex vivo .
# ::alignments 9-10|0.2.0 8-9|0.2 7-8|0.1 6-7|0.1.0 5-6|0 4-5|0.0.0 3-4|0.0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:44.274
(a / affect-01 
      :ARG0 (l / lack-01 
            :ARG1 (a2 / A7 
                  :mod (a3 / annexin))) 
      :ARG1 (h / haemostasi 
            :mod (p / primary)) 
      :ARG2 (e / ex 
            :mod-of (v / vivo)))

# ::snt The use of an advanced electronic cell counter/flow cytometer ( ADVIA 120 ) allowed us to screen other parameters as well despite of the limited murine blood volume .
# ::tok The use of an advanced electronic cell counter/flow cytometer ( ADVIA 120 ) allowed us to screen other parameters as well despite of the limited murine blood volume .
# ::alignments 27-28|0.1.0.0.0.1 26-27|0.1.0.0.0.2 25-26|0.1.0.0.0.0 24-25|0.1.0.0.0 18-19|0.1.0.1.0.0 17-18|0.1.0.1.0.0.0 16-17|0.1 13-14|0 11-12|0.0 10-11|0.1.0.0.1.0+0.1.0.0.1+0.1.0.0 8-9|0.1.0.1 6-7|0.1.0.1.1 5-6|0.1.0.1.1.0 4-5|0.1.0.1.0 1-2|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:49.000
(a / allow-01 
      :ARG0 120 
      :ARG1 (s / screen 
            :ARG2-of (u / use-01 
                  :ARG0 (o2 / organization 
                        :ARG0-of (l / limit-01 
                              :ARG1 (m / murine) 
                              :ARG2 (v / volume) 
                              :ARG3 (b / blood)) 
                        :name (n / name 
                              :op1 "ADVIA")) 
                  :ARG1 (c / cytomet 
                        :ARG1-of (a2 / advanced-02 
                              :ARG0 (p / parameter 
                                    :mod (o / other))) 
                        :mod (c2 / cell 
                              :mod (e / electronic))))))

# ::snt We analysed leukocytes , red blood cells , haemoglobin content , haematocrit , mean cellular volume , mean cellular haemoglobin , mean cellular haemoglobin concentration , platelets , neutrophiles , lymphocytes , monocytes , eosinophiles and basophiles .
# ::tok We analysed leukocytes , red blood cells , haemoglobin content , haematocrit , mean cellular volume , mean cellular haemoglobin , mean cellular haemoglobin concentration , platelets , neutrophiles , lymphocytes , monocytes , eosinophiles and basophiles .
# ::alignments 36-37|0.0.1.1.0.4 35-36|0.0.1.1.0 34-35|0.0.1.1.0.3 32-33|0.0.1.1.0.2 30-31|0.0.1.1.0.1 28-29|0.0.1.1.0.0 26-27|0.0.1.1 24-25|0.0 23-24|0 22-23|0.0.1.0.0.0.0.0 21-22|0.0.1 19-20|0.0.1.0 18-19|0.0.1.0.1 17-18|0.0.1.0.0 15-16|0.0.1.0.0.0.2 14-15|0.0.1.0.0.0.2.0 13-14|0.0.1.0.0.0 11-12|0.0.1.0.0.0.1 9-10|0.0.3.0 8-9|0.0.3 6-7|0.0.2.0 5-6|0.0.2 4-5|0.0.2.0.0 2-3|0.0.0 0-1|0.0.1.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:52.054
(h / haemoglobin 
      :ARG1-of (c / concentrate-02 
            :ARG0 (l2 / leukocyt) 
            :ARG2-of (m2 / mean-01 
                  :ARG0 (h2 / haemoglobin 
                        :ARG2-of (m3 / mean-01 
                              :ARG1 (m4 / mean-01 
                                    :ARG0 (w / we 
                                          :poss-of (c2 / cell)) 
                                    :ARG1 (h3 / haematocrit) 
                                    :ARG2 (v / volume 
                                          :mod (c4 / cell)))) 
                        :mod (c3 / cell)) 
                  :ARG1 (p / platelet 
                        :op1-of (a / and 
                              :op2 (n / neutrophil) 
                              :op3 (l / lymphocyt) 
                              :op4 (m / monocyt) 
                              :op5 (e / eosinophil) 
                              :op6 (b / basophil)))) 
            :location (b2 / blood 
                  :mod-of (c6 / cell 
                        :mod (r / red))) 
            :location (h4 / haemoglobin 
                  :mod-of (c5 / content))))

# ::snt In these tests of whole blood we found only a change in the platelet numbers , whereas all other haematological parameters were not affected .
# ::tok In these tests of whole blood we found only a change in the platelet numbers , whereas all other haematological parameters were not affected .
# ::alignments 23-24|0.3 22-23|0.3.2 20-21|0.3.0 19-20|0.3.0.1 18-19|0.3.0.0 17-18|0.3.0.2 16-17|0.3.1 14-15|0.1.0 13-14|0.1.0.0 10-11|0.1 8-9|0.2 7-8|0 6-7|0.0 5-6|0.0.0.0 4-5|0.0.0.0.0 2-3|0.0.0 1-2|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:52.947
(f / find-01 
      :ARG0 (w2 / we 
            :ARG0-of (t / test-01 
                  :ARG1 (b / blood 
                        :mod (w3 / whole)) 
                  :mod (t2 / this))) 
      :ARG1 (c / change-01 
            :ARG1 (n / number 
                  :mod (p2 / platelet))) 
      :location (o2 / only) 
      :time (a / affect-01 
            :ARG1 (p / parameter 
                  :mod (o / other) 
                  :mod (h / haematological) 
                  :quant (a2 / all)) 
            :op1-of (w / whereas) 
            :polarity -))

# ::snt The mean platelet counts from wild type and anxA7 - / - mutant mice are determined as 674  103/l and 774  103/l , respectively .
# ::tok The mean platelet counts from wild type and anxA7 - / - mutant mice are determined as 674  103/l and 774  103/l , respectively .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:52.969
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt The platelet counts in knock out mice are significantly higher ( p = 0.0275 ; n knock out = 11 , n wild type = 14 ) .
# ::tok The platelet counts in knock out mice are significantly higher ( p = 0.0275 ; n knock out = 11 , n wild type = 14 ) .
# ::alignments 25-26|0.0.0.0 23-24|0.0.1.0.0 22-23|0.0.1.0 19-20|0.1.0.0 16-17|0.1.0 15-16|0.1 14-15|0 9-10|0.0.1 8-9|0.0.1.1 6-7|0.0.0.1 4-5|0.0.0 2-3|0.0 1-2|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:54.163
(a / and 
      :ARG0-of (c / count-03 
            :ARG1 (k2 / knock-01 
                  :ARG0 14 
                  :ARG1 (m / mouse)) 
            :compared-to-of (h / high-02 
                  :ARG1 (w / wild 
                        :mod-of (t / type)) 
                  :ARG1-of (s / significant-02)) 
            :mod (p / platelet)) 
      :op1 (n / n 
            :ARG1-of (k / knock-01 
                  :ARG0 11)))

# ::snt An increase in platelet counts is a rather uncommon disorder .
# ::tok An increase in platelet counts is a rather uncommon disorder .
# ::alignments 9-10|0 8-9|0.1 4-5|0.0.0 3-4|0.0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:54.447
(d / disord 
      :ARG0-of (i / increase-01 
            :ARG1 (c2 / count-03 
                  :ARG1 (p / platelet))) 
      :mod (c / common))

# ::snt In humans , platelet counts normally increase only transiently as in reactive thrombocytosis and under postoperative conditions or are largely increased in neoplastic diseases .
# ::tok In humans , platelet counts normally increase only transiently as in reactive thrombocytosis and under postoperative conditions or are largely increased in neoplastic diseases .
# ::alignments 23-24|0.3.2 22-23|0.3.2.0 20-21|0.3 19-20|0.3.0 17-18|0.3.1 16-17|0.3.1.0.0 15-16|0.3.1.0 13-14|0.4 12-13|0.0.0.0 11-12|0.0.0 8-9|0.1 7-8|0.1.0 6-7|0 5-6|0.2 4-5|0.0 3-4|0.0.1 1-2|0.5 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:56.177
(i2 / increase-01 
      :ARG0 (c2 / count-03 
            :ARG0 (r / reactive 
                  :mod-of (t / thrombocytosi)) 
            :ARG1 (p2 / platelet)) 
      :ARG1 (t2 / transiently 
            :mod (o2 / only)) 
      :ARG1-of (n2 / normal-02) 
      :ARG1-of (i / increase-01 
            :ARG2 (l / large) 
            :op1-of (o / or 
                  :poss-of (p / postoperative 
                        :mod-of (c / condition))) 
            :time (d / disease 
                  :mod (n / neoplastic))) 
      :location (a / and) 
      :time (h / human))

# ::snt By contrast , the anxA7 - / - mice are healthy and viable .
# ::tok By contrast , the anxA7 - / - mice are healthy and viable .
# ::alignments 12-13|0.1 11-12|0 10-11|0.1.0.0 8-9|0.1.0 6-7|0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:56.283
(a / and 
      :op1 (c / contrast-01 
            :ARG1 (s / slash)) 
      :op2 (v / viable 
            :domain (m / mouse 
                  :domain-of (h / healthy))))

# ::snt Therefore we tested the platelet function and performed aggregometry measurements with platelet rich plasma .
# ::tok Therefore we tested the platelet function and performed aggregometry measurements with platelet rich plasma .
# ::alignments 13-14|0.1.0.1 12-13|0.1.0.1.0 11-12|0.1.0.1.1 9-10|0.1.0 8-9|0.1.0.0 7-8|0.1 6-7|0 5-6|0.0.0.0 4-5|0.0.0.0.0 2-3|0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:56.522
(a2 / and 
      :op1 (t / test-01 
            :ARG0 (w / we 
                  :ARG0-of (f / function-01 
                        :ARG1 (p4 / platelet)))) 
      :op2 (p3 / perform-02 
            :ARG1 (m / measure-01 
                  :ARG1 (a / aggregometry) 
                  :ARG2 (p / plasma 
                        :mod (r / rich) 
                        :mod (p2 / platelet)))))

# ::snt Platelet activation is observed as a morphological change from the resting discoid state to activated spherical cells with pseudopods .
# ::tok Platelet activation is observed as a morphological change from the resting discoid state to activated spherical cells with pseudopods .
# ::alignments 18-19|0.0.0.0.2.0.0 16-17|0.0 15-16|0 14-15|0.0.0 12-13|0.0.0.0.2 11-12|0.0.0.0.2.1 10-11|0.0.0.0.2.0 7-8|0.0.0.0 6-7|0.0.0.0.0 3-4|0.0.0.0.1 1-2|0.0.0.0.1.0 0-1|0.0.0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:56.860
(s / spherical 
      :mod-of (c / cell 
            :ARG1-of (a / activate-01 
                  :purpose-of (c2 / change-01 
                        :ARG1 (m / morphological) 
                        :ARG2-of (o / observe-01 
                              :ARG1 (a2 / activation 
                                    :mod (p2 / platelet))) 
                        :source (s2 / state 
                              :ARG1-of (r / rest-01 
                                    :op1-of (p / pseudopod)) 
                              :mod (d / discoid))))))

# ::snt The morphological changes are due to cytoskeletal rearrangements .
# ::tok The morphological changes are due to cytoskeletal rearrangements .
# ::alignments 7-8|0.1 6-7|0 2-3|0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:56.958
(c / cytoskeletal 
      :ARG0-of (c2 / change-01 
            :ARG1 (m / morphological)) 
      :mod-of (r / rearrangement))

# ::snt In vitro the activated cells form aggregates recruiting additional cells in the solution thereby reducing its cloudiness .
# ::tok In vitro the activated cells form aggregates recruiting additional cells in the solution thereby reducing its cloudiness .
# ::alignments 16-17|0.0.1 14-15|0.0 13-14|0 12-13|0.0.0 9-10|0.0.0.0.1 8-9|0.0.0.0.1.0 7-8|0.0.0.0 6-7|0.0.0.0.0.1 5-6|0.0.0.0.0.2 4-5|0.0.0.0.0 3-4|0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:07:59.762
(t / thereby 
      :manner-of (r / reduce-01 
            :ARG0 (s / solution 
                  :ARG2-of (r2 / recruit-01 
                        :ARG0 (c3 / cell 
                              :ARG1-of (a3 / activate-01) 
                              :ARG1-of (a2 / aggregate-01) 
                              :mod-of (f / form)) 
                        :ARG1 (c2 / cell 
                              :mod (a / additional)))) 
            :ARG1 (c / cloudines)))

# ::snt Analysis of the transmission values of aggregation curves after platelet activation by ristocetin addition ( von Willebrand cofactor ) showed that both curves differed significantly at the time point of seven seconds after platelet initiation ( p = 0.0287 , n knock out = 16 , n wild type = 15 ; Fig. 6 ) .
# ::tok Analysis of the transmission values of aggregation curves after platelet activation by ristocetin addition ( von Willebrand cofactor ) showed that both curves differed significantly at the time point of seven seconds after platelet initiation ( p = 0.0287 , n knock out = 16 , n wild type = 15 ; Fig. 6 ) .
# ::alignments 53-54|0.0.0.0.0.1.0.1 52-53|0.2.0.0+0.2.0+0.2 51-52|0 50-51|0.1 48-49|0.0.0.1.0 47-48|0.0.0.1 44-45|0.0.0.0.1.1.0.2.1 41-42|0.0.0.0.1.1.0.2 34-35|0.0.0.0.0.1.1 33-34|0.0.0.0.0.1.1.0 32-33|0.0.0.0.0.1 31-32|0.0.0.0.0.1.0.2+0.0.0.0.0.1.0 30-31|0.0.0.0.0.1.0.0 28-29|0.0.0.0.0 27-28|0.0.0.0.0.0 24-25|0.0.0.0.2 23-24|0.0.0.0 22-23|0.0.0 21-22|0.0 19-20|0.0.0.0.1 17-18|0.0.0.0.1.1.0.2.0 15-17|0.0.0.0.1.1.0.2.0.0.0.1+0.0.0.0.1.1.0.2.0.0.0.0+0.0.0.0.1.1.0.2.0.0.0+0.0.0.0.1.1.0.2.0.0 13-14|0.0.0.0.2.0 12-13|0.0.0.0.2.0.0 10-11|0.0.0.0.1.0 9-10|0.0.0.0.1.0.0 8-9|0.0.0.0.1.1 7-8|0.0.0.0.1.1.0 6-7|0.0.0.0.1.1.0.1 4-5|0.0.0.0.1.1.0.0.0 3-4|0.0.0.0.1.1.0.0.0.0 0-1|0.0.0.0.1.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:09.702
(a / and 
      :mod (b / both 
            :mod-of (c2 / curve-01 
                  :ARG0-of (d / differ-01 
                        :ARG1 (p2 / point 
                              :mod (t3 / time) 
                              :time (a2 / after 
                                    :duration (t2 / temporal-quantity 
                                          :quant 7 
                                          :quant 6 
                                          :unit (s / second)) 
                                    :op1 (i / initiation 
                                          :mod (p / platelet)))) 
                        :ARG1-of (s3 / show-01 
                              :ARG0 (a4 / activation 
                                    :mod (p3 / platelet)) 
                              :op1-of (a5 / after 
                                    :time-of (c4 / curve-01 
                                          :ARG0 (a7 / analysi 
                                                :poss (v2 / value 
                                                      :mod (t5 / transmission))) 
                                          :ARG1 (a6 / aggregation) 
                                          :ARG2 (k / knock-01 
                                                :ARG0 (c3 / cofactor 
                                                      :mod (t4 / thing 
                                                            :name (n2 / name 
                                                                  :op1 (v / von) 
                                                                  :op2 (w2 / Willebrand)))) 
                                                :ARG1 16)))) 
                        :ARG2 (s2 / significant-02 
                              :ARG1 (a3 / addition 
                                    :mod (r / ristocetin)))) 
                  :ARG1 (w / wild 
                        :mod-of (t / type)))) 
      :op1 15 
      :op2 (c / country 
            :name (n / name 
                  :op1 "Fig.")))

# ::snt Annexin A7 deficient platelets showed a slightly lowered aggregation velocity .
# ::tok Annexin A7 deficient platelets showed a slightly lowered aggregation velocity .
# ::alignments 9-10|0.1 8-9|0.1.1 7-8|0.1.0 6-7|0.1.0.0 4-5|0 3-4|0.0 2-3|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:09.833
(s2 / show-01 
      :ARG0 (p / platelet 
            :mod (d / deficient)) 
      :ARG1 (v / velocity 
            :ARG1-of (l / lower-05 
                  :degree (s / slight)) 
            :mod (a / aggregation)))

# ::snt When we compared the aggregation curves of human platelets from a healthy donor with the ones obtained from an individual with a von Willebrand factor type 1 defect , we found that the difference in the curves was much more pronounced as observed in our studies of healthy mouse platelets and anxA7 - / - platelets .
# ::tok When we compared the aggregation curves of human platelets from a healthy donor with the ones obtained from an individual with a von Willebrand factor type 1 defect , we found that the difference in the curves was much more pronounced as observed in our studies of healthy mouse platelets and anxA7 - / - platelets .
# ::alignments 55-56|0.0.0.0.0.0.0.1.0.0.0 53-54|0.0.0.0.0.0.0.1.0.0.1.0 51-52|0.0.0.0.0.0.0.1.1.2.1 50-51|0.0.0.0.0.0.0.1.1.2 49-50|0.0.0.0.0.0.0.1.1.2.0 48-49|0.0.0.0.0.0.0.1.1.2.0.1 47-48|0.0.0.0.0.0.0.1.1.2.0.0 45-46|0.0.0.0.0.0.0.1.1 44-45|0.0.0.0.0.0.0.1.1.0 42-43|0.0.0.0.0.0.0.1.1.1 40-41|0.0.0.0.0.0.0.1.0.0.1.1 39-40|0.0.0.0.0.0.0.1.0.0.1.1.0 38-39|0.0.0.0.0.0.0.1.0.0.1.1.0.0 36-37|0.0.0.0.0.0.0.1.0.0 33-34|0.0.0.0.0.0.0.1.0.0.1 30-31|0.0.0.0.0.0.0.1 29-30|0.0.0.0.0.0.0.1.0 27-28|0.0.0.0 26-27|0.0.0.0.0.0.0.0.0 25-26|0.0 24-25|0 22-24|0.0.0.1.1+0.0.0.1.0+0.0.0.1+0.0.0 19-20|0.0.0.0.0.2 16-17|0.0.0.0.0 15-16|0.0.0.0.0.1 12-13|0.0.0.0.0.0.1 11-12|0.0.0.0.0.0.1.0 8-9|0.0.0.0.0.0.0.0.1 7-8|0.0.0.0.0.0.0.0.1.0 5-6|0.0.0.0.0.0.0.0 4-5|0.0.0.0.0.0.0.0.2 2-3|0.0.0.0.0.0.0 1-2|0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:19.045
(f2 / factor 
      :mod-of (t / type 
            :mod (t2 / thing 
                  :ARG1-of (d2 / defect-01 
                        :manner-of (o2 / obtain-01 
                              :ARG0 (w4 / we 
                                    :ARG0-of (c3 / compare-01 
                                          :ARG1 (c2 / curve-01 
                                                :ARG0 1 
                                                :ARG1 (p4 / platelet 
                                                      :mod (h3 / human)) 
                                                :mod (a3 / aggregation)) 
                                          :time-of (f / find-01 
                                                :ARG0 (w2 / we 
                                                      :ARG0-of (c / curve-01 
                                                            :ARG1 (p / platelet) 
                                                            :prep-in-of (d / differ-02 
                                                                  :ARG1 (s / slash) 
                                                                  :ARG1-of (p3 / pronounce-01 
                                                                        :degree (m2 / more 
                                                                              :degree (m3 / much)))))) 
                                                :ARG1 (s2 / study-01 
                                                      :ARG1 (w / we) 
                                                      :ARG2-of (o / observe-01) 
                                                      :op1-of (a2 / and 
                                                            :op2 (p2 / platelet 
                                                                  :mod (h / healthy) 
                                                                  :mod (m / mouse)) 
                                                            :op3 (a / anxA7))))) 
                                    :poss-of (d3 / donor 
                                          :mod (h2 / healthy))) 
                              :ARG1 (o3 / one) 
                              :ARG2 (i / individual))) 
                  :name (n / name 
                        :op1 (v / von) 
                        :op2 (w3 / Willebrand)))))

# ::snt Furthermore we found that murine platelets responded immediately to the initiating chemical whereas human platelets have a lag phase [ 23 ] .
# ::tok Furthermore we found that murine platelets responded immediately to the initiating chemical whereas human platelets have a lag phase [ 23 ] .
# ::alignments 20-21|0.1.1.0.0 18-19|0.1.1.0.1.1 17-18|0.1.1.0.1 14-15|0.1.1.0.1.0 13-14|0.1.1.0.1.0.0 12-13|0.1.3 11-12|0.1.1 10-11|0.1.1.0 7-8|0.1.2 6-7|0.1 5-6|0.1.0 4-5|0.1.0.0 2-3|0 1-2|0.0 0-1|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:20.577
(f / find-01 
      :ARG0 (w2 / we) 
      :ARG1 (r / respond-01 
            :ARG0 (p3 / platelet 
                  :mod (m / murine)) 
            :ARG1 (c / chemical 
                  :ARG1-of (i / initiate-01 
                        :ARG0 23 
                        :ARG1-of (l / lag-01 
                              :ARG0 (p2 / platelet 
                                    :mod (h / human)) 
                              :mod-of (p / phase)))) 
            :time (i2 / immediate) 
            :time (w / whereas)) 
      :location (f2 / furthermore))

# ::snt Platelet aggregation curves from platelet rich plasma of annexin A7 knock out and wild type mice .
# ::tok Platelet aggregation curves from platelet rich plasma of annexin A7 knock out and wild type mice .
# ::alignments 15-16|0.2 14-15|0.2.0 13-14|0.2.1 12-13|0 10-11|0.1 9-10|0.1.1 8-9|0.1.1.0 6-7|0.1.0 5-6|0.1.0.0 4-5|0.1.0.1 2-3|0.0 1-2|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:21.463
(a / and 
      :ARG1-of (c / curve-01 
            :ARG0 (a4 / aggregation 
                  :mod (p3 / platelet))) 
      :op1 (k / knock-01 
            :ARG0 (p / plasma 
                  :mod (r / rich) 
                  :mod (p2 / platelet)) 
            :ARG1 (a2 / A7 
                  :mod (a3 / annexin))) 
      :op2 (m / mouse 
            :mod (t / type) 
            :mod (w / wild)))

# ::snt The transmission values were measured with an APACT photometer and aggregation was initiated by adding ristocetin .
# ::tok The transmission values were measured with an APACT photometer and aggregation was initiated by adding ristocetin .
# ::alignments 15-16|0.0.0.1 14-15|0.0.0 12-13|0.0 10-11|0.2 9-10|0 8-9|0.1 7-8|0.1.0.0.0+0.1.0.0+0.1.0 4-5|0.0.1 2-3|0.0.1.0 1-2|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:22.110
(a3 / and 
      :ARG1-of (i / initiate-01 
            :ARG2 (a / add-02 
                  :ARG0 (t2 / transmission) 
                  :ARG1 (r / ristocetin)) 
            :time-of (m / measure-01 
                  :ARG1 (v / value))) 
      :op1 (p / photomet 
            :mod (t / thing 
                  :name (n / name 
                        :op1 "APACT"))) 
      :op2 (a2 / aggregation))

# ::snt The first thirty seconds are given .
# ::tok The first thirty seconds are given .
# ::alignments 5-6|0 3-4|0.0.0+0.0 2-3|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:22.167
(g / give-01 
      :ARG1 (t / temporal-quantity 
            :unit (s / second 
                  :mod (t2 / thirty))))

# ::snt Constant platelet counts were used throughout all experiments .
# ::tok Constant platelet counts were used throughout all experiments .
# ::alignments 7-8|0.1 6-7|0.1.1 5-6|0.1.0 4-5|0 2-3|0.0 1-2|0.0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:22.279
(u / use-01 
      :ARG1 (c / count-03 
            :mod (p / platelet) 
            :mod (c2 / constant)) 
      :ARG2 (e / experiment-01 
            :op1-of (t / throughout) 
            :quant (a / all)))

# ::snt The aggregation curve data were analysed for slope values , the maximal aggregation amplitude of every single curve was set to 100 % .
# ::tok The aggregation curve data were analysed for slope values , the maximal aggregation amplitude of every single curve was set to 100 % .
# ::alignments 22-23|0.0.0.0.0.0 21-22|0.0.0.0.0.0.0 17-18|0.0.0.0.0 16-17|0.0.0.0.0.1 15-16|0.0.0.0.0.1.0 13-14|0.0.0.0.0.2 12-13|0.0.0.0.0.2.0 11-12|0.0.0.0.0.2.1 8-9|0.0.0.0.1 7-8|0.0.0.0 3-4|0.0 2-3|0.0.0 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:23.398
(a3 / aggregation 
      :source-of (d / data 
            :source (c2 / curve-01 
                  :ARG1 (s2 / slope-01 
                        :ARG0 (c / curve-01 
                              :ARG1 (p / percentage-entity 
                                    :value 100) 
                              :ARG1-of (s / single-02 
                                    :mod (e / every)) 
                              :poss-of (a / amplitude 
                                    :mod (a2 / aggregation) 
                                    :mod (m / maximum))) 
                        :mod-of (v / value)))))

# ::snt Both murine curves differ significantly at a time point of seven seconds after platelet initiation , the mutant shows a slightly lower aggregation velocity ( p = 0.0287 , n knock out = 16 , n wild type = 15 , mean knock out = 67.7 % transmission , mean wild type = 77.1 % transmission , standard error knock out = 8.3 % transmission , standard error wild type = 13.8 % transmission ) .
# ::tok Both murine curves differ significantly at a time point of seven seconds after platelet initiation , the mutant shows a slightly lower aggregation velocity ( p = 0.0287 , n knock out = 16 , n wild type = 15 , mean knock out = 67.7 % transmission , mean wild type = 77.1 % transmission , standard error knock out = 8.3 % transmission , standard error wild type = 13.8 % transmission ) .
# ::alignments 73-74|0.0.1.0.0.0.0 72-73|0.0.1.0.0.0 69-70|0.2.2.1.0.0 68-69|0.2.2.1.0 67-68|0.2.2.1 66-67|0.2.2 64-65|0.2.0 63-64|0.2.0.0 59-60|0.0.1.0.0 58-59|0.0.1.0 57-58|0.0.1.0.1 54-55|0.2.2.0 51-52|0.0.0.0 50-51|0.0.0.0.0 49-50|0.0.0 47-48|0.2.1 46-47|0.2.1.0 42-43|0.2 41-42|0 39-40|0.1.2 37-38|0.0.1.0.1.0.0 36-37|0.0.1.0.1.0 33-34|0.1.0.0.0.0.0 30-31|0.0.1 29-30|0.0 23-24|0.1.1 22-23|0.1.1.1 21-22|0.1.1.0 20-21|0.1.1.0.0 18-19|0.1 17-18|0.1.0 14-15|0.1.0.0.0.1.0 13-14|0.1.0.0.0.1.0.0 12-13|0.1.0.0.0.1 11-12|0.1.0.0.0.0.1.0.0+0.1.0.0.0.0.1.0 10-11|0.1.0.0.0.0.1 8-9|0.1.0.0.0.2 7-8|0.1.0.0.0.2.0 4-5|0.1.0.0.0.0 3-4|0.1.0.0.0 2-3|0.1.0.0 1-2|0.1.0.0.1 0-1|0.1.0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:40.966
(m2 / mean-01 
      :ARG0 (n / n 
            :ARG0-of (m / mean-01 
                  :ARG1 (t4 / type 
                        :mod (w2 / wild))) 
            :ARG0-of (k3 / knock-01 
                  :ARG1 (e2 / error 
                        :ARG0-of (k / knock-01 
                              :ARG1 (p / percentage-entity 
                                    :mod-of (t / transmission))) 
                        :ARG1-of (s2 / standard-02 
                              :ARG0 (w3 / wild 
                                    :mod-of (t6 / type)))))) 
      :ARG1 (s4 / show-01 
            :ARG0 (m3 / mutant 
                  :ARG0-of (c / curve-01 
                        :ARG1-of (d / differ-02 
                              :ARG2 (s6 / significant-02 
                                    :ARG0 16 
                                    :ARG1 (7 / 7 
                                          :quant-of (t7 / temporal-quantity 
                                                :unit (s5 / second)))) 
                              :time (a2 / after 
                                    :op1 (i / initiation 
                                          :mod (p5 / platelet))) 
                              :time (p6 / point 
                                    :mod (t8 / time))) 
                        :mod (m4 / murine) 
                        :mod (b / both))) 
            :ARG1 (v / velocity 
                  :ARG1-of (l / low-04 
                        :degree (s3 / slight)) 
                  :mod (a / aggregation)) 
            :ARG2 15) 
      :ARG2 (k2 / knock-01 
            :ARG0 (t3 / transmission 
                  :mod (p2 / percentage-entity)) 
            :ARG1 (t5 / transmission 
                  :mod (p4 / percentage-entity)) 
            :ARG2-of (s / standard-02 
                  :ARG0 (p3 / percentage-entity) 
                  :ARG1 (e / error 
                        :location (w / wild 
                              :mod-of (t2 / type))))))

# ::snt Murine platelets react immediately to the initiating chemical and show no lag phase like the normal human platelets .
# ::tok Murine platelets react immediately to the initiating chemical and show no lag phase like the normal human platelets .
# ::alignments 17-18|0.0.1.0.0 16-17|0.0.1.0.0.1 15-16|0.0.1.0.0.0 13-14|0.0.1.0 12-13|0.0.1 11-12|0.0.1.1 10-11|0.0.2 9-10|0.0 8-9|0 7-8|0.0.0.0.0 6-7|0.0.0.0.0.0 3-4|0.0.0.0.1 2-3|0.0.0.0 1-2|0.0.0 0-1|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:41.585
(a / and 
      :op1 (s / show-01 
            :ARG0 (p3 / platelet 
                  :ARG0-of (r2 / react-01 
                        :ARG1 (c / chemical 
                              :ARG1-of (i / initiate-01)) 
                        :time (i2 / immediate)) 
                  :mod (m / murine)) 
            :ARG1 (p2 / phase 
                  :ARG1-of (r / resemble-01 
                        :ARG2 (p / platelet 
                              :ARG1-of (n / normal-02) 
                              :mod (h / human))) 
                  :mod (l / lag-01)) 
            :polarity -))

# ::snt For comparison of the range of the platelet impairment slightly affected human platelets are shown as well ( von Willebrand syndrome ) .
# ::tok For comparison of the range of the platelet impairment slightly affected human platelets are shown as well ( von Willebrand syndrome ) .
# ::alignments 20-21|0.1.0.0.0 18-20|0.1.0.0.1.1+0.1.0.0.1.0+0.1.0.0.1+0.1.0.0 14-15|0 12-13|0.0 11-12|0.0.1 10-11|0.0.0 9-10|0.0.0.0 8-9|0.1.0.1 7-8|0.1.0.1.0 4-5|0.1.0 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:42.753
(s2 / show-01 
      :ARG1 (p / platelet 
            :ARG1-of (a / affect-01 
                  :manner (s3 / slight)) 
            :mod (h / human)) 
      :purpose (c / compare-01 
            :ARG1 (r / range-01 
                  :ARG0 (t / thing 
                        :mod-of (s / syndrome) 
                        :name (n / name 
                              :op1 (v / von) 
                              :op2 (w / Willebrand))) 
                  :ARG1 (i / impairment 
                        :mod (p2 / platelet)))))

# ::snt Annexin A7 is thought to have a role in vesicle fusion and in regulating and stabilizing membrane domains [ 1 ] .
# ::tok Annexin A7 is thought to have a role in vesicle fusion and in regulating and stabilizing membrane domains [ 1 ] .
# ::alignments 19-20|0.0.0.0 17-18|0.0.0.2.0.0 16-17|0.0.0.2.0.0.0 15-16|0.0.0 14-15|0.0.0.2 13-14|0.0.0.2.0 11-12|0.0.0.1 10-11|0.0.0.2.0.0.0.0 9-10|0.0.0.2.0.0.0.0.0 7-8|0.0.0.2.0.0.0.0.1 3-4|0 0-2|0.0.1.1+0.0.1.0+0.0.1+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:43.240
(t / think-01 
      :ARG1 (t2 / thing 
            :ARG0-of (s / stabilize-01 
                  :ARG1 1 
                  :op1-of (a2 / and) 
                  :op2-of (a / and 
                        :op1 (r / regulate-01 
                              :ARG1 (d / domain 
                                    :mod (m / membrane 
                                          :mod-of (f / fusion 
                                                :mod (v / vesicle) 
                                                :mod-of (r2 / role))))))) 
            :name (n / name 
                  :op1 (a3 / Annexin) 
                  :op2 (a4 / A7))))

# ::snt The protein has been localized to the plasma membrane including raft subdomains , furthermore it is present in the cytosol where it is found on subcellular vesicle-like structures .
# ::tok The protein has been localized to the plasma membrane including raft subdomains , furthermore it is present in the cytosol where it is found on subcellular vesicle-like structures .
# ::alignments 27-28|0.0.1 23-24|0.0 19-20|0 16-17|0.1 13-14|0.1.0 11-12|0.0.0.1 10-11|0.0.0 8-9|0.0.0.0.0.0 7-8|0.0.0.0.0.0.0 4-5|0.0.0.0.0 1-2|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:44.593
(c / cytosol 
      :ARG1-of (f / find-01 
            :manner-of (r / raft-01 
                  :ARG0 (p3 / protein 
                        :ARG1-of (l / localize-01 
                              :ARG2 (m / membrane 
                                    :mod (p2 / plasma)))) 
                  :ARG1 (s2 / subdomain)) 
            :medium (s / structure)) 
      :location-of (p / present 
            :mod (f2 / furthermore)))

# ::snt This distribution appears to be independent of the tissue or cell type analysed .
# ::tok This distribution appears to be independent of the tissue or cell type analysed .
# ::alignments 11-12|0.0.0 10-11|0.0.0.0 9-10|0.0.0.0.0 8-9|0.0.0.0.0.0 5-6|0.0.2+0.0 2-3|0 1-2|0.0.1 0-1|0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:45.448
(a / appear-02 
      :ARG1 (d / depend-01 
            :ARG1 (t / type 
                  :mod (c / cell 
                        :op2-of (o / or 
                              :op1 (t2 / tissue)))) 
            :ARG2 (d2 / distribute-01 
                  :mod (t3 / this)) 
            :polarity -))

# ::snt In specialized or terminally differentiated cells , expression levels increase and frequently the larger of the two isoforms is being expressed [ 6,34,35 ] .
# ::tok In specialized or terminally differentiated cells , expression levels increase and frequently the larger of the two isoforms is being expressed [ 6,34,35 ] .
# ::alignments 20-21|0.2 17-18|0.2.0 16-17|0.2.0.0 13-14|0.1.1.0.0 11-12|0.2.1 10-11|0 9-10|0.1 8-9|0.1.0 7-8|0.0 5-6|0.1.1 4-5|0.1.1.1 3-4|0.1.1.2.0 2-3|0.1.1.2 1-2|0.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:46.946
(a / and 
      :op1 (e2 / express-01) 
      :op2 (i2 / increase-01 
            :ARG1 (l2 / level) 
            :time (c / cell 
                  :ARG1-of (s / specialize-01 
                        :ARG0 (l / large)) 
                  :ARG1-of (d / differentiate-01) 
                  :op2-of (o / or 
                        :op1 (t / terminally)))) 
      :op3 (e / express-01 
            :ARG1 (i / isoform 
                  :quant 2) 
            :ARG1-of (f / frequent-02)))

# ::snt Red blood cells , which were thought to be devoid of annexin A7 , were recently shown to harbor the 47 kDa isoform together with its binding partner sorcin [ 7 ] .
# ::tok Red blood cells , which were thought to be devoid of annexin A7 , were recently shown to harbor the 47 kDa isoform together with its binding partner sorcin [ 7 ] .
# ::alignments 30-31|0.0.0.0.0.0 28-29|0.0.0.0.0.1.0 27-28|0.0.0.0.0.1 26-27|0.0.0.0.0.1.1 23-24|0.0.2 22-23|0.0.1 21-22|0.0.1.0 20-21|0.0.1.1 18-19|0.0 16-17|0 15-16|0.1 12-13|0.0.0.0.1 11-12|0.0.0.0.1.0 9-10|0.0.0.0 6-7|0.0.0.0.0 2-3|0.0.0 1-2|0.0.0.1 0-1|0.0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:47.600
(s2 / show-01 
      :ARG1 (h / harbor-01 
            :ARG0 (c / cell 
                  :domain-of (d / devoid 
                        :ARG1-of (t2 / think-01 
                              :ARG0 7 
                              :ARG1-of (p / partner-01 
                                    :ARG0 (s / sorcin) 
                                    :ARG1-of (b / binding-07))) 
                        :topic (a / A7 
                              :mod (a2 / annexin))) 
                  :mod (b2 / blood) 
                  :mod (r2 / red)) 
            :ARG1 (i / isoform 
                  :mod (k / kDa) 
                  :quant 47) 
            :manner (t / together)) 
      :time (r / recent))

# ::snt We showed the presence of the 51 kDa isoform as well , adding red blood cells to the list of cells that harbor this isoform .
# ::tok We showed the presence of the 51 kDa isoform as well , adding red blood cells to the list of cells that harbor this isoform .
# ::alignments 23-24|0.2 22-23|0.1.0.0.0 20-21|0.1.0.0 18-19|0.1.0 15-16|0.1.0.1.1 14-15|0.1.0.1.1.0 13-14|0.1.0.1.1.1 12-13|0.1.0.1 7-8|0.1.0.1.0 6-7|0.1.0.0.0.0 3-4|0.1 1-2|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:49.402
(s / show-01 
      :ARG0 (w / we) 
      :ARG1 (p / presence 
            :ARG0-of (l / list-01 
                  :ARG1 (c / cell 
                        :ARG0-of (h / harbor-01 
                              :ARG1 51)) 
                  :ARG2-of (a / add-02 
                        :ARG0 (k / kDa) 
                        :ARG1 (c2 / cell 
                              :mod (b / blood) 
                              :mod (r / red))))) 
      :op1-of (t / this))

# ::snt Salzer et al. [ 7 ] not only demonstrated the presence of annexin A7 in red blood cells , they also showed that annexin A7 and sorcin were enriched in membrane raft domains of nanovesicles formed from red blood cells in vitro .
# ::tok Salzer et al. [ 7 ] not only demonstrated the presence of annexin A7 in red blood cells , they also showed that annexin A7 and sorcin were enriched in membrane raft domains of nanovesicles formed from red blood cells in vitro .
# ::alignments 41-42|0.1.2 39-40|0.1.3.0 38-39|0.1.3.0.0 37-38|0.1.3.0.1 35-36|0.1.3 34-35|0.1.3.1 32-33|0.1.0 31-32|0.1.0.0 30-31|0.1.0.1 28-29|0.1 26-27|0.1.1.2 25-26|0.1.1 21-22|0 20-21|0.2 19-20|0.0 17-18|0.1.1.1.2 16-17|0.1.1.1.2.0 15-16|0.1.1.1.2.1 13-14|0.1.1.1.1.0 12-13|0.1.1.1.1.0.0 10-11|0.1.1.1.1 8-9|0.1.1.1 7-8|0.1.1.1.0 6-7|0.1.1.1.0.0 4-5|0.1.0.0.0 0-3|0.1.1.0.0.2+0.1.1.0.0.1+0.1.1.0.0.0+0.1.1.0.0+0.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:53.078
(s2 / show-01 
      :ARG0 (t / they) 
      :ARG1 (e / enrich-01 
            :ARG0 (d / domain 
                  :ARG1-of (r2 / raft-01 
                        :ARG0 7) 
                  :mod (m / membrane)) 
            :ARG1 (a / and 
                  :op1 (t2 / thing 
                        :name (n2 / name 
                              :op1 "Salzer" 
                              :op2 "et" 
                              :op3 "al.")) 
                  :op2 (d2 / demonstrate-01 
                        :ARG0 (o / only 
                              :polarity -) 
                        :ARG1 (p / presence 
                              :mod (a3 / A7 
                                    :mod (a4 / annexin))) 
                        :location (c2 / cell 
                              :mod (b2 / blood) 
                              :mod (r3 / red))) 
                  :op3 (s / sorcin)) 
            :ARG2 (v / vitro) 
            :purpose (f / form-01 
                  :ARG0 (c / cell 
                        :mod (b / blood) 
                        :mod (r / red)) 
                  :ARG1 (n / nanovesicl))) 
      :mod (a2 / also))

# ::snt Raft domains in general are considered key players in membrane organization and in mediating the vesiculation process .
# ::tok Raft domains in general are considered key players in membrane organization and in mediating the vesiculation process .
# ::alignments 16-17|0.0.2.0.0 15-16|0.0.2.0.0.0 13-14|0.0.2.0 11-12|0.0.2 10-11|0.0.0.1 9-10|0.0.0.1.0 7-8|0.0.0+0.0 6-7|0.0.1 5-6|0 3-4|0.1 1-2|0.0.0.0 0-1|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:54.514
(c / consider-01 
      :ARG1 (p2 / person 
            :ARG0-of (p3 / play-01 
                  :ARG1 (d / domain 
                        :ARG1-of (r / raft-01)) 
                  :location (o / organization 
                        :mod (m2 / membrane))) 
            :ARG1-of (k / key-02) 
            :op1-of (a / and 
                  :op2 (m / mediate-01 
                        :ARG1 (p / process-02 
                              :ARG1 (v / vesiculation))))) 
      :ARG1-of (g / general-02))

# ::snt They result from the clustering of sphingolipids and cholesterol in the outer leaflet of the membrane connected to phospholipids and cholesterol in the inner leaflet and are enriched in special proteins .
# ::tok They result from the clustering of sphingolipids and cholesterol in the outer leaflet of the membrane connected to phospholipids and cholesterol in the inner leaflet and are enriched in special proteins .
# ::alignments 30-31|0 29-30|0.0 27-28|0.1 25-26|0.1.0 24-25|0.2.0 23-24|0.2 20-21|0.1.0.0.3.0 19-20|0.1.0.0.3 18-19|0.1.0.0.2 16-17|0.1.0.0 15-16|0.1.0.0.1 12-13|0.1.0.0.1.0 11-12|0.1.0.0.1.0.0 8-9|0.1.0.0.0.0.1 7-8|0.1.0.0.0.0 6-7|0.1.0.0.0 4-5|0.1.0.0.0.0.0 1-2|0.1.0.0.0.0.0.0 0-1|0.1.0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:08:56.824
(p / protein 
      :ARG1-of (s / special-02) 
      :ARG2-of (e / enrich-01 
            :ARG1 (a / and 
                  :op1 (c2 / connect-01 
                        :ARG0 (s2 / sphingolipid 
                              :op1-of (a3 / and 
                                    :ARG1-of (c4 / cluster-01 
                                          :ARG2-of (r / result-01 
                                                :ARG1 (t / they))) 
                                    :op2 (c3 / cholesterol))) 
                        :ARG1 (m / membrane 
                              :poss-of (l2 / leaflet 
                                    :mod (o / outer))) 
                        :ARG2 (p2 / phospholipid) 
                        :op1-of (a2 / and 
                              :op2 (c / cholesterol))))) 
      :mod (i / inner 
            :mod-of (l / leaflet)))

# ::snt Biochemically rafts are defined as membranes that are resistant to extraction by cold Triton X-100 and can be floated to low densities in sucrose gradient centrifugation [ 36 ] .
# ::tok Biochemically rafts are defined as membranes that are resistant to extraction by cold Triton X-100 and can be floated to low densities in sucrose gradient centrifugation [ 36 ] .
# ::alignments 27-28|0.0.0 25-26|0.2.1.1.0 24-25|0.2.1.0 23-24|0.2.1.1.1.0 21-22|0.0.1 20-21|0.0.1.0 18-19|0.0 16-17|0.1 15-16|0 13-15|0.3.1.1+0.3.1.0+0.3.1+0.3 12-13|0.3.0 10-11|0.2.1 8-9|0.2 5-6|0.2.0 3-4|0.2.1.1 1-2|0.2.1.1.1 0-1|0.2.1.1.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:00.765
(a / and 
      :ARG1-of (f / float-01 
            :ARG0 36 
            :ARG2 (d / densiti 
                  :ARG1-of (l / low-04))) 
      :ARG1-of (p / possible-01) 
      :op1 (r / resist-01 
            :ARG0 (m / membran) 
            :ARG1 (e / extract-01 
                  :ARG0 (g / gradient) 
                  :ARG1 (d2 / define-01 
                        :ARG0 (c / centrifugation) 
                        :ARG1 (r2 / raft-01 
                              :ARG0 (s / sucrose) 
                              :mod (b / biochemically))))) 
      :op2 (p2 / person 
            :mod (c2 / cold) 
            :name (n / name 
                  :op1 "Triton" 
                  :op2 "X-100")))

# ::snt The findings of Caohuy et al. [ 37 ] that annexin A7 mediates membrane aggregation also suggested that annexin A7 is an essential component during vesiculation .
# ::tok The findings of Caohuy et al. [ 37 ] that annexin A7 mediates membrane aggregation also suggested that annexin A7 is an essential component during vesiculation .
# ::alignments 25-26|0 23-24|0.0.0.0.0 22-23|0.0.0.0.0.0 16-17|0.0.0.0 15-16|0.0.0.0.1 14-15|0.0.0 13-14|0.0.0.1 12-13|0.0 10-11|0.1 7-8|0.2 3-6|0.0.0.0.0.0.0.1.0.2+0.0.0.0.0.0.0.1.0.1+0.0.0.0.0.0.0.1.0.0+0.0.0.0.0.0.0.1.0+0.0.0.0.0.0.0.1 1-2|0.0.0.0.0.0.0+0.0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:02.452
(v / vesiculation 
      :ARG2-of (m2 / mediate-01 
            :ARG0 (a2 / aggregation 
                  :ARG0-of (s / suggest-01 
                        :ARG1 (c / component 
                              :mod (e / essential 
                                    :ARG0-of (f / find-01 
                                          :ARG1 (t2 / thing) 
                                          :ARG2 (t / thing 
                                                :name (n / name 
                                                      :op1 "Caohuy" 
                                                      :op2 "et" 
                                                      :op3 "al."))))) 
                        :mod (a / also)) 
                  :mod (m / membrane))) 
      :mod-of (a3 / annexin) 
      :poss-of 37)

# ::snt In addition they reported a further activation of the vesiculation process by GTP and proposed that annexin A7 acts as a GTPase .
# ::tok In addition they reported a further activation of the vesiculation process by GTP and proposed that annexin A7 acts as a GTPase .
# ::alignments 18-19|0.2.0 17-18|0.2.0.0 16-17|0.2.0.0.0 14-15|0.0.0 13-14|0.2 12-13|0.2.0.1.0.0+0.2.0.1.0+0.2.0.1 10-11|0.0.0.0 9-10|0.0.0.0.0 6-7|0.1 5-6|0.1.0 3-4|0 2-3|0.0 1-2|0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:02.891
(r / report-01 
      :ARG0 (t / they 
            :ARG0-of (p / propose-01 
                  :ARG1 (p2 / process-02 
                        :ARG1 (v / vesiculation) 
                        :mod (a6 / addition)))) 
      :ARG1 (a5 / activation 
            :mod (f / further)) 
      :op1-of (a4 / and 
            :op2 (a / act-02 
                  :ARG0 (a2 / A7 
                        :mod (a3 / annexin)) 
                  :ARG1 (o / organization 
                        :name (n / name 
                              :op1 "GTP")))))

# ::snt Similarly , the presence of GTP enhanced the secretion of surfactant by annexin A7 .
# ::tok Similarly , the presence of GTP enhanced the secretion of surfactant by annexin A7 .
# ::alignments 13-14|0.0.0.0.0 12-13|0.0.0.0 10-11|0.0.0 8-9|0.0 6-7|0 5-6|0.1.0.0.0+0.1.0.0+0.1.0 3-4|0.1 0-1|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:03.631
(e / enhance-01 
      :ARG1 (s2 / secretion 
            :mod (s / surfactant 
                  :location (a2 / annexin 
                        :mod-of (a / A7)))) 
      :manner (p / presence 
            :poss (o / organization 
                  :name (n / name 
                        :op1 "GTP"))) 
      :time (s3 / similarly))

# ::snt These results were thought to support a direct role for annexin A7 in surfactant secretion , but in these studies annexin A7 mediated membrane fusion was separated from a second GTP-dependent mechanism [ 38 ] .
# ::tok These results were thought to support a direct role for annexin A7 in surfactant secretion , but in these studies annexin A7 mediated membrane fusion was separated from a second GTP-dependent mechanism [ 38 ] .
# ::alignments 33-34|0.0.1.1.1.0.0.0 31-32|0.1.1 26-27|0.1 24-25|0.1.0 23-24|0.1.0.1 22-23|0.1.0.0 19-20|0.0.1.1.1.0.0 18-19|0.0.1.2 16-17|0 14-15|0.0.0 13-14|0.0.0.0 11-12|0.0.1.1.1 10-11|0.0.1.1.1.0 8-9|0.0.1.1 7-8|0.0.1.1.0 5-6|0.0.1 3-4|0.0 1-2|0.0.1.0.0+0.0.1.0 0-1|0.0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:05.646
(c / contrast-01 
      :ARG1 (t2 / think-01 
            :ARG0 (s3 / secretion 
                  :mod (s4 / surfactant)) 
            :ARG1 (s5 / support-01 
                  :ARG0 (t3 / thing 
                        :ARG2-of (r2 / result-01) 
                        :mod (t4 / this)) 
                  :ARG1 (r / role 
                        :ARG1-of (d / direct-02) 
                        :mod (a / A7 
                              :mod (a2 / annexin 
                                    :mod-of (s2 / study-01 
                                          :ARG0 38)))) 
                  :time (t / this))) 
      :ARG2 (s / separate-01 
            :ARG1 (f / fusion 
                  :ARG1-of (m3 / mediate-01) 
                  :mod (m2 / membrane)) 
            :ARG2 (m / mechanism)))

# ::snt Having an annexin A7 knockout mouse we tested the involvement of annexin A7 in budding of red blood cell vesicles .
# ::tok Having an annexin A7 knockout mouse we tested the involvement of annexin A7 in budding of red blood cell vesicles .
# ::alignments 19-20|0 18-19|0.1 17-18|0.1.0 16-17|0.2 14-15|0.0 9-10|0.0.0 7-8|0.0.0.0 6-7|0.0.0.0.0 5-6|0.0.0.0.0.0.0 4-5|0.0.0.0.0.0.0.0 0-1|0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:06.342
(v / vesicl 
      :ARG1-of (b2 / bud-01 
            :ARG1-of (i / involve-01 
                  :ARG1-of (t / test-01 
                        :ARG0 (w / we 
                              :ARG0-of (h / have-03 
                                    :ARG1 (m / mouse 
                                          :mod (k / knockout))))))) 
      :mod (c / cell 
            :mod (b / blood)) 
      :mod (r / red))

# ::snt Our data suggest that the efficiency of micro - and nanovesicle formation is not significantly different in wild type and mutant red blood cells .
# ::tok Our data suggest that the efficiency of micro - and nanovesicle formation is not significantly different in wild type and mutant red blood cells .
# ::alignments 23-24|0.1.2 22-23|0.1.2.0 21-22|0.1.2.1 20-21|0.1.2.2 19-20|0.1 18-19|0.1.1 17-18|0.1.1.0 15-16|0.1.0 14-15|0.1.0.1 13-14|0.1.0.2 11-12|0.1.0.0.0 9-10|0.1.0.0.1 7-8|0.1.0.0.1.0 5-6|0.1.0.0 2-3|0 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:07.762
(s2 / suggest-01 
      :ARG0 (d2 / data 
            :poss (w2 / we)) 
      :ARG1 (a / and 
            :ARG2-of (d / differ-02 
                  :ARG1 (e / efficient-01 
                        :ARG1 (f / form-01) 
                        :ARG2 (a2 / and 
                              :op1 (m2 / micro))) 
                  :ARG1-of (s / significant-02) 
                  :polarity -) 
            :op1 (t / type 
                  :mod (w / wild)) 
            :op2 (c / cell 
                  :mod (b / blood) 
                  :mod (r / red) 
                  :mod (m / mutant))))

# ::snt Likewise , Dictyostelium discoideum cells , in which the single annexin gene was inactivated , were not impaired in processes requiring membrane fusion [ [ 39 ] ; and data unpublished ] .
# ::tok Likewise , Dictyostelium discoideum cells , in which the single annexin gene was inactivated , were not impaired in processes requiring membrane fusion [ [ 39 ] ; and data unpublished ] .
# ::alignments 30-31|0.2.1 29-30|0.2.0.0.0 28-29|0.2 27-28|0 25-26|0.2.0.0.1.0 22-23|0.2.0.1.2 21-22|0.2.0.1.0 20-21|0.2.0 19-20|0.2.0.0 17-18|0.2.0.0.1 16-17|0.2.0.0.1.2 11-12|0.2.0.1.1 10-11|0.2.0.1.1.0 9-10|0.2.0.1 4-5|0.2.0.0.1.1 3-4|0.2.0.0.1.1.0 2-3|0.1.0.0+0.1.0+0.1 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:10.405
(a2 / and 
      :mod (l / likewise) 
      :op1 (p2 / person 
            :name (n / name 
                  :op1 "Dictyostelium")) 
      :op1-of (a / and 
            :ARG1-of (r / require-01 
                  :ARG0 (p / process-02 
                        :ARG1 (d / data) 
                        :ARG2-of (i / impair-01 
                              :ARG0 39 
                              :ARG1 (c / cell 
                                    :mod (d2 / discoideum)) 
                              :polarity -)) 
                  :purpose-of (s / single-02 
                        :ARG0 (m / membrane) 
                        :ARG1 (g / gene 
                              :mod (a3 / annexin)) 
                        :op1-of (f / fusion))) 
            :mod (u / unpublish)))

# ::snt It might well be that the observed fusion of phospholipid layers by annexin A7 in the presence of high Ca2 + concentrations may turn out to be an in vitro effect .
# ::tok It might well be that the observed fusion of phospholipid layers by annexin A7 in the presence of high Ca2 + concentrations may turn out to be an in vitro effect .
# ::alignments 30-31|0.0 29-30|0.0.0 23-24|0.0.2 22-23|0.0.2.2 21-22|0.0.1.1 18-19|0.0.1.1.0 16-17|0.0.1 13-14|0.0.1.0 12-13|0.0.1.0.0 10-11|0.0.2.0.1 9-10|0.0.2.0.1.0 7-8|0.0.2.0 6-7|0.0.2.0.0 1-2|0 0-1|0.0.2.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:11.709
(p4 / possible-01 
      :ARG1 (e / effect-03 
            :ARG0 (v / vitro) 
            :ARG1 (p2 / presence 
                  :location-of (a / A7 
                        :mod (a2 / annexin)) 
                  :mod (c / concentration 
                        :ARG1-of (h / high-02))) 
            :ARG2-of (t / turn-02 
                  :ARG0 (f / fusion 
                        :ARG1-of (o / observe-01) 
                        :mod (l / layer 
                              :mod (p3 / phospholipid))) 
                  :ARG1 (i / it) 
                  :ARG1-of (p / possible-01))))

# ::snt Similarly , the high abundance of annexin A7 in micro - and nanovesicles might be fortuitous as a significant percentage of the red blood cell membrane , with which annexin A7 associates when the Ca2 + levels rise , appears to be involved in the formation of exovesicles .
# ::tok Similarly , the high abundance of annexin A7 in micro - and nanovesicles might be fortuitous as a significant percentage of the red blood cell membrane , with which annexin A7 associates when the Ca2 + levels rise , appears to be involved in the formation of exovesicles .
# ::alignments 47-48|0.3.0.1.1 45-46|0.3.0.1 42-43|0.3.0 39-40|0.3.0.0 37-38|0.3.0.1.0.1 36-37|0.3.0.1.0.1.0 34-35|0.0 31-32|0.3.0.1.0.1.1 25-26|0.1.0.0.0 24-25|0.1.0.0 23-24|0.1.0 22-23|0.1.0.0.0.0 19-20|0.3.0.1.0 18-19|0.3.0.1.0.0 15-16|0.1 13-14|0 12-13|0.3.1 11-12|0.3 9-10|0.3.0.1.0.1.1.0 7-8|0.3.2 6-7|0.3.2.0 4-5|0.3.2.1 3-4|0.3.2.1.0 0-1|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:15.129
(p2 / possible-01 
      :ARG0 (c / Ca2) 
      :ARG1 (f2 / fortuitou 
            :prep-with (b / blood 
                  :mod-of (c2 / cell 
                        :mod-of (m / membrane 
                              :mod (r2 / red))))) 
      :mod (s2 / similarly) 
      :op2-of (a3 / and 
            :ARG1-of (i / involve-01 
                  :ARG1-of (a / appear-02) 
                  :ARG2 (f / form-01 
                        :ARG0 (p / percentage 
                              :ARG1-of (s / significant-02) 
                              :ARG3-of (r / rise-01 
                                    :ARG0 (l / level) 
                                    :ARG1 (a2 / associate-01 
                                          :ARG1 (m2 / micro)))) 
                        :ARG1 (e / exovesicl))) 
            :op1 (n / nanovesicl) 
            :topic-of (a4 / A7 
                  :mod (a5 / annexin) 
                  :mod-of (a6 / abundance 
                        :ARG1-of (h / high-02)))))

# ::snt Furthermore , the distribution of both annexin A7 isoforms in gradients of red blood cells indicates a function which differs from organizing subcellular membranes or membrane pathways .
# ::tok Furthermore , the distribution of both annexin A7 isoforms in gradients of red blood cells indicates a function which differs from organizing subcellular membranes or membrane pathways .
# ::alignments 26-27|0.1.1.0.1.1 25-26|0.1.1.0.1.1.0 24-25|0.1.1.0.1 23-24|0.1.1.0.1.0 22-23|0.1.1.0.1.0.0 21-22|0.1.1.0 19-20|0.1.1 17-18|0.1 15-16|0 14-15|0.1.0 13-14|0.1.0.0 12-13|0.1.0.1 10-11|0.1.0.2 8-9|0.0.0 5-6|0.0.0.0 3-4|0.0 0-1|0.1.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:18.117
(i / indicate-01 
      :ARG0 (d2 / distribute-01 
            :ARG1 (i2 / isoform 
                  :mod (b2 / both))) 
      :ARG1 (f / function-01 
            :ARG0 (c / cell 
                  :mod (b / blood) 
                  :mod (r / red) 
                  :mod-of (g / gradient)) 
            :ARG0-of (d / differ-01 
                  :ARG1 (o2 / organize-01 
                        :ARG0 (f2 / furthermore) 
                        :ARG1 (o / or 
                              :op1 (m2 / membran 
                                    :mod (s / subcellular)) 
                              :op2 (p / pathway 
                                    :mod (m / membrane)))))))

# ::snt Whereas annexin A2 is tightly associated with endosomes and may have functions in membrane fusion and the endosomal pathway , annexin A7 distributes with plasma membrane raft domains of different types and densities .
# ::tok Whereas annexin A2 is tightly associated with endosomes and may have functions in membrane fusion and the endosomal pathway , annexin A7 distributes with plasma membrane raft domains of different types and densities .
# ::alignments 32-33|0.0.1.0.1.1.2 31-32|0.0.1.0.1.1 30-31|0.0.1.0.1.1.1 29-30|0.0.1.0.1.1.0 27-28|0.0.1.0.1 26-27|0.0.1.0.1.0 25-26|0.0.1.0.1.0.0 24-25|0.0.0 22-23|0.0.1.0 21-22|0.0.1.0.0 18-19|0.2 15-16|0 14-15|0.1 13-14|0.1.0 11-12|0.0 9-10|0.0.1.2 8-9|0.0.1 7-8|0.0.1.1.2 5-6|0.0.1.1 4-5|0.0.1.1.1 1-3|0.0.1.1.0.0.1+0.0.1.1.0.0.0+0.0.1.1.0.0+0.0.1.1.0 0-1|0.0.1.1.3 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:20.339
(a3 / and 
      :op1 (f2 / function-01 
            :ARG1 (p / plasma) 
            :op3-of (a4 / and 
                  :ARG1-of (d4 / distribute-01 
                        :ARG0 (a2 / A7) 
                        :ARG2 (d3 / domain 
                              :ARG0-of (r / raft-01 
                                    :ARG1 (m / membrane)) 
                              :op1-of (a / and 
                                    :ARG1-of (d2 / differ-02) 
                                    :op2 (t / type) 
                                    :op3 (d / densiti)))) 
                  :op1 (a5 / associate-01 
                        :ARG1 (t3 / thing 
                              :name (n / name 
                                    :op1 (a6 / annexin) 
                                    :op2 (a7 / A2))) 
                        :ARG1-of (t2 / tight-05) 
                        :ARG2 (e / endosom) 
                        :op1-of (w / wherea)) 
                  :op2 (p3 / possible-01))) 
      :op2 (f / fusion 
            :mod (m2 / membrane)) 
      :op3 (p2 / pathway))

# ::snt Interestingly , in vesicles of red blood cells lacking annexin A7 the amount of sorcin is lowered , indicating that its localisation is affected by the loss of annexin A7 or its expression during red blood cell development was reduced .
# ::tok Interestingly , in vesicles of red blood cells lacking annexin A7 the amount of sorcin is lowered , indicating that its localisation is affected by the loss of annexin A7 or its expression during red blood cell development was reduced .
# ::alignments 39-40|0.0.1 37-38|0.0 36-37|0.0.0 35-36|0.0.0.0 34-35|0.1.0.0.0.1 32-33|0 30-31|0.1 26-27|0.1.0 23-24|0.1.0.0 21-22|0.1.0.0.0 18-19|0.1.0.0.1 16-17|0.0.2 14-15|0.0.2.0.0 12-13|0.0.2.0 10-11|0.0.2.1 9-10|0.0.2.1.1 8-9|0.0.2.1.0 7-8|0.0.2.1.0.0 6-7|0.0.2.1.0.0.0 5-6|0.0.2.1.0.0.1 3-4|0.0.2.1.0.0.2 0-1|0.1.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:23.878
(e / express-01 
      :ARG1 (d / develop-02 
            :ARG1 (c / cell 
                  :mod (b / blood)) 
            :ARG1-of (r / reduce-01) 
            :ARG2 (l3 / lower-05 
                  :ARG0 (a2 / amount 
                        :quant-of (s / sorcin)) 
                  :ARG1 (a3 / A7 
                        :ARG1-of (l4 / lack-01 
                              :ARG0 (c2 / cell 
                                    :mod (b2 / blood) 
                                    :mod (r3 / red) 
                                    :mod-of (v / vesicl))) 
                        :mod (a4 / annexin)))) 
      :op1-of (o / or 
            :poss-of (l / loss 
                  :ARG0-of (a / affect-01 
                        :ARG1 (l2 / localize-01 
                              :ARG0 (i2 / interesting) 
                              :ARG1 (r2 / red)) 
                        :ARG1-of (i / indicate-01)))))

# ::snt Having excluded a direct role in vesicle formation and membrane fusion , annexin A7 might act by its property as Ca2 + - binding protein [ 17 ] .
# ::tok Having excluded a direct role in vesicle formation and membrane fusion , annexin A7 might act by its property as Ca2 + - binding protein [ 17 ] .
# ::alignments 26-27|0.0.0.0.0.0.0 24-25|0.0.0.0.0.2.0.0.0 23-24|0.0.0.0.0.2.0.0 18-19|0.0.1 15-16|0.0 14-15|0 12-14|0.0.0.1.1+0.0.0.1.0+0.0.0.1+0.0.0 10-11|0.0.0.0.0.2.1 9-10|0.0.0.0.0.2.1.0 8-9|0.0.0.0.0.2 7-8|0.0.0.0.0.2.0 6-7|0.0.0.0.0.2.0.1 4-5|0.0.0.0.0 3-4|0.0.0.0.0.0 1-2|0.0.0.0 0-1|0.0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:26.302
(p3 / possible-01 
      :ARG1 (a / act-02 
            :ARG0 (t / thing 
                  :ARG0-of (e / exclude-01 
                        :ARG1 (r / role 
                              :ARG1-of (d / direct-02 
                                    :ARG0 17) 
                              :ARG1-of (h / have-03) 
                              :op1-of (a4 / and 
                                    :op2 (f2 / form-01 
                                          :ARG1 (b / binding-07 
                                                :ARG1 (p / protein)) 
                                          :mod (v / vesicle)) 
                                    :op3 (f / fusion 
                                          :mod (m / membrane))))) 
                  :name (n / name 
                        :op1 (a2 / annexin) 
                        :op2 (a3 / A7))) 
            :ARG1 (p2 / property)))

# ::snt Previous results in which annexin A7 was shown to play a role in membrane aggregation might be explained by a supportive function of annexin A7 in that it interferes with the local Ca2 + homeostasis thus influencing membrane organization .
# ::tok Previous results in which annexin A7 was shown to play a role in membrane aggregation might be explained by a supportive function of annexin A7 in that it interferes with the local Ca2 + homeostasis thus influencing membrane organization .
# ::alignments 38-39|0.0.0.1.0.1 37-38|0.0.0.1.0.1.0 36-37|0.0.0.1.0 35-36|0.0.0.1.0.2 34-35|0.0.0.1.0.0 31-32|0.0.0.1.0.0.0 28-29|0.0.0.1 21-22|0.0.0 20-21|0.0.0.0 17-18|0.0 15-16|0 14-15|0.0.1.1.0.2 13-14|0.0.1.1.0.2.0 11-12|0.0.1.1.0.1 9-10|0.0.1.1.0 7-8|0.0.1.1 4-6|0.0.1.1.0.0.0.1+0.0.1.1.0.0.0.0+0.0.1.1.0.0.0+0.0.1.1.0.0 1-2|0.0.1.0+0.0.1 0-1|0.0.1.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:30.698
(p / possible-01 
      :ARG1 (e / explain-01 
            :ARG0 (f / function-01 
                  :ARG1 (s / support-01) 
                  :ARG1-of (i2 / interfere-01 
                        :ARG2 (i / influence-01 
                              :ARG0 (h / homeostasi 
                                    :ARG1-of (l / local-02)) 
                              :ARG1 (o / organization 
                                    :mod (m / membrane)) 
                              :time (t / thus-far)))) 
            :ARG1 (t3 / thing 
                  :ARG2-of (r2 / result-01) 
                  :ARG2-of (s2 / show-01 
                        :ARG1 (p2 / play-01 
                              :ARG0 (t2 / thing 
                                    :name (n / name 
                                          :op1 (a2 / annexin) 
                                          :op2 (a3 / A7))) 
                              :ARG1 (r / role) 
                              :location (a / aggregation 
                                    :mod (m2 / membrane)))) 
                  :mod (p3 / previou))))

# ::snt As the annexins belong to a wide spread and evolutionarily conserved protein family , redundant , but not identical functions are expected .
# ::tok As the annexins belong to a wide spread and evolutionarily conserved protein family , redundant , but not identical functions are expected .
# ::alignments 21-22|0.1.0 19-20|0.1 18-19|0.1.1 17-18|0.1.1.0 16-17|0 14-15|0.0 12-13|0.1.0.0.1 11-12|0.1.0.0.2.1.0 10-11|0.1.0.0.2.1 9-10|0.1.0.0.2.1.1 8-9|0.1.0.0.2 7-8|0.1.0.0.2.0 6-7|0.1.0.0.2.0.0 3-4|0.1.0.0 2-3|0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:31.307
(c / contrast-01 
      :ARG1 (r / redundant) 
      :ARG1-of (f / function-01 
            :ARG1-of (e / expect-01 
                  :concession (b / belong-01 
                        :ARG0 (a2 / annexin) 
                        :ARG1 (f2 / family) 
                        :ARG2 (a / and 
                              :op1 (s / spread-02 
                                    :ARG1-of (w / wide-02)) 
                              :op2 (c2 / conserve-01 
                                    :ARG1 (p / protein) 
                                    :degree (e2 / evolutionarily))))) 
            :ARG1-of (i / identical-01 
                  :polarity -)))

# ::snt However , so far no other members of the annexin family , which may substitute for annexin A7 , have been described in red blood cells .
# ::tok However , so far no other members of the annexin family , which may substitute for annexin A7 , have been described in red blood cells .
# ::alignments 25-26|0.0.0.1.0 24-25|0.0.0.1.0.0 23-24|0.0.0.1.0.1 21-22|0.0.0.1 17-18|0 14-15|0.0 13-14|0.0.1 10-11|0.0.0.0.0 9-10|0.0.0.0.0.0 6-7|0.0.0.0.1+0.0.0.0+0.0.0 5-6|0.0.0.2 4-5|0.0.0.1.0.0.0 3-4|0.0.0.3 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:32.342
(a / A7 
      :ARG2-of (s / substitute-01 
            :ARG0 (p2 / person 
                  :ARG0-of (h / have-org-role-91 
                        :ARG1 (f / family 
                              :mod (a2 / annexin)) 
                        :ARG2 (m / member)) 
                  :ARG2-of (d / describe-01 
                        :ARG1 (c / cell 
                              :mod (b / blood 
                                    :poss -) 
                              :mod (r / red))) 
                  :mod (o / other) 
                  :mod (f2 / far)) 
            :ARG1-of (p / possible-01)))

# ::snt The structural basis for the elasticy of red blood cells in circulation are long range molecular functions of the plasma membrane and the membrane associated part of the cytoskeleton [ 40-43 ] .
# ::tok The structural basis for the elasticy of red blood cells in circulation are long range molecular functions of the plasma membrane and the membrane associated part of the cytoskeleton [ 40-43 ] .
# ::alignments 28-29|0.0.1.0.0.2 24-25|0.0.1.0.0.1 23-24|0.0.1.0.0.0 21-22|0 20-21|0.0.0 19-20|0.0.0.0 16-17|0.0 15-16|0.0.2 14-15|0.0.1 13-14|0.0.1.0 11-12|0.0.1.0.0 9-10|0.0.1.0.0.2.0.0 8-9|0.0.1.0.0.2.0.0.0 7-8|0.0.1.0.0.2.0 5-6|0.0.1.0.0.2.0.0.1 1-2|0.0.1.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:33.645
(a2 / and 
      :op1 (f / function-01 
            :ARG1 (m2 / membrane 
                  :mod (p / plasma)) 
            :ARG1-of (r / range-01 
                  :ARG2 (l / long-03 
                        :ARG1 (c2 / circulate-01 
                              :ARG1 (m / membrane) 
                              :ARG1-of (a / associate-01 
                                    :ARG0 (s / structure)) 
                              :ARG2 (c / cytoskeleton 
                                    :mod (r2 / red 
                                          :mod-of (c3 / cell 
                                                :mod (b / blood) 
                                                :mod-of (e / elasticy))))))) 
            :mod (m3 / molecule)))

# ::snt Major constituents of the membrane skeleton are spectrin tetramers linked together by short actin filaments and several other proteins covering the entire cytoplasmic surface of the red blood cell membrane [ 44 ] .
# ::tok Major constituents of the membrane skeleton are spectrin tetramers linked together by short actin filaments and several other proteins covering the entire cytoplasmic surface of the red blood cell membrane [ 44 ] .
# ::alignments 31-32|0.1.0.1.0 28-29|0.1.0.0.0 27-28|0.1.0.0.0.1 26-27|0.1.0.0.0.2 23-24|0.1.0.0 22-23|0.1.0.0.2 21-22|0.1.0.0.1 19-20|0.1.0 18-19|0 17-18|0.0 16-17|0.2 15-16|0.1 14-15|0.1.1 13-14|0.1.1.0 12-13|0.1.1.1 10-11|0.1.0.1.2 9-10|0.1.0.1 8-9|0.1.0.1.1 7-8|0.1.0.1.1.0 5-6|0.1.0.0.0.0.0.0 4-5|0.1.0.0.0.0.0.0.0 1-2|0.1.0.0.0.0.0 0-1|0.1.0.0.0.0.1+0.1.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:36.770
(p / protein 
      :mod (o / other) 
      :op2-of (a / and 
            :ARG0-of (c3 / cover-01 
                  :ARG1 (s / surface 
                        :domain (c / cell 
                              :ARG1-of (h / have-org-role-91 
                                    :ARG0 (c4 / constituent 
                                          :poss (s5 / skeleton 
                                                :mod (m / membrane))) 
                                    :ARG2 (m2 / major)) 
                              :mod (b / blood) 
                              :mod (r / red)) 
                        :mod (e / entire) 
                        :mod (c2 / cytoplasmic)) 
                  :manner-of (l / link-01 
                        :ARG0 44 
                        :ARG1 (t2 / tetramer 
                              :mod (s4 / spectrin)) 
                        :manner (t / together))) 
            :op1 (f / filament 
                  :mod (a2 / actin) 
                  :mod (s3 / short))) 
      :quant (s2 / several))

# ::snt Membrane cholesterol diminishes red blood cell haemolysis by the complement complex , whereas depletion of raft cholesterol abrogates association of all raft proteins with no significant effect on areas in the rest of the cell membrane and deformability [ 45,46 ] .
# ::tok Membrane cholesterol diminishes red blood cell haemolysis by the complement complex , whereas depletion of raft cholesterol abrogates association of all raft proteins with no significant effect on areas in the rest of the cell membrane and deformability [ 45,46 ] .
# ::alignments 36-37|0.2.2 35-36|0.2.2.2 34-35|0.2.2.1.0 31-32|0.2.2.1 28-29|0.0.1.0 26-27|0.0.1 25-26|0.0.1.1 24-25|0.2.0.0.0 22-23|0.2.1 21-22|0.0.0 20-21|0.2.0.0.1 18-19|0.2 16-17|0.2.2.0 15-16|0.0.0.0 13-14|0.2.2.0.0 12-13|0.2.2.0.0.0 10-11|0.2.0 9-10|0.2.0.0 6-7|0.1 5-6|0.1.0 4-5|0.1.0.0 3-4|0.1.1 2-3|0 1-2|0.0 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:41.777
(d2 / diminish-01 
      :ARG0 (c6 / cholesterol 
            :ARG1-of (r2 / raft-01 
                  :ARG1-of (r3 / raft-01)) 
            :ARG1-of (e / effect-03 
                  :ARG0 (a2 / area) 
                  :ARG1-of (s / significant-02)) 
            :mod (m2 / membrane)) 
      :ARG1 (h / haemolysi 
            :mod (c5 / cell 
                  :mod (b / blood)) 
            :mod (r4 / red)) 
      :purpose (a4 / associate-01 
            :ARG0 (c3 / complex 
                  :mod (c4 / complement-01 
                        :ARG0 - 
                        :ARG1 (a3 / all))) 
            :ARG1 (p / protein) 
            :concession (a / and 
                  :domain (c2 / cholesterol 
                        :mod-of (d / depletion 
                              :op1-of (w / whereas))) 
                  :op1 (r / rest 
                        :mod (c / cell)) 
                  :op2 (m / membrane))))

# ::snt Annexin A7 knock out mouse red blood cells show a more flat shape and have a higher osmotic resistance .
# ::tok Annexin A7 knock out mouse red blood cells show a more flat shape and have a higher osmotic resistance .
# ::alignments 18-19|0.1.0.0 17-18|0.1.0.0.2 16-17|0.1.0.0.1 13-14|0 12-13|0.0.0 11-12|0.1.0.0.0 10-11|0.1.0.0.0.0 8-9|0.0 7-8|0.0.0.0 6-7|0.0.0.0.0 5-6|0.0.0.0.1 4-5|0.1.1 2-3|0.1 0-2|0.1.0.1.1+0.1.0.1.0+0.1.0.1+0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:45.962
(a / and 
      :ARG0-of (s2 / show-01 
            :ARG1 (s / shape-01 
                  :ARG0 (c / cell 
                        :mod (b / blood) 
                        :mod (r2 / red)))) 
      :op1 (k / knock-01 
            :ARG0 (t / thing 
                  :ARG0-of (r / resist-01 
                        :ARG1 (f / flat 
                              :degree (m / more)) 
                        :ARG1-of (h / high-02) 
                        :mod (o / osmotic)) 
                  :name (n / name 
                        :op1 (a2 / Annexin) 
                        :op2 (a3 / A7))) 
            :ARG1 (m2 / mouse)))

# ::snt The presence of annexin A7 may alter the membrane flexibility in that it supports the typical biconcave membrane shape and leads to a lower minimal osmotic resistance .
# ::tok The presence of annexin A7 may alter the membrane flexibility in that it supports the typical biconcave membrane shape and leads to a lower minimal osmotic resistance .
# ::alignments 26-27|0.0.1.0.1.0 25-26|0.0.1.0.1.0.3 24-25|0.0.1.0.1.0.2 23-24|0.0.1.0.1.0.1 20-21|0.0.1.0.1.1 19-20|0.0.1.0.1 18-19|0.0.1.0.0 17-18|0.0.1.0.0.0 16-17|0.0.1.0.1.0.0 15-16|0.0.1.0.0.1 13-14|0.0.1.0 9-10|0.0.1 8-9|0.0.1.1 6-7|0.0 5-6|0 4-5|0.0.0.0 3-4|0.0.0.0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:46.736
(p / possible-01 
      :ARG1 (a2 / alter-01 
            :ARG0 (p2 / presence 
                  :mod (a3 / A7 
                        :mod (a4 / annexin))) 
            :ARG1 (f / flexibility 
                  :ARG0-of (s2 / support-01 
                        :ARG1 (s / shape-01 
                              :ARG1 (m2 / membrane) 
                              :ARG1-of (t / typical-02)) 
                        :op1-of (a / and 
                              :ARG0-of (r / resist-01 
                                    :ARG1 (b / biconcave) 
                                    :ARG1-of (l / low-04) 
                                    :ARG1-of (m / minimal-02) 
                                    :mod (o / osmotic)) 
                              :op2 (l2 / lead-03))) 
                  :mod (m3 / membrane))))

# ::snt Annexin A7 does not appear to have an influence on plasma membrane integrity itself as the maximal osmotic resistance value stays constant .
# ::tok Annexin A7 does not appear to have an influence on plasma membrane integrity itself as the maximal osmotic resistance value stays constant .
# ::alignments 21-22|0.1.1 20-21|0.1 19-20|0.1.0 18-19|0.1.0.0 17-18|0.1.0.0.0 16-17|0.0.0.0.0 12-13|0.0.0 11-12|0.0.0.1 10-11|0.0.1 8-9|0.0.0.0 4-5|0 3-4|0.1.0.0.1 0-2|0.0.2.1+0.0.2.0+0.0.2+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:48.229
(a / appear-02 
      :ARG1 (t / thing 
            :mod-of (i / integrity 
                  :ARG1-of (i2 / influence-01 
                        :ARG0 (m / maximum)) 
                  :mod (m2 / membrane)) 
            :mod-of (p / plasma) 
            :name (n / name 
                  :op1 (a2 / Annexin) 
                  :op2 (a3 / A7))) 
      :purpose (s / stay-on-02 
            :ARG1 (v / value-01 
                  :ARG1 (r / resist-01 
                        :ARG0 (o / osmotic) 
                        :ARG1 -)) 
            :ARG2 (c / constant)))

# ::snt Ca2 + and membrane skeletal proteins are known to play key roles on the red blood cell membrane shape and stability [ 47 ] .
# ::tok Ca2 + and membrane skeletal proteins are known to play key roles on the red blood cell membrane shape and stability [ 47 ] .
# ::alignments 22-23|0.1.0.0.0 20-21|0.1.1.1 19-20|0.1.1 18-19|0.1.1.0 17-18|0.1.1.0.0 16-17|0.1.1.0.0.0 15-16|0.1.1.0.1 14-15|0.1.0.0.1 11-12|0.1.0 10-11|0.1.0.0 9-10|0.1 7-8|0 5-6|0.0.0 4-5|0.0.0.0 3-4|0.0.0.1 2-3|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:51.433
(k2 / know-02 
      :ARG1 (a2 / and 
            :op1 (p2 / protein 
                  :mod (s3 / skeletal) 
                  :mod (m2 / membrane))) 
      :ARG2 (p / play-01 
            :ARG1 (r2 / role 
                  :ARG1-of (k / key-02 
                        :ARG0 47 
                        :ARG2 (r / red))) 
            :ARG2 (a / and 
                  :op1 (s2 / shape-01 
                        :ARG1 (m / membrane 
                              :mod (c / cell)) 
                        :ARG2 (b / blood)) 
                  :op2 (s / stability))))

# ::snt Annexins have been reported to bind directly to F-actin , we could however exclude such an activity for annexin A7 .
# ::tok Annexins have been reported to bind directly to F-actin , we could however exclude such an activity for annexin A7 .
# ::alignments 19-20|0.0.1.0 16-17|0.0.1 14-15|0.0.1.1 13-14|0.0 11-12|0 10-11|0.0.0 8-9|0.0.0.0.0.2.0.0+0.0.0.0.0.2.0+0.0.0.0.0.2 6-7|0.0.0.0.0.1 5-6|0.0.0.0.0 3-4|0.0.0.0 0-1|0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:52.298
(p / possible-01 
      :ARG1 (e / exclude-01 
            :ARG0 (w / we 
                  :ARG0-of (r / report-01 
                        :ARG1 (b / bind-01 
                              :ARG0 (a3 / annexin) 
                              :ARG1-of (d / direct-02) 
                              :ARG2 (t / thing 
                                    :name (n / name 
                                          :op1 "F-actin"))))) 
            :ARG1 (a2 / activity-06 
                  :ARG1 (a / A7) 
                  :mod (s / such))))

# ::snt Nevertheless it might interact with other components and have a role in organizing the membrane cytoskeleton , controlling raft protein associations or influencing the ionic strength of red blood cells on its own or by interfering with other signaling pathways .
# ::tok Nevertheless it might interact with other components and have a role in organizing the membrane cytoskeleton , controlling raft protein associations or influencing the ionic strength of red blood cells on its own or by interfering with other signaling pathways .
# ::alignments 39-40|0.0.0.0.0 38-39|0.0.0.0.0.0 37-38|0.0.0.0.0.1 35-36|0.0.0.0 33-34|0.0.1.0.1.0 29-30|0.0.1.0.1.1.0 28-29|0.0.1.0.1.1.0.0 27-28|0.0.1.0.1.1.0.1 25-26|0.0.1.0.1.1 24-25|0.0.1.0.1.1.1 22-23|0.0.1.0.1 21-22|0.0.1.0 20-21|0.0 19-20|0 18-19|0.0.0 17-18|0.0.1 15-16|0.0.1.0.0.0 14-15|0.0.1.0.0.0.0 12-13|0.0.1.0.0 10-11|0.0.1.0.0.1 7-8|0.0.1.0.0.1.0 6-7|0.0.1.0.0.1.0.0.1 5-6|0.0.1.0.0.1.0.0.1.0 3-4|0.0.1.0.0.1.0.0 2-3|0.0.1.0.0.1.0.0.2 0-1|0.0.1.0.0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:55.473
(p2 / protein 
      :mod-of (a / association 
            :ARG0-of (r2 / raft-01 
                  :ARG1 (i / interfere-01 
                        :ARG1 (p / pathway 
                              :ARG1-of (s / signal-01) 
                              :mod (o / other)))) 
            :ARG1-of (c2 / control-01 
                  :op2-of (o3 / or 
                        :op1 (o4 / organize-01 
                              :ARG1 (c3 / cytoskeleton 
                                    :mod (m / membrane)) 
                              :purpose-of (r3 / role 
                                    :op2-of (a2 / and 
                                          :op1 (i4 / interact-01 
                                                :ARG0 (n / nevertheles) 
                                                :ARG1 (c4 / component 
                                                      :mod (o5 / other)) 
                                                :ARG1-of (p3 / possible-01))))) 
                        :op3 (i3 / influence-01 
                              :ARG0 (o2 / or) 
                              :ARG1 (s2 / strength 
                                    :mod (c / cell 
                                          :mod (b / blood) 
                                          :mod (r / red)) 
                                    :mod (i2 / ionic)))))))

# ::snt As discussed above annexin A7 could be involved in the cytoplasmic Ca2 + homeostasis .
# ::tok As discussed above annexin A7 could be involved in the cytoplasmic Ca2 + homeostasis .
# ::alignments 13-14|0.0.1 10-11|0.0.1.0 7-8|0.0 5-6|0 4-5|0.0.0.0.0 3-4|0.0.0.0.0.0 2-3|0.0.0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:55.635
(p / possible-01 
      :ARG1 (i / involve-01 
            :ARG1 (d / discuss-01 
                  :ARG1 (a3 / above 
                        :op1 (a / A7 
                              :mod (a2 / annexin)))) 
            :ARG2 (h / homeostasi 
                  :mod (c / cytoplasmic))))

# ::snt It has been demonstrated that micromolar changes of the intracellular Ca2 + concentration exert a profound effect on the membrane properties that regulate red blood cell deformability [ 48,49 ] .
# ::tok It has been demonstrated that micromolar changes of the intracellular Ca2 + concentration exert a profound effect on the membrane properties that regulate red blood cell deformability [ 48,49 ] .
# ::alignments 25-26|0.0.0.0.1.0.0 24-25|0.0.0.0.1.0.0.0 23-24|0.0.0.0.1.0.0.1 22-23|0.0.0.0.1.0 20-21|0.0.0.0.1 19-20|0.0.0.0.1.1 16-17|0.0.0 15-16|0.0.0.1 13-14|0.0.0.0 12-13|0.0.0.0.0.1 9-10|0.0.0.0.0.1.0 6-7|0.0.0.0.0 5-6|0.0.0.0.0.0 3-4|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:58.088
(d / demonstrate-01 
      :ARG1 (i2 / it 
            :ARG0-of (e / effect-03 
                  :ARG1-of (e2 / exert-01 
                        :ARG0 (c3 / change-01 
                              :ARG0 (m2 / micromolar) 
                              :ARG1 (c2 / concentrate-02 
                                    :ARG1 (i / intracellular))) 
                        :ARG2 (p / property 
                              :ARG0-of (r2 / regulate-01 
                                    :ARG1 (c / cell 
                                          :mod (b / blood) 
                                          :mod (r / red))) 
                              :mod (m / membrane))) 
                  :mod (p2 / profound))))

# ::snt Furthermore , the intracellular Ca2 + was shown to regulate the membrane stability through modulation of cytoskeletal protein interactions [ 50 ] .
# ::tok Furthermore , the intracellular Ca2 + was shown to regulate the membrane stability through modulation of cytoskeletal protein interactions [ 50 ] .
# ::alignments 20-21|0.0.0 18-19|0.0.2.0 17-18|0 14-15|0.0.3 12-13|0.0.1 11-12|0.0.1.0 9-10|0.0 7-8|0.0.2 4-5|0.0.1.0.0.0 3-4|0.0.1.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:09:59.090
(p / protein 
      :topic-of (r / regulate-01 
            :ARG0 (5 / 50 
                  :poss (f / furthermore)) 
            :ARG1 (s / stability 
                  :mod (m2 / membrane 
                        :mod-of (i2 / intracellular 
                              :mod-of (c / Ca2)))) 
            :ARG1-of (s2 / show-01 
                  :ARG0 (i / interaction)) 
            :manner (m / modulation)))

# ::snt Ca2 + also induces a transbilayer phospholipid redistribution inducing a shape change of red blood cells [ 51 ] .
# ::tok Ca2 + also induces a transbilayer phospholipid redistribution inducing a shape change of red blood cells [ 51 ] .
# ::alignments 17-18|0.0.0.1 15-16|0.0.0.0.0 14-15|0.0.0.0.0.0 13-14|0.0.0.0.0.1 11-12|0.0.0.0 10-11|0.0.0.0.1 8-9|0.0.0 7-8|0.0 6-7|0.0.1 5-6|0.0.2 3-4|0 2-3|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:00.761
(i2 / induce-01 
      :ARG1 (r2 / redistribution 
            :ARG0-of (i / induce-01 
                  :ARG1 (c2 / change-01 
                        :ARG1 (c / cell 
                              :mod (b / blood) 
                              :mod (r / red)) 
                        :ARG2 (s / shape-01)) 
                  :time 51) 
            :mod (p / phospholipid) 
            :mod (t / transbilay)) 
      :mod (a / also))

# ::snt In addition , Ca2 + ions can drive spiculation of the membrane bilayer without involving the cytoskeleton [ 52 ] .
# ::tok In addition , Ca2 + ions can drive spiculation of the membrane bilayer without involving the cytoskeleton [ 52 ] .
# ::alignments 18-19|0.0 16-17|0.1.1.0.0.1 14-15|0.1.1.0 12-13|0.1.1.0.0 11-12|0.1.1.0.0.0 8-9|0.1.1 7-8|0.1 6-7|0 5-6|0.1.0 1-2|0.1.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:01.873
(p / possible-01 
      :ARG0 52 
      :ARG1 (d / drive-01 
            :ARG0 (i2 / ion) 
            :ARG1 (s / spiculation 
                  :ARG0-of (i / involve-01 
                        :ARG1 (b / bilay 
                              :mod (m / membrane) 
                              :mod (c / cytoskeleton)))) 
            :ARG2 (a / addition)))

# ::snt We have also observed a defect in platelet function in the annexin A7 mutant .
# ::tok We have also observed a defect in platelet function in the annexin A7 mutant .
# ::alignments 13-14|0.1.0.0 8-9|0.1.0 7-8|0.1.0.1 5-6|0.1 3-4|0 2-3|0.2 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:02.179
(o / observe-01 
      :ARG0 (w / we) 
      :ARG1 (d / defect-01 
            :ARG1 (f / function-01 
                  :ARG0 (m / mutant) 
                  :ARG1 (p / platelet))) 
      :mod (a / also))

# ::snt In the platelet aggregation experiments the initial aggregation velocity was slightly , but significantly lower in platelets lacking annexin A7 .
# ::tok In the platelet aggregation experiments the initial aggregation velocity was slightly , but significantly lower in platelets lacking annexin A7 .
# ::alignments 18-20|0.1.2.0.0.0.1+0.1.2.0.0.0.0+0.1.2.0.0.0+0.1.2.0.0 17-18|0.1.2.0 16-17|0.1.2 14-15|0.1 13-14|0.1.1 12-13|0 10-11|0.1.0 8-9|0.0 7-8|0.0.0 6-7|0.0.1 4-5|0.1.3 3-4|0.1.3.0 2-3|0.1.3.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:04.138
(c / contrast-01 
      :ARG1 (v / velocity 
            :mod (a3 / aggregation) 
            :mod (i / initial)) 
      :ARG2 (l2 / low-04 
            :ARG1 (s2 / slight) 
            :ARG1-of (s / significant-02) 
            :ARG2 (p / platelet 
                  :ARG0-of (l / lack-01 
                        :ARG1 (t / thing 
                              :name (n / name 
                                    :op1 (a / annexin) 
                                    :op2 (a2 / A7))))) 
            :time (e / experiment-01 
                  :mod (a4 / aggregation) 
                  :mod (p2 / platelet))))

# ::snt These data are not reflected by a change in the in vivo bleeding time .
# ::tok These data are not reflected by a change in the in vivo bleeding time .
# ::alignments 13-14|0.1.1 12-13|0.0 11-12|0 7-8|0.1 4-5|0.1.0 3-4|0.1.0.1 1-2|0.1.0.0 0-1|0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:04.373
(v / vivo 
      :ARG1-of (b / bleed-01) 
      :prep-without-of (c / change-01 
            :ARG0-of (r / reflect-01 
                  :ARG1 (d / data 
                        :mod (t2 / this)) 
                  :polarity -) 
            :ARG1 (t / time)))

# ::snt However the reaction speed of murine platelets is much higher than those of human and due to the technical setup we might have missed larger changes in the mouse samples .
# ::tok However the reaction speed of murine platelets is much higher than those of human and due to the technical setup we might have missed larger changes in the mouse samples .
# ::alignments 29-30|0+0.1 28-29|0.0 25-26|0.1.0 24-25|0.1.0.2 23-24|0.1.0.1 21-22|0.1.0.1.1 20-21|0.1.0.1.0 19-20|0.1.0.1.1.0 18-19|0.1.0.1.1.0.0 14-15|0.1.0.1.1.1 13-14|0.1.0.1.1.1.0.0.0.0 9-10|0.1.0.1.1.1.0 8-9|0.1.0.0 6-7|0.1.0.1.1.1.0.0.1 5-6|0.1.0.1.1.1.0.0.1.0 3-4|0.1.0.1.1.1.0.0 2-3|0.1.0.1.1.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:08.774
(s / sample-01 
      :ARG0 (m / mouse) 
      :ARG1 (t / thing 
            :ARG1-of (c / change-01 
                  :ARG0 (m3 / much) 
                  :ARG1-of (m2 / miss-02 
                        :ARG0 (w / we) 
                        :ARG1-of (p / possible-01 
                              :domain-of (s2 / setup 
                                    :mod (t2 / technical)) 
                              :op2-of (a / and 
                                    :op1 (h2 / high-02 
                                          :ARG1 (s3 / speed 
                                                :mod (r / react-01 
                                                      :ARG1 (h / human)) 
                                                :poss (p2 / platelet 
                                                      :mod (m4 / murine))))))) 
                  :mod (l / large))))

# ::snt The immediate reaction of mouse platelets and the absence of a lag phase after triggering may be caused by an immediately initiated thrombin generation [ 22 ] .
# ::tok The immediate reaction of mouse platelets and the absence of a lag phase after triggering may be caused by an immediately initiated thrombin generation [ 22 ] .
# ::alignments 25-26|0.1.1.0.0 23-24|0.0 22-23|0.0.1 21-22|0.0.0 20-21|0.0.0.0 17-18|0 15-16|0.2 14-15|0.1.1.0 13-14|0.1.1.0.1 12-13|0.1.1.1 11-12|0.1.1.1.0 8-9|0.1.1 6-7|0.1 5-6|0.1.0.0 4-5|0.1.0.0.0 2-3|0.1.0 1-2|0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:10.174
(c / cause-01 
      :ARG0 (g / generation 
            :ARG1-of (i / initiate-01 
                  :time (i2 / immediate)) 
            :mod (t / thrombin)) 
      :ARG1 (a3 / and 
            :ARG0-of (r / react-01 
                  :ARG1 (p3 / platelet 
                        :mod (m / mouse)) 
                  :mod (i3 / immediate)) 
            :op1 (a2 / absent-01 
                  :ARG1 (t2 / trigger-01 
                        :ARG1 22 
                        :op1-of (a / after)) 
                  :ARG2 (p2 / phase 
                        :mod (l / lag-01)))) 
      :ARG1-of (p / possible-01))

# ::snt As known from the frequent human vWF-syndrome or other haemostatic diseases , small defects often are clinically silent and do not result in physiological changes under normal conditions .
# ::tok As known from the frequent human vWF-syndrome or other haemostatic diseases , small defects often are clinically silent and do not result in physiological changes under normal conditions .
# ::alignments 27-28|0.0.2.0 26-27|0.0.2.0.0 24-25|0.0.2 23-24|0.0.2.1 21-22|0.0 20-21|0.0.3 18-19|0 17-18|0.0.0.1 16-17|0.0.0.1.0 14-15|0.0.0.2 13-14|0.0.0 12-13|0.0.0.3 10-11|0.0.0.0.0.0 8-9|0.0.0.0.0.0.0 7-8|0.0.0.0.0 5-6|0.0.1 4-5|0.0.2.0.0.0 1-2|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:10.965
(a / and 
      :op1 (r / result-01 
            :ARG0 (d / defect-01 
                  :ARG1-of (k / know-02 
                        :ARG2 (o3 / or 
                              :op1 (d2 / disease 
                                    :mod (o2 / other)))) 
                  :domain-of (s / silent 
                        :mod (c3 / clinically)) 
                  :frequency (o / often) 
                  :mod (s2 / small)) 
            :ARG1 (h / human) 
            :ARG2 (c2 / change-01 
                  :ARG1 (c / condition 
                        :ARG1-of (n / normal-02 
                              :ARG1-of (f / frequent-02))) 
                  :mod (p / physiological)) 
            :polarity -))

# ::snt Only in situations with severe physical injury , distinct environmental influences or additional platelet attributes like the platelet antigen polymorphism [ 53 ] differences might become apparent .
# ::tok Only in situations with severe physical injury , distinct environmental influences or additional platelet attributes like the platelet antigen polymorphism [ 53 ] differences might become apparent .
# ::alignments 26-27|0.0.2 25-26|0.0 24-25|0 23-24|0.0.0 21-22|0.0.0.1.0.3.0.0 19-20|0.0.0.1.0.1 18-19|0.0.0.1.0.1.0 17-18|0.0.0.0 15-16|0.0.1 14-15|0.0.0.1.0 13-14|0.0.0.1.0.2 12-13|0.0.0.1 11-12|0.0.0.1.0.3 10-11|0.0.0.1.0.3.1 9-10|0.0.0.1.0.3.1.0 8-9|0.0.0.1.0.3.1.1 6-7|0.0.0.1.0.3.0 5-6|0.0.0.1.0.3.0.1 4-5|0.0.0.1.0.3.0.2 2-3|0.0.0.1.0.3.2 0-1|0.0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:12.784
(p / possible-01 
      :ARG1 (b / become-01 
            :ARG1 (d / differ-01 
                  :ARG1 (p3 / platelet) 
                  :prep-for-of (a4 / additional 
                        :mod-of (a3 / attribute-01 
                              :ARG0 (o2 / only) 
                              :ARG1 (p2 / polymorphism 
                                    :mod (a2 / antigen)) 
                              :mod (p4 / platelet) 
                              :op3-of (o / or 
                                    :op1 (i2 / injure-01 
                                          :ARG1 53 
                                          :mod (p5 / physical) 
                                          :mod (s / severe)) 
                                    :op2 (i / influence 
                                          :mod (e / environment) 
                                          :mod (d2 / distinct)) 
                                    :poss (s2 / situation))))) 
            :ARG1-of (r / resemble-01) 
            :ARG2 (a / apparent)))

# ::snt In this paper we report the presence of both annexin A7 isoforms in red blood cells where they are abundant in nanovesicles that form upon Ca2 + addition .
# ::tok In this paper we report the presence of both annexin A7 isoforms in red blood cells where they are abundant in nanovesicles that form upon Ca2 + addition .
# ::alignments 27-28|0.2 23-24|0.2.0 21-22|0.2.0.0 19-20|0.2.0.0.0 17-18|0.2.0.0.0.0 15-16|0.1.0.1.0 14-15|0.1.0.1 13-14|0.1.0.1.0.0 11-12|0.1.0 8-9|0.1.0.0 6-7|0.1 4-5|0 3-4|0.0 2-3|0.3 1-2|0.3.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:15.473
(r2 / report-01 
      :ARG0 (w / we) 
      :ARG1 (p / presence 
            :quant-of (i / isoform 
                  :mod (b2 / both) 
                  :source (b / blood 
                        :mod-of (c / cell 
                              :mod (r / red))))) 
      :ARG2 (a / addition 
            :topic-of (f / form 
                  :consist (n / nanovesicl 
                        :location-of (a2 / abundance 
                              :domain (t / they))))) 
      :source (p2 / paper 
            :mod (t2 / this)))

# ::snt The proteins are however not required for the vesiculation process .
# ::tok The proteins are however not required for the vesiculation process .
# ::alignments 9-10|0.1 8-9|0.1.0 5-6|0 4-5|0.2 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:15.690
(r / require-01 
      :ARG1 (p2 / protein) 
      :ARG2 (p / process-02 
            :mod (v / vesiculation)) 
      :polarity -)

# ::snt They are also not essential for the formation of specific membrane domains such as lipid rafts , as exogenously added recombinant annexin A7 redistributed to similar positions in a density gradient containing membranes derived from red blood cells of anxA7 - / - mice .
# ::tok They are also not essential for the formation of specific membrane domains such as lipid rafts , as exogenously added recombinant annexin A7 redistributed to similar positions in a density gradient containing membranes derived from red blood cells of anxA7 - / - mice .
# ::alignments 43-44|0.1.0.1.2 41-42|0.2.2.0 37-38|0.1.0.1 36-37|0.1.0.1.0 35-36|0.1.0.1.1 33-34|0.1.0 32-33|0.1 31-32|0 30-31|0.0 29-30|0.0.0 26-27|0.2.1.0.0 25-26|0.2.1.0 23-24|0.2.1.1 22-23|0.2.1 20-21|0.2.1.2 19-20|0.2 18-19|0.2.0 15-16|0.2.2 14-15|0.2.2.1 12-13|0.1.0.0 11-12|0.2.2.1.0.0 10-11|0.2.2.1.0.0.1 9-10|0.2.2.1.0.0.0 7-8|0.2.2.1.0 4-5|0.2.2.1.0.1 3-4|0.2.2.1.0.1.2 2-3|0.2.2.1.0.1.1 0-1|0.2.2.1.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:21.445
(c2 / contain-01 
      :ARG0 (g / gradient 
            :mod (d2 / density)) 
      :ARG1 (m2 / membran 
            :ARG1-of (d / derive-01 
                  :ARG0 (s2 / such) 
                  :ARG2 (c / cell 
                        :mod (b / blood) 
                        :mod (r / red) 
                        :part-of (m / mouse)))) 
      :manner-of (a2 / add-01 
            :ARG0 (e / exogenously) 
            :ARG1 (a / A7 
                  :ARG0-of (r2 / resemble-01 
                        :ARG1 (p / position)) 
                  :ARG1-of (r3 / redistribute-01) 
                  :mod (r4 / recombinant)) 
            :ARG2 (r5 / raft-01 
                  :ARG0 (s / slash) 
                  :ARG1 (l / lipid 
                        :ARG0-of (f / form-01 
                              :ARG1 (d3 / domain 
                                    :ARG1-of (s3 / specific-02) 
                                    :mod (m3 / membrane)) 
                              :purpose-of (e2 / essential 
                                    :domain (t / they) 
                                    :mod (a3 / also) 
                                    :polarity -))))))

# ::snt The observed cell shape change of erythrocytes lacking annexin A7 might be due to alterations in the erythrocyte cytoskeleton .
# ::tok The observed cell shape change of erythrocytes lacking annexin A7 might be due to alterations in the erythrocyte cytoskeleton .
# ::alignments 18-19|0.0.0 17-18|0.0 14-15|0.0.0.0 10-11|0 9-10|0.1.1 8-9|0.1.1.0 7-8|0.1 6-7|0.1.0 4-5|0.1.0.0 3-4|0.1.0.0.1 2-3|0.1.0.0.1.0 1-2|0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:23.256
(p / possible-01 
      :ARG1 (e / erythrocyte 
            :mod-of (c / cytoskeleton 
                  :location-of (a / alteration))) 
      :ARG3-of (l / lack-01 
            :ARG0 (e2 / erythrocyt 
                  :ARG1-of (c2 / change-01 
                        :ARG1-of (o / observe-01) 
                        :ARG2 (s / shape-01 
                              :mod (c3 / cell)))) 
            :ARG1 (a2 / A7 
                  :mod (a3 / annexin))))

# ::snt As a direct interaction with F-actin was ruled out , this effect might be mediated by annexin 's Ca2 + - binding activity .
# ::tok As a direct interaction with F-actin was ruled out , this effect might be mediated by annexin 's Ca2 + - binding activity .
# ::alignments 22-23|0.0.0.0 21-22|0.0.0.0.0 18-19|0.1.0.0 14-15|0.0 12-13|0 11-12|0.0.0 10-11|0.0.0.1 7-8|0.1 5-6|0.1.0.2.0.0+0.1.0.2.0+0.1.0.2 3-4|0.1.0 2-3|0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:24.880
(p / possible-01 
      :ARG1 (m / mediate-01 
            :ARG1 (e / effect-03 
                  :ARG1 (a / activity-06 
                        :ARG1-of (b / binding-07)) 
                  :mod (t / this))) 
      :condition (r / rule-03 
            :ARG1 (i / interact-01 
                  :ARG1 (c / Ca2) 
                  :ARG1-of (d / direct-02) 
                  :ARG2 (t2 / thing 
                        :name (n / name 
                              :op1 "F-actin")))))

# ::snt Acquisition of murine and human blood samples .
# ::tok Acquisition of murine and human blood samples .
# ::alignments 6-7|0.0.1.0+0.0.1 5-6|0.0.1.0.0 4-5|0.0.1.0.0.0 3-4|0.0 2-3|0.0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:25.031
(a2 / acquisition 
      :op1-of (a / and 
            :op2 (m / murine) 
            :op3 (t / thing 
                  :ARG1-of (s / sample-01 
                        :ARG2 (b / blood 
                              :mod (h / human))))))

# ::snt Blood from 129Sv wild type and annexin A7 knock out mice ( anxA7 - / - ) kept under pathogen-free conditions and fed with regular food , was collected in 1 ml syringes with a 22 gauge needle punctating the right cardiac ventricle immediately after they had been killed by cervical dislocation .
# ::tok Blood from 129Sv wild type and annexin A7 knock out mice ( anxA7 - / - ) kept under pathogen-free conditions and fed with regular food , was collected in 1 ml syringes with a 22 gauge needle punctating the right cardiac ventricle immediately after they had been killed by cervical dislocation .
# ::alignments 51-52|0.2.0.0.1.0.0.0.0.2.0 50-51|0.2.0.0.1.0.0.0.0.2.0.0 48-49|0.2.0.0.1.0.0.0.0.2 45-46|0.2.0.0.1.0.0.0.0.2.1 44-45|0.2.0.0.1.0.0.0.0.2.2 43-44|0.2.0.0.1.0.0.0.0.2.2.0 42-43|0.2.0.0.1.0.0.0.0.2.1.0 41-42|0.2.0.0.1.0.0.0.0.2.1.0.0 40-41|0.2.0.0.1.0.0.0.0.2.1.0.1 37-38|0.2.0.0.1.0.0.0.0 36-37|0.2.0.0.1.0.0.0 35-36|0.2.0.0.1.0.0.0.0.1 32-33|0.2.0.0.1.0 31-32|0.2.0.0.1.0.0 30-31|0.0.0 28-29|0.2.0.0.1 25-26|0.2.1 24-25|0.2.1.0 22-23|0.2 21-22|0 20-21|0.1 17-18|0.0 14-15|0.2.0.0.1.0.0.0.0.0 12-13|0.2.1.0.0 10-11|0.2.0 8-9|0.2.0.0 6-8|0.2.0.0.0.1.0.1+0.2.0.0.0.1.0.0+0.2.0.0.0.1.0+0.2.0.0.0.1 5-6|0.2.0.0.0 4-5|0.2.0.0.0.0.0 3-4|0.2.0.0.0.0.0.0 0-1|0.2.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:31.518
(a2 / and 
      :op1 (k2 / keep-01 
            :ARG1 1) 
      :op2 (c4 / condition) 
      :op3 (f2 / feed-up-03 
            :ARG1 (m2 / mouse 
                  :ARG1-of (k3 / knock-01 
                        :ARG0 (a6 / and 
                              :ARG0-of (b / blood-01 
                                    :ARG1 (t3 / type 
                                          :mod (w / wild))) 
                              :op1 (t2 / thing 
                                    :name (n2 / name 
                                          :op1 (a4 / annexin) 
                                          :op2 (a5 / A7)))) 
                        :ARG1-of (c3 / collect-01 
                              :ARG2 (s / syrinx 
                                    :mod (m / ml 
                                          :ARG1-of (g / gauge-01 
                                                :ARG1-of (n / needle-01 
                                                      :ARG0 (s2 / slash) 
                                                      :ARG2 22 
                                                      :condition (k / kill-01 
                                                            :ARG0 (d / dislocation 
                                                                  :mod (c / cervical)) 
                                                            :ARG1 (t / they 
                                                                  :poss-of (v / ventricle 
                                                                        :mod (c2 / cardiac) 
                                                                        :mod (r / right))) 
                                                            :op1-of (a / after 
                                                                  :mod (i / immediate)))))))))) 
            :ARG2 (f / food 
                  :ARG1-of (r2 / regular-02 
                        :ARG0 (a3 / anxA7)))))

# ::snt Coagulation generally was inhibited with 1/10 volume of 10 mM NaEDTA , pH 7.5 , already present in the syringe .
# ::tok Coagulation generally was inhibited with 1/10 volume of 10 mM NaEDTA , pH 7.5 , already present in the syringe .
# ::alignments 19-20|0.0.1.0 16-17|0.0.2.0.2 15-16|0.0.2.0.2.0 12-13|0 10-11|0.0.2.0.1.0+0.0.2.0.1+0.0.2.0 9-10|0.0.2.0.0 8-9|0.0.1.1 6-7|0.0.2 3-4|0.0 1-2|0.0.1 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:31.982
(p2 / ph 
      :ARG0-of (i / inhibit-01 
            :ARG1 (c / coagulation) 
            :ARG1-of (g / general-02 
                  :ARG0 (s / syringe) 
                  :ARG2 10) 
            :ARG2 (v / volume 
                  :mod-of (t / thing 
                        :mod (m / mm) 
                        :name (n / name 
                              :op1 "NaEDTA") 
                        :time (p / present 
                              :time (a / already))))))

# ::snt The mice were killed by cervical dislocation in order to avoid any effect of anaesthetic chemicals on blood parameters .
# ::tok The mice were killed by cervical dislocation in order to avoid any effect of anaesthetic chemicals on blood parameters .
# ::alignments 18-19|0.2.0.1 17-18|0.2.0.1.0 15-16|0.2.0.0 14-15|0.2.0.0.0 12-13|0.2.0 11-12|0.2.0.2 10-11|0.2 6-7|0.0 5-6|0.0.0 3-4|0 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:32.181
(k / kill-01 
      :ARG0 (d / dislocation 
            :mod (c2 / cervical)) 
      :ARG1 (m / mouse) 
      :purpose (a3 / avoid-01 
            :ARG1 (e / effect-03 
                  :ARG0 (c / chemical 
                        :mod (a / anaesthetic)) 
                  :ARG1 (p / parameter 
                        :mod (b / blood)) 
                  :mod (a2 / any))))

# ::snt The wild type and mutant mice were matched regarding their age , weight and sex .
# ::tok The wild type and mutant mice were matched regarding their age , weight and sex .
# ::alignments 14-15|0 13-14|0.0 12-13|0.0.1 10-11|0.0.0 8-9|0.0.0.0 7-8|0.0.0.0.0 5-6|0.0.0.0.0.0.1 4-5|0.0.0.0.0.0.1.0 3-4|0.0.0.0.0.0 2-3|0.0.0.0.0.0.0 1-2|0.0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:32.612
(s / sex 
      :op3-of (a / and 
            :op1 (a2 / age-01 
                  :ARG1-of (r / regard-01 
                        :time-of (m / match-01 
                              :ARG1 (a3 / and 
                                    :op1 (t / type 
                                          :mod (w2 / wild)) 
                                    :op2 (m2 / mouse 
                                          :mod (m3 / mutant)))))) 
            :op2 (w / weight)))

# ::snt The daytime of blood collection , sampling site and collection method were kept constant during all experiments .
# ::tok The daytime of blood collection , sampling site and collection method were kept constant during all experiments .
# ::alignments 16-17|0.0.1.0.1 15-16|0.0.1.0.1.0 13-14|0.0.1.0.0 12-13|0.0.1.0 10-11|0.0.1.2 9-10|0.0.1.2.0 8-9|0.0.1 7-8|0.0 6-7|0 4-5|0.0.1.1 3-4|0.0.1.1.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:33.059
(s2 / sample-01 
      :ARG1 (s / site 
            :mod (d / daytime) 
            :op2-of (a2 / and 
                  :ARG1-of (k / keep-01 
                        :ARG2 (c / constant) 
                        :time (e / experiment-01 
                              :quant (a / all))) 
                  :op1 (c3 / collect-01 
                        :ARG1 (b / blood)) 
                  :op3 (m / method 
                        :mod (c2 / collect-01)))))

# ::snt A typical murine blood sample volume consisted of 550 l , with variations ranging from 200 l to 900 l .
# ::tok A typical murine blood sample volume consisted of 550 l , with variations ranging from 200 l to 900 l .
# ::alignments 15-16|0.0.0.0 13-14|0.2.0 12-13|0.2 9-10|0.2.0.0 6-7|0 5-6|0.0 4-5|0.1 3-4|0.1.0 2-3|0.2.0.1 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:33.501
(c / consist-01 
      :ARG0 (v2 / volume 
            :ARG1-of (t / typical-02 
                  :ARG0 200)) 
      :ARG1 (s / sample-01 
            :ARG1 (b / blood)) 
      :ARG2 (v / variation 
            :ARG1-of (r / range-01 
                  :ARG0 (l / l) 
                  :ARG2 (m / murine))))

# ::snt Human blood samples from the authors were collected by vein puncture using common EDTA-monovettes ( Sarstedt ) .
# ::tok Human blood samples from the authors were collected by vein puncture using common EDTA-monovettes ( Sarstedt ) .
# ::alignments 15-16|0.0.0.0.0.0.0+0.0.0.0.0.0+0.0.0.0.0 13-14|0.1.1.1.0+0.1.1.1+0.1.1 12-13|0.1.1.0 11-12|0.1 10-11|0.1.0 9-10|0.1.0.0 7-8|0 5-6|0.0.0.0 2-3|0.0.0+0.0 1-2|0.0.0.1 0-1|0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:35.222
(c3 / collect-01 
      :ARG1 (t2 / thing 
            :ARG1-of (s / sample-01 
                  :ARG2 (a / author-01 
                        :ARG1 (c / country 
                              :name (n / name 
                                    :op1 "Sarstedt"))) 
                  :mod (b / blood 
                        :mod (h / human)))) 
      :manner (u / use-01 
            :ARG0 (p / puncture-01 
                  :ARG1 (v / vein-01)) 
            :ARG1 (t / thing 
                  :mod (c2 / common) 
                  :name (n2 / name 
                        :op1 "EDTA-monovettes"))))

# ::snt We performed our studies using well standardized sampling conditions , as differences in the blood sampling site , for example between tail and heart , show large changes in all cell type counts .
# ::tok We performed our studies using well standardized sampling conditions , as differences in the blood sampling site , for example between tail and heart , show large changes in all cell type counts .
# ::alignments 32-33|0.0.0.0.1.0.0.0.0.0.0.0 31-32|0.0.0.0.1.0.0.0.0.0.0.0.0 30-31|0.0.0.0.1.0.0.0.0.0.0.0.0.0 29-30|0.0.0.0.1.0.0.0.0.0.0.0.1 27-28|0.0.0.0.1.0.0.0.0.0.0 26-27|0.0.0.0.1.0.0.0.0.0.0.1 25-26|0.0.0.0.1.0.0.0.0.0 23-24|0.0.0.0.1.0.0.0.0.0.1.1 22-23|0.0.0.0.1.0.0.0.0.0.1 21-22|0.0.0.0.1.0.0.0.0.0.1.0 19-20|0.0.0.0.1.0.0.1 16-17|0.0 15-16|0 14-15|0.0.1 11-12|0.0.0 8-9|0.0.0.0 7-8|0.0.0.0.2 6-7|0.0.0.0.0 4-5|0.0.0.0.1 3-4|0.0.0.0.1.0.0.0 2-3|0.0.0.0.1.0.0.0.0 1-2|0.0.0.0.1.0.0 0-1|0.0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:40.126
(s3 / sample-01 
      :ARG1 (s2 / site 
            :ARG2-of (d / differ-01 
                  :ARG1 (c4 / condition 
                        :ARG1-of (s5 / standardize-01) 
                        :ARG1-of (u / use-01 
                              :ARG0 (w2 / we 
                                    :ARG0-of (p / perform-02 
                                          :ARG1 (s6 / study-01 
                                                :ARG1 (w / we 
                                                      :ARG0-of (s / show-01 
                                                            :ARG1 (c3 / change-01 
                                                                  :ARG1 (c / count-03 
                                                                        :ARG1 (t / type 
                                                                              :mod (c2 / cell)) 
                                                                        :mod (a / all)) 
                                                                  :mod (l / large)) 
                                                            :ARG2 (a2 / and 
                                                                  :op1 (t2 / tail-01) 
                                                                  :op2 (h / heart))))) 
                                          :mod (e / example)))) 
                        :mod (s4 / sample-01))) 
            :mod (b / blood)))

# ::snt First and second sample draw affect blood measurements , too [ 22 ] .
# ::tok First and second sample draw affect blood measurements , too [ 22 ] .
# ::alignments 11-12|0.0.0.0.0 9-10|0.0.0.0.1 7-8|0.1 6-7|0.1.0 5-6|0 4-5|0.0.0 3-4|0.0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:40.440
(a / affect-01 
      :ARG0 (a2 / and 
            :op1 (d / draw-02 
                  :ARG1 (s / sample-01 
                        :ARG0 22 
                        :ARG1 (t / too)))) 
      :ARG1 (m / measure-01 
            :ARG1 (b / blood)))

# ::snt Also the genetic background in common laboratory and transgenic mice affects the phenotype .
# ::tok Also the genetic background in common laboratory and transgenic mice affects the phenotype .
# ::alignments 12-13|0.1 10-11|0 9-10|0.0.1.1 7-8|0.0.1 6-7|0.0.1.0 5-6|0.0.1.0.0 3-4|0.0 2-3|0.0.0 0-1|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:40.821
(a / affect-01 
      :ARG0 (b / background 
            :mod (g / gene) 
            :topic (a2 / and 
                  :op1 (l / laboratory 
                        :mod (c / common)) 
                  :op2 (m / mouse))) 
      :ARG1 (p / phenotype) 
      :mod (a3 / also))

# ::snt A change from one strain to another may protect mice from effects of the primarily induced genetic defect .
# ::tok A change from one strain to another may protect mice from effects of the primarily induced genetic defect .
# ::alignments 17-18|0.0.2.0 16-17|0.0.0.0 15-16|0.0.2.0.1 14-15|0.0.2.0.1.0 11-12|0.0.2 9-10|0.0.1 8-9|0.0 7-8|0 6-7|0.0.2.0.0 4-5|0.0.0.1.0+0.0.0.1 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:41.006
(p3 / possible-01 
      :ARG1 (p2 / protect-01 
            :ARG0 (c / change-01 
                  :ARG1 (g / gene) 
                  :ARG2 (s / strain 
                        :wiki "Influenza_A_virus_subtype_H5N1")) 
            :ARG1 (m / mouse) 
            :ARG2 (e / effect 
                  :poss (d / defect-01 
                        :ARG1 (a / another) 
                        :ARG1-of (i / induce-01 
                              :degree (p / primary))))))

# ::snt For example , BALB/c mice have a significantly increased velocity of platelet aggregation as compared to 129Sv mice , which were used throughout this study [ 23 ] .
# ::tok For example , BALB/c mice have a significantly increased velocity of platelet aggregation as compared to 129Sv mice , which were used throughout this study [ 23 ] .
# ::alignments 26-27|0.1.1 24-25|0.0.0 23-24|0.0.0.1 22-23|0.0.0.2 21-22|0.0 17-18|0 14-15|0.1 12-13|0.1.0.2 11-12|0.1.0.2.0 9-10|0.1.0 8-9|0.1.0.0 7-8|0.1.0.1 4-5|0.1.0.0.0 1-2|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:41.531
(m / mouse 
      :ARG1-of (u / use-01 
            :ARG2 (s / study-01 
                  :ARG1 (e / example) 
                  :mod (t / this) 
                  :op1-of (t2 / throughout))) 
      :ARG2-of (c / compare-01 
            :ARG0 (v / velocity 
                  :ARG1-of (i / increase-01 
                        :ARG0 (m2 / mouse)) 
                  :ARG1-of (s2 / significant-02) 
                  :mod (a / aggregation 
                        :mod (p / platelet))) 
            :ARG1 23))

# ::snt Self forming iodixanol density gradients of human red blood cells .
# ::tok Self forming iodixanol density gradients of human red blood cells .
# ::alignments 9-10|0.1 8-9|0.1.0 7-8|0.1.1 6-7|0.1.0.0 4-5|0.1.2 3-4|0.1.2.0 1-2|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:41.790
(f / form-01 
      :ARG0 (s / self) 
      :ARG1 (c / cell 
            :mod (b / blood 
                  :mod (h / human)) 
            :mod (r / red) 
            :mod-of (g / gradient 
                  :mod (d / density))))

# ::snt The subcellular distribution of annexin A7 was addressed according to [ 24 ] .
# ::tok The subcellular distribution of annexin A7 was addressed according to [ 24 ] .
# ::alignments 11-12|0.0.0.0 8-9|0 7-8|0.0 5-6|0.0.0.1 4-5|0.0.0.1.0 2-3|0.0.0 1-2|0.0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:42.125
(s / say-01 
      :ARG1 (a / address-02 
            :ARG1 (d / distribute-01 
                  :ARG0 24 
                  :ARG1 (a2 / A7 
                        :mod (a3 / annexin)) 
                  :mod (s2 / subcellular))))

# ::snt Red blood cells were centrifuged and washed in isotonic buffered salt solution , collected in ice cold lysis buffer ( 20 mM Hepes , pH 7.4 , 200 M CaCl2 , 0.25 M sucrose , and proteinase inhibitors ( Roche ) ) , homogenized by a loosely fitting dounce homogenizer and additional passages through a 22 gauge needle .
# ::tok Red blood cells were centrifuged and washed in isotonic buffered salt solution , collected in ice cold lysis buffer ( 20 mM Hepes , pH 7.4 , 200 M CaCl2 , 0.25 M sucrose , and proteinase inhibitors ( Roche ) ) , homogenized by a loosely fitting dounce homogenizer and additional passages through a 22 gauge needle .
# ::alignments 57-58|0.1.0.1.0 56-57|0.1.0.1 55-56|0.1.0.1.0.0 52-53|0.2 51-52|0.2.0 50-51|0 49-50|0.1 48-49|0.1.1 47-48|0.1.0 46-47|0.1.0.2 39-40|0.0.2.5.0.0+0.0.2.5.0+0.0.2.5 37-38|0.0.2.4 36-37|0.0.2.4.0 35-36|0.0.2 33-34|0.0.2.3 32-33|0.0.2.3.0.1+0.0.2.3.0.0.0+0.0.2.3.0.0+0.0.2.3.0 29-30|0.0.2.2 28-29|0.0.2.2.0.1+0.0.2.2.0.0.0+0.0.2.2.0.0+0.0.2.2.0 27-28|0.0.2.0.0.0.0.0.0 25-26|0.1.0.0 24-25|0.0.2.1 22-23|0.0.1.0+0.0.1+0.0 21-22|0.0.0 20-21|0.0.3 18-19|0.0.2.0.0 17-18|0.0.2.0.0.2 16-17|0.0.2.0.0.1 15-16|0.0.2.0.0.3 13-14|0.0.2.0 11-12|0.0.2.0.0.0.0 10-11|0.0.2.0.0.0.0.2 9-10|0.0.2.0.0.0 8-9|0.0.2.0.0.0.0.1 6-7|0.0.2.0.0.0.0.0 5-6|0.0.2.0.0.0.0.0.2 2-3|0.0.2.0.0.0.0.0.1 1-2|0.0.2.0.0.0.0.0.1.0 0-1|0.0.2.0.0.0.0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:46.043
(a2 / and 
      :op1 (p5 / person 
            :mod (m / mm) 
            :name (n5 / name 
                  :op1 "Hepes") 
            :op1-of (a3 / and 
                  :ARG0-of (c3 / collect-01 
                        :ARG2 (b / buffer-01 
                              :ARG0 (b2 / buffer-01 
                                    :mod-of (s2 / solution 
                                          :ARG2-of (w / wash-01 
                                                :ARG0 200 
                                                :ARG1 (c4 / cell 
                                                      :mod (b3 / blood) 
                                                      :mod (r / red)) 
                                                :op1-of (a4 / and)) 
                                          :mod (i3 / isotonic) 
                                          :mod (s3 / salt))) 
                              :mod (c2 / cold) 
                              :mod (l2 / lysi) 
                              :op1-of (i2 / ice))) 
                  :op2 (p4 / ph) 
                  :op3 (c / CaCl2 
                        :mod (v2 / vehicle 
                              :name (n4 / name 
                                    :op1 "M1") 
                              :wiki "M1_Abrams")) 
                  :op4 (s / sucrose 
                        :mod (v / vehicle 
                              :name (n3 / name 
                                    :op1 "M1") 
                              :wiki "M1_Abrams")) 
                  :op5 (i / inhibitor 
                        :mod (p3 / proteinase)) 
                  :op6 (p2 / person 
                        :name (n2 / name 
                              :op1 "Roche"))) 
            :quant 20) 
      :op2 (h / homogeniz 
            :ARG1-of (f / fit-01 
                  :ARG0 7.4 
                  :ARG1-of (g / gauge-01 
                        :ARG1-of (n / needle-01 
                              :ARG2 22)) 
                  :degree (l / loosely)) 
            :mod (d / dounce)) 
      :op3 (p / passage 
            :mod (a / additional)))

# ::snt A 50 % iodixanol solution was established by mixing Optiprep solution ( 60 % iodixanol ; Sigma ) with buffer ( 120 mM Hepes , pH 7.4 , 1.2 mM CaCl2 , 0.25 M sucrose ) .
# ::tok A 50 % iodixanol solution was established by mixing Optiprep solution ( 60 % iodixanol ; Sigma ) with buffer ( 120 mM Hepes , pH 7.4 , 1.2 mM CaCl2 , 0.25 M sucrose ) .
# ::alignments 34-35|0.0.1.0.2.0 33-34|0.0.1.0.2.2+0.0.1.0.2.1.0+0.0.1.0.2.1+0.0.1.0.2 30-31|0.0.1.0.4 26-27|0.0.1.0.1.1 25-26|0.0.1.0.3 23-24|0.2.1.0+0.2.1+0.2 22-23|0.2.0 21-22|0.2.2 19-20|0.0.1.0.0 16-17|0.1 15-16|0 13-14|0.0.1.1 12-13|0.0.1.1.0 10-11|0.0.1 9-10|0.0.0.0+0.0.0+0.0 8-9|0.0.1.0 6-7|0.0.1.0.1 4-5|0.0.1.0.1.0 2-3|0.0.1.0.0.0.0 1-2|0.0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:47.526
(a / and 
      :op1 (t / thing 
            :name (n3 / name 
                  :op1 "Optiprep") 
            :poss-of (s3 / solution 
                  :ARG1-of (m2 / mix-01 
                        :ARG2 (b / buffer-01 
                              :ARG1 (5 / 50 
                                    :value-of (p4 / percentage-entity))) 
                        :ARG2-of (e / establish-01 
                              :ARG1 (s4 / solution) 
                              :op1-of 7.4) 
                        :op1-of (v / vehicle 
                              :mod-of (s / sucrose) 
                              :name (n / name 
                                    :op1 "M1") 
                              :wiki "M1_Abrams") 
                        :op1-of (p / ph) 
                        :op1-of (c / CaCl2)) 
                  :mod (p3 / percentage-entity 
                        :value 60))) 
      :op2 (s2 / sigma) 
      :op3 (p2 / person 
            :mod (m / mm) 
            :name (n2 / name 
                  :op1 "Hepes") 
            :quant 120))

# ::snt Seven parts of this 50 % iodixanol solution were mixed with thirteen parts of the red blood cell solution , generating a gradient solution containing 17.5 % iodixanol .
# ::tok Seven parts of this 50 % iodixanol solution were mixed with thirteen parts of the red blood cell solution , generating a gradient solution containing 17.5 % iodixanol .
# ::alignments 26-27|0.0 24-25|0.1.1.0 23-24|0.1.1 22-23|0.1.1.1 20-21|0.1 18-19|0.2.1 17-18|0.2.1.0 16-17|0.2.1.0.0 15-16|0.2.1.1 12-13|0.2 11-12|0.2.0 9-10|0 7-8|0.1.0.0 5-6|0.1.1.0.1.0 4-5|0.1.1.0.1 3-4|0.1.1.0.0 1-2|0.1.0 0-1|0.1.1.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:48.578
(m / mix-01 
      :ARG0 (p / percentage-entity) 
      :ARG1 (g2 / generate-01 
            :ARG0 (p4 / part 
                  :part-of (s3 / solution)) 
            :ARG1 (s / solution 
                  :ARG0-of (c / contain-01 
                        :ARG1 (t2 / this) 
                        :op1-of (5 / 50 
                              :value-of (p3 / percentage-entity)) 
                        :op1-of 7) 
                  :mod (g / gradient))) 
      :ARG2 (p2 / part 
            :mod (t / thirteen) 
            :poss (s2 / solution 
                  :mod (c2 / cell 
                        :mod (b / blood)) 
                  :mod (r / red))))

# ::snt The mixture was filled into a centrifuge tube underlayed by cushions of 30 % and 35 % iodixanol and centrifuged for 3 hours at 270,000  g in a SW41 Ti swing out rotor ( Beckman ) to achieve a nearly linear density gradient ( approximately 1.06 g/ml to 1.20 g/ml ) [ 24 ] .
# ::tok The mixture was filled into a centrifuge tube underlayed by cushions of 30 % and 35 % iodixanol and centrifuged for 3 hours at 270,000  g in a SW41 Ti swing out rotor ( Beckman ) to achieve a nearly linear density gradient ( approximately 1.06 g/ml to 1.20 g/ml ) [ 24 ] .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:48.587
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt Fractions of 0.6 ml were collected from the top of the gradient by a 1 ml syringe without using a needle and immediately frozen in liquid nitrogen for further use .
# ::tok Fractions of 0.6 ml were collected from the top of the gradient by a 1 ml syringe without using a needle and immediately frozen in liquid nitrogen for further use .
# ::alignments 29-30|0.4.0.2 28-29|0.4.0.2.1 26-27|0.4.0.1 25-26|0.4.0.1.0 23-24|0.4.0 22-23|0.4.0.3 21-22|0.4 20-21|0.3.0 18-19|0.3 16-17|0.0 14-15|0.4.0.2.0 11-12|0.2.0 8-9|0.2 5-6|0 3-4|0.1 0-1|0.4.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:49.305
(c / collect-01 
      :ARG0 (s / syringe) 
      :ARG1 (m / ml) 
      :ARG2 (t / top 
            :part-of (g / gradient)) 
      :manner (u2 / use-01 
            :ARG1 (n2 / needle-01)) 
      :op1-of (a / and 
            :op2 (f2 / freeze-02 
                  :ARG1 (f3 / fraction-01) 
                  :ARG2 (n / nitrogen 
                        :mod (l / liquid)) 
                  :purpose (u / use-01 
                        :ARG1 1 
                        :mod (f / further)) 
                  :time (i / immediate))))

# ::snt Exovesicle generation from human and murine red blood cells .
# ::tok Exovesicle generation from human and murine red blood cells .
# ::alignments 8-9|0.0 7-8|0.0.0 6-7|0.0.1 5-6|0 4-5|0.1 3-4|0.0.2 1-2|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:49.364
(m / murine 
      :mod-of (c / cell 
            :mod (b / blood) 
            :mod (r / red) 
            :mod (h / human)) 
      :op1-of (a / and 
            :quant (g / generation)))

# ::snt Red blood cells naturally can form hemoglobin containing exovesicles .
# ::tok Red blood cells naturally can form hemoglobin containing exovesicles .
# ::alignments 8-9|0.0.0.0.0 7-8|0.0.0.0 6-7|0.0.0 5-6|0.0 4-5|0 3-4|0.0.1 2-3|0.0.0.1.0 1-2|0.0.0.1 0-1|0.0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:49.569
(p / possible-01 
      :ARG1 (f / form-01 
            :ARG1 (h / hemoglobin 
                  :ARG0-of (c / contain-01 
                        :ARG1 (e / exovesicl)) 
                  :poss-of (b / blood 
                        :mod-of (c2 / cell 
                              :mod (r / red)))) 
            :ARG1-of (n / natural-03)))

# ::snt In vitro these vesicle formation is Ca2 + induced .
# ::tok In vitro these vesicle formation is Ca2 + induced .
# ::alignments 8-9|0.0 4-5|0 3-4|0.1 2-3|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:49.598
(f / form-01 
      :ARG1-of (i / induce-01) 
      :mod (v / vesicle) 
      :mod (t / this))

# ::snt Freshly collected lithium-heparin anticoagulated blood samples were centrifuged for 5 minutes at 400  g and 4 C .
# ::tok Freshly collected lithium-heparin anticoagulated blood samples were centrifuged for 5 minutes at 400  g and 4 C .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:49.602
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt The erythrocytes were washed five times with 20 mM Hepes , pH 7.5 , and 150 mM NaCl ( washing buffer ) .
# ::tok The erythrocytes were washed five times with 20 mM Hepes , pH 7.5 , and 150 mM NaCl ( washing buffer ) .
# ::alignments 20-21|0 19-20|0.1 15-16|0.1.0 14-15|0.0.3 11-12|0.0.3.1 9-10|0.0.2.0+0.0.2+0.0 8-9|0.0.0 7-8|0.0.3.2 4-5|0.0.1 3-4|0.0.3.0 1-2|0.0.3.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:50.017
(b / buffer-01 
      :ARG0 (p2 / person 
            :mod (m / mm) 
            :mod-of 5 
            :name (n / name 
                  :op1 "Hepes") 
            :op1-of (a / and 
                  :ARG0-of (w2 / wash-01 
                        :ARG1 (e / erythrocyt)) 
                  :op2 (p / ph) 
                  :quant 20)) 
      :ARG1-of (w / wash-01 
            :ARG0 150))

# ::snt A volume of 500 l washed red blood cells were combined with 3 ml of vesiculation buffer ( 20 mM Hepes , pH 7.5 , 150 mM NaCl , 1 mM CaCl2 adjusted to 5 M Ca2 + ionophore A23187 ) and incubated for 30 minutes at 37 C .
# ::tok A volume of 500 l washed red blood cells were combined with 3 ml of vesiculation buffer ( 20 mM Hepes , pH 7.5 , 150 mM NaCl , 1 mM CaCl2 adjusted to 5 M Ca2 + ionophore A23187 ) and incubated for 30 minutes at 37 C .
# ::alignments 48-49|0.2.1.0.0.0.1 47-48|0.2.1.0.0.0.2 45-46|0.2.1.1.0.1.0.1+0.2.1.1.0.1.0 44-45|0.2.1.1.0.1.0.0 42-43|0.2 41-42|0 39-40|0.1.1 38-39|0.1.1.0 35-36|0.2.1.0.2.1+0.2.1.0.2.0.0+0.2.1.0.2.0+0.2.1.0.2 34-35|0.2.1.0.1 32-33|0.1 31-32|0.1.0 29-30|0.2.1.1.0.1 25-26|0.2.0 22-23|0.2.2 20-21|0.0.1.0+0.0.1+0.0 19-20|0.0.0 18-19|0.0.2 16-17|0.2.1.0.0.0 15-16|0.2.1.0.0.0.0 13-14|0.2.1.0.0 12-13|0.2.1.0.0.1 10-11|0.2.1.0 8-9|0.2.1.1.0.0 7-8|0.2.1.1.0.0.0 6-7|0.2.1.1.0.0.1 5-6|0.2.1.1.0 4-5|0.2.1.1 3-4|0.1.2 1-2|0.2.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:52.530
(a / and 
      :op1 (p2 / person 
            :mod (m2 / mm) 
            :name (n2 / name 
                  :op1 "Hepes") 
            :quant 20) 
      :op2 (a3 / adjust-01 
            :ARG1 (c2 / CaCl2) 
            :ARG2 (a2 / A23187 
                  :mod (i2 / ionophore)) 
            :op1-of 500) 
      :op3 (i / incubate-01 
            :ARG0 150 
            :ARG1 (v3 / volume 
                  :ARG1-of (c3 / combine-01 
                        :ARG2 (m3 / ml 
                              :mod (b / buffer-01 
                                    :ARG1 (v2 / vesiculation) 
                                    :op1-of (c / C) 
                                    :op1-of 37) 
                              :quant 3) 
                        :op1-of 5 
                        :op1-of (v / vehicle 
                              :name (n / name 
                                    :op1 "M1") 
                              :wiki "M1_Abrams")) 
                  :mod-of (l / l 
                        :ARG0-of (w / wash-01 
                              :ARG1 (c4 / cell 
                                    :mod (b2 / blood) 
                                    :mod (r / red)) 
                              :op1-of (1 / 1 
                                    :quant-of (t / temporal-quantity 
                                          :quant 30 
                                          :unit (m / minute)))))) 
            :op1-of (p / ph)))

# ::snt After incubation EDTA was added to the solution to a final concentration of 5 mM and centrifuged for 5 minutes at 400  g and 4 C .
# ::tok After incubation EDTA was added to the solution to a final concentration of 5 mM and centrifuged for 5 minutes at 400  g and 4 C .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:52.538
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt The supernatant was collected and centrifuged for 20 minutes at 15,000  g and 4 C .
# ::tok The supernatant was collected and centrifuged for 20 minutes at 15,000  g and 4 C .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:52.544
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt The resulting pellet was resuspended in washing buffer and centrifuged at 400  g again to collect a supernatant enriched with red blood cell microvesicles .
# ::tok The resulting pellet was resuspended in washing buffer and centrifuged at 400  g again to collect a supernatant enriched with red blood cell microvesicles .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:52.552
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt The supernatant of the 15,000  g step was further centrifuged for 60 minutes at 100,000  g and 4 C .
# ::tok The supernatant of the 15,000  g step was further centrifuged for 60 minutes at 100,000  g and 4 C .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:52.563
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt The final pellet of this step was resuspended in washing buffer and centrifuged at 15,000  g again to purify a supernatant enriched in nanovesicles according to [ 7,20 ] .
# ::tok The final pellet of this step was resuspended in washing buffer and centrifuged at 15,000  g again to purify a supernatant enriched in nanovesicles according to [ 7,20 ] .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:52.567
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt The vesicles were assayed for acetylcholine esterase activity and used for further analysis .
# ::tok The vesicles were assayed for acetylcholine esterase activity and used for further analysis .
# ::alignments 12-13|0.0.2 11-12|0.0.2.1 9-10|0.0 8-9|0 7-8|0.0.2.0 5-6|0.0.1 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:52.700
(a2 / and 
      :op1 (u / use-01 
            :ARG0 (v / vesicl) 
            :ARG1 (a4 / acetylcholine) 
            :ARG2 (a / analyze-01 
                  :ARG1 (a3 / activity-06) 
                  :mod (f / further))))

# ::snt A 30 l sample of red blood cell vesicles was mixed with an equal volume of buffer ( 20 mM Hepes , pH 7.6 , 150 mM NaCl , 0.5 % Triton X-100 ) , vortexed and incubated for 5 minutes at 37 C .
# ::tok A 30 l sample of red blood cell vesicles was mixed with an equal volume of buffer ( 20 mM Hepes , pH 7.6 , 150 mM NaCl , 0.5 % Triton X-100 ) , vortexed and incubated for 5 minutes at 37 C .
# ::alignments 43-44|0.0.1.0.0.0 42-43|0.0.1.0.0 40-41|0.0.1.1.0.0.0+0.0.1.1.0.0 39-40|0.0.1.1.0 37-38|0.2 36-37|0 31-33|0.2.1.0.1.1+0.2.1.0.1.0+0.2.1.0.1+0.2.1.0 30-31|0.2.1.0.0 29-30|0.2.1.0.0.0 25-26|0.2.1.2 23-24|0.2.0 22-23|0.0.0 20-21|0.1.1.0+0.1.1+0.1 19-20|0.1.0 18-19|0.1.2 16-17|0.0.1.1 14-15|0.0.1 13-14|0.0.1.0 10-11|0.0 8-9|0.2.1.1 7-8|0.2.1.1.0 6-7|0.2.1.1.0.0 5-6|0.2.1.1.1 3-4|0.2.1 2-3|0.2.1.3 1-2|0.2.1.4 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:10:57.431
(a / and 
      :ARG1-of (m3 / mix-01 
            :ARG0 (p3 / ph) 
            :ARG2 (v / volume 
                  :ARG1-of (e / equal-01 
                        :ARG0 (3 / 37 
                              :era (c / C))) 
                  :mod-of (b / buffer-01 
                        :ARG0 (5 / 5 
                              :quant-of (t / temporal-quantity 
                                    :unit (m / minute)))))) 
      :op1 (p4 / person 
            :mod (m2 / mm) 
            :name (n2 / name 
                  :op1 "Hepes") 
            :quant 20) 
      :op2 (i / incubate-01 
            :ARG0 7.6 
            :ARG1 (s / sample-01 
                  :ARG0 (p / person 
                        :mod (p2 / percentage-entity 
                              :value 0.5) 
                        :name (n / name 
                              :op1 "Triton" 
                              :op2 "X-100")) 
                  :ARG1 (v2 / vesicl 
                        :mod (c2 / cell 
                              :mod (b2 / blood)) 
                        :mod (r / red)) 
                  :ARG2 150 
                  :mod (l / l) 
                  :quant 30)))

# ::snt Subsequently 640 l sodium phosphate buffer ( 100 mM Na2PO4 , pH 7.6 ) , 50 l DTNB ( 5,5 ' - dithiobis - ( 2-nitrobenzoic acid ) , 10 mM in sodium phosphate buffer ) , and 50 l acetylthiocholine chloride ( 12,5 mM in H2O ) were added .
# ::tok Subsequently 640 l sodium phosphate buffer ( 100 mM Na2PO4 , pH 7.6 ) , 50 l DTNB ( 5,5 ' - dithiobis - ( 2-nitrobenzoic acid ) , 10 mM in sodium phosphate buffer ) , and 50 l acetylthiocholine chloride ( 12,5 mM in H2O ) were added .
# ::alignments 49-50|0 46-47|0.1.1.0.0.0+0.1.1.0.0+0.1.1.0 41-42|0.1.3 40-41|0.1.3.0 38-39|0.1.3.1 37-38|0.1 34-35|0.2 33-34|0.2.0 32-33|0.2.0.0 29-30|0.2.6.0 26-27|0.1.2 22-23|0.0 17-18|0.1.1.1.0+0.1.1.1+0.1.1 15-16|0.1.1.2 12-13|0.2.4 11-12|0.2.1 9-10|0.2.3 8-9|0.2.3.0 7-8|0.2.2 5-6|0.2.6 4-5|0.2.6.1 3-4|0.2.6.1.0 2-3|0.1.0 0-1|0.2.5 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:02.087
(a / add-01 
      :ARG0 (d / dithiobi) 
      :ARG1 (a3 / and 
            :op1 (l / l) 
            :op2 (p2 / person 
                  :mod (c / country 
                        :name (n / name 
                              :op1 "H2O")) 
                  :name (n2 / name 
                        :op1 "DTNB") 
                  :quant 50) 
            :op3 (a4 / acid) 
            :op4 (c2 / chloride 
                  :mod (a2 / acetylthiocholine) 
                  :quant 50)) 
      :purpose-of (b / buffer-01 
            :ARG1 (p / phosphate 
                  :mod (s / sodium)) 
            :op1-of (p3 / ph) 
            :op1-of 100 
            :op1-of (n3 / Na2PO4 
                  :mod (m / mm)) 
            :op1-of 7.6 
            :op1-of (s3 / subsequent) 
            :purpose-of (b2 / buffer-01 
                  :ARG0 10 
                  :ARG1 (p4 / phosphate 
                        :mod (s2 / sodium)))))

# ::snt The reaction took place at room temperature and was measured photometrically at a wavelength of 405 nm according to the Ellmann ' method [ 25 ] .
# ::tok The reaction took place at room temperature and was measured photometrically at a wavelength of 405 nm according to the Ellmann ' method [ 25 ] .
# ::alignments 24-25|0.1.1.0.0 22-23|0.0 20-21|0.1.2.0.0+0.1.2.0+0.1.2 17-18|0 16-17|0.1.1.1.0 15-16|0.1.1.1.0.0 13-14|0.1.1.1 10-11|0.1.1.2 9-10|0.1.1 7-8|0.1 6-7|0.1.0.0 5-6|0.1.0.0.0 3-4|0.1.0 1-2|0.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:03.352
(s / say-01 
      :ARG0 (m / method) 
      :ARG1 (a / and 
            :op1 (p3 / place 
                  :location (t / temperature 
                        :consist-of (r / room))) 
            :op2 (m2 / measure-01 
                  :ARG0 (r2 / react-01 
                        :ARG1 25) 
                  :ARG1 (w / wavelength 
                        :mod (n2 / nm 
                              :mod 405)) 
                  :manner (p2 / photometrically)) 
            :op3 (p / person 
                  :name (n / name 
                        :op1 "Ellmann"))))

# ::snt Determination of the osmotic resistance of red blood cells .
# ::tok Determination of the osmotic resistance of red blood cells .
# ::alignments 8-9|0.0.0 7-8|0.0.0.0 6-7|0.0.0.1 4-5|0.0 3-4|0.0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:03.454
(d / determination 
      :topic (r2 / resist-01 
            :ARG1 (c / cell 
                  :mod (b / blood) 
                  :mod (r / red)) 
            :mod (o / osmotic)))

# ::snt A Na2HPO4/NaH2PO4 buffered NaCl gradient ( pH 7.4 ) comprised of the following NaCl steps was used for this assay : 0.90 % , 0.65 % , 0.60 % , 0.55 % , 0.50 % , 0.45 % , 0.40 % , 0.35 % , 0.30 % , 0.10 % .
# ::tok A Na2HPO4/NaH2PO4 buffered NaCl gradient ( pH 7.4 ) comprised of the following NaCl steps was used for this assay : 0.90 % , 0.65 % , 0.60 % , 0.55 % , 0.50 % , 0.45 % , 0.40 % , 0.35 % , 0.30 % , 0.10 % .
# ::alignments 49-50|0.1.2 46-47|0.1.5 43-44|0.1.7 40-41|0.1.1 37-38|0.1.4 34-35|0.1.0.1 31-32|0.1.3 28-29|0.1.6 25-26|0.3.0.0 22-23|0.0 19-20|0.3.1.0 18-19|0.3.1.0.0 16-17|0.3.1 14-15|0.1 12-13|0.1.0 9-10|0 7-8|0.2 6-7|0.1.0.0 4-5|0.3 2-3|0.3.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:07.040
(c / comprise-01 
      :ARG0 (p10 / percentage-entity) 
      :ARG1 (s / step-01 
            :ARG1-of (f / follow-01 
                  :ARG2 (p11 / ph) 
                  :op1-of (p6 / percentage-entity)) 
            :op1-of (p4 / percentage-entity) 
            :op1-of (p / percentage-entity) 
            :op1-of (p7 / percentage-entity) 
            :op1-of (p5 / percentage-entity) 
            :op1-of (p2 / percentage-entity) 
            :op1-of (p8 / percentage-entity) 
            :op1-of (p3 / percentage-entity)) 
      :ARG2 7.4 
      :purpose-of (g / gradient 
            :ARG1-of (b / buffer-01 
                  :ARG0 (p9 / percentage-entity)) 
            :ARG1-of (u / use-01 
                  :ARG2 (a / assay 
                        :mod (t / this)))))

# ::snt For each step 5 ml of the gradient step solution and 50 l blood sample were carefully inverted four times and incubated for 30 minutes in the dark .
# ::tok For each step 5 ml of the gradient step solution and 50 l blood sample were carefully inverted four times and incubated for 30 minutes in the dark .
# ::alignments 27-28|0.1.1 24-25|0.0.0.1.0.0.1+0.0.0.1.0.0 23-24|0.0.0.1.0.0.0 21-22|0.1 20-21|0 18-19|0.1.1.0 17-18|0.0 16-17|0.0.2 14-15|0.0.0.1 13-14|0.0.0.1.1 12-13|0.0.0.1.2 11-12|0.0.0.1.3 10-11|0.0.0 9-10|0.0.0.0 8-9|0.0.0.0.0 7-8|0.0.0.0.0.0 4-5|0.1.0 3-4|0.0.0.1.0 2-3|0.0.1 1-2|0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:09.037
(a / and 
      :op1 (i2 / invert-01 
            :ARG1 (a2 / and 
                  :op1 (s2 / solution 
                        :mod (s3 / step 
                              :mod (g / gradient))) 
                  :op2 (s / sample-01 
                        :ARG0 (52 / 5 
                              :quant-of (t / temporal-quantity 
                                    :quant 30 
                                    :unit (m / minute))) 
                        :ARG1 (b / blood) 
                        :mod (l / l) 
                        :quant 50)) 
            :ARG2 (s4 / step 
                  :mod (e / each)) 
            :manner (c / careful)) 
      :op2 (i / incubate-01 
            :ARG1 (m2 / ml) 
            :ARG1-of (d / dark-02 
                  :ARG0 4)))

# ::snt Samples were carefully inverted again and centrifuged at 1,500  g for 10 minutes .
# ::tok Samples were carefully inverted again and centrifuged at 1,500  g for 10 minutes .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:09.054
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt From 1 ml supernatant of each step the extinction at 546 nm wavelength was measured .
# ::tok From 1 ml supernatant of each step the extinction at 546 nm wavelength was measured .
# ::alignments 14-15|0 12-13|0.0 11-12|0.0.0 8-9|0.1 6-7|0.2.1 5-6|0.2.1.0 3-4|0.2 2-3|0.2.0 1-2|0.2.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:09.764
(m / measure-01 
      :ARG0 (w / wavelength 
            :mod (n / nm)) 
      :ARG1 (e / extinction) 
      :ARG4 (s2 / supernatant 
            :mod (m2 / ml 
                  :quant 1) 
            :poss (s / step 
                  :mod (e2 / each))))

# ::snt The experiment was performed at room temperature .
# ::tok The experiment was performed at room temperature .
# ::alignments 6-7|0.0.0 5-6|0.0.0.0 3-4|0.0 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:09.953
(e / experiment-01 
      :ARG1-of (p / perform-02 
            :ARG0 (t / temperature 
                  :consist-of (r / room))))

# ::snt Approximately 500 l of murine blood were centrifuged at 200  g for 15 minutes .
# ::tok Approximately 500 l of murine blood were centrifuged at 200  g for 15 minutes .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:09.998
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt The resulting supernatants were transferred to new tubes and used as platelet rich plasma ( PRP ) .
# ::tok The resulting supernatants were transferred to new tubes and used as platelet rich plasma ( PRP ) .
# ::alignments 15-16|0.0.0.1.0.0.0+0.0.0.1.0.0+0.0.0.1.0 13-14|0.0.0.0.0 12-13|0.0.0.0.0.0 11-12|0.0.0.0.0.1 9-10|0.0.0.0 8-9|0 7-8|0.0.1 6-7|0.0.1.0 4-5|0.0 2-3|0.0.0 1-2|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:10.591
(a / and 
      :op1 (t2 / transfer-01 
            :ARG1 (s / supernatant 
                  :ARG1-of (u / use-01 
                        :ARG2 (p / plasma 
                              :mod (r / rich) 
                              :mod (p2 / platelet))) 
                  :ARG1-of (r2 / result-01 
                        :ARG0 (o / organization 
                              :name (n / name 
                                    :op1 "PRP")))) 
            :ARG2 (t / tube 
                  :mod (n2 / new))))

# ::snt The platelet aggregation measurements were done according to the method developed by Born and Cross [ 26 ] using an APACT photometer ( Labor , Ahrendsburg , FRG ) and the APACT software ( APACT 1.4 ) .
# ::tok The platelet aggregation measurements were done according to the method developed by Born and Cross [ 26 ] using an APACT photometer ( Labor , Ahrendsburg , FRG ) and the APACT software ( APACT 1.4 ) .
# ::alignments 35-36|0.0.0.1.0.1.0 32-33|0.0.0.1.1.1 29-30|0.0.0.1.1 27-28|0.1.0.0.0+0.1.0.0+0.1.0 25-26|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 23-24|0.0.0.1.0.1.1 21-22|0.0.0.1.1.0 18-19|0.0.0.1 16-17|0.1.1.0 14-15|0.0.0.1.0.1 13-14|0.0.0.1.0 12-13|0.0.0.1.0.0.0.0+0.0.0.1.0.0.0+0.0.0.1.0.0 10-11|0.0.0 9-10|0.0 6-7|0 5-6|0.1 3-4|0.1.1 2-3|0.1.1.1 1-2|0.1.1.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:23.240
(s2 / say-01 
      :ARG0 (m / method 
            :ARG1-of (d / develop-02 
                  :ARG0 (c2 / country 
                        :name (n2 / name 
                              :op1 "Ahrendsburg")) 
                  :manner (u / use-01 
                        :ARG0 (a2 / and 
                              :op1 (p2 / person 
                                    :name (n3 / name 
                                          :op1 "Born")) 
                              :op2 (c3 / cross-01 
                                    :ARG0 1.4 
                                    :ARG1 (l / labor))) 
                        :ARG1 (a / and 
                              :op1 (p / photomet) 
                              :op2 (s / software))))) 
      :ARG1 (d2 / do-02 
            :ARG0 (c / country 
                  :name (n / name 
                        :op1 "FRG")) 
            :ARG1 (m2 / measure-01 
                  :ARG0 26 
                  :ARG1 (a3 / aggregation) 
                  :mod (p3 / platelet))))

# ::snt Subsequently samples of the PRP were adjusted with buffer ( 5 mM Hepes , 150 mM NaCl , pH 7.3 ) to 250,000 platelets/l .
# ::tok Subsequently samples of the PRP were adjusted with buffer ( 5 mM Hepes , 150 mM NaCl , pH 7.3 ) to 250,000 platelets/l .
# ::alignments 18-19|0 14-15|0.0.1 12-13|0.0.0.0.0.0.0.1.0+0.0.0.0.0.0.0.1+0.0.0.0.0.0.0 11-12|0.0.0.0.0.0.0.0 10-11|0.0.0.0.0.0.0.2 8-9|0.0.0.0.0.0 6-7|0.0 4-5|0.0.0.0.0.1.0+0.0.0.0.0.1+0.0.0.0.0 1-2|0.0.0.0+0.0.0 0-1|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:24.378
(p / ph 
      :ARG0-of (a / adjust-01 
            :ARG1 (t / thing 
                  :ARG1-of (s / sample-01 
                        :ARG0 (o / organization 
                              :ARG1-of (b / buffer-01 
                                    :ARG0 (p2 / person 
                                          :mod (m / mm) 
                                          :name (n / name 
                                                :op1 "Hepes") 
                                          :quant 5)) 
                              :name (n2 / name 
                                    :op1 "PRP"))) 
                  :mod (s2 / subsequent)) 
            :ARG2 150))

# ::snt A constant platelet count was used throughout allowing comparisons between wild type and knock out murine and human samples .
# ::tok A constant platelet count was used throughout allowing comparisons between wild type and knock out murine and human samples .
# ::alignments 18-19|0+0.0 17-18|0.1 16-17|0.0.0 15-16|0.0.0.0.0 13-14|0.0.0.0 12-13|0.0.0.0.1 11-12|0.0.0.0.1.0.0.0 10-11|0.0.0.0.1.0.0.0.0 8-9|0.0.0.0.1.0.0 7-8|0.0.0.0.1.0 6-7|0.0.0.0.1.0.2 5-6|0.0.0.0.1.0.1 3-4|0.0.0.0.1.0.1.0 2-3|0.0.0.0.1.0.1.0.0 1-2|0.0.0.0.1.0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:25.970
(s / sample-01 
      :ARG1 (t / thing 
            :op1-of (a / and 
                  :ARG0-of (k / knock-01 
                        :ARG1 (m / murine) 
                        :op2-of (a2 / and 
                              :op1 (a3 / allow-01 
                                    :ARG1 (c / compare-01 
                                          :ARG1 (t2 / type 
                                                :mod (w / wild))) 
                                    :ARG2-of (u / use-01 
                                          :ARG1 (c2 / count-01 
                                                :ARG1 (p / platelet) 
                                                :manner (c3 / constant))) 
                                    :op1-of (t3 / throughout)))))) 
      :ARG2 (h / human))

# ::snt 250 l adjusted platelets were prewarmed to 37 C and used in the assay , and the aggregation process was started by adding 25 l of a prewarmed 16.5 mg/ml ristocetin solution ( DiaMed Diagnostica , Bensheim , FRG ; concentration in the assay : 1.5 mg/ml ) , a reagent which worked reliably in our hands with mouse and human platelets .
# ::tok 250 l adjusted platelets were prewarmed to 37 C and used in the assay , and the aggregation process was started by adding 25 l of a prewarmed 16.5 mg/ml ristocetin solution ( DiaMed Diagnostica , Bensheim , FRG ; concentration in the assay : 1.5 mg/ml ) , a reagent which worked reliably in our hands with mouse and human platelets .
# ::alignments 61-62|0.0.0.2.0.3 60-61|0.0.0.2.0.3.0 59-60|0.0.0.2.0 58-59|0.0.0.2.0.2.1 56-57|0.0.0.2.1.1 55-56|0.0.0.2.1.1.0 53-54|0.0.0.2.0.2.2 52-53|0.0.0.2.0.2 50-51|0.0.0.2.0.2.0 45-46|0.0.0.0 43-44|0.2.1 40-41|0.2 39-40|0 38-39|0.1.0.0+0.1.0+0.1 36-37|0.0.0.2.0.1.0.0+0.0.0.2.0.1.0+0.0.0.2.0.1 33-35|0.0.0.2.0.0.0.1+0.0.0.2.0.0.0.0+0.0.0.2.0.0.0+0.0.0.2.0.0 31-32|0.0.0.2.1 30-31|0.0.0.2.1.0 23-24|0.0.0.3.0.0.0.0 22-23|0.0.0.2 20-21|0.0.0 18-19|0.0.0.1 17-18|0.0.0.1.0 15-16|0.0 13-14|0.0.0.3.0.1 10-11|0.0.0.3.0 9-10|0.0.0.3 8-9|0.0.0.2.2 7-8|0.2.0 3-4|0.0.0.3.0.0 2-3|0.0.0.3.0.0.0 0-1|0.0.0.2.3 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:33.177
(a3 / and 
      :op1 (a6 / and 
            :op1 (s2 / start-01 
                  :ARG0 1.5 
                  :ARG1 (p3 / process-02 
                        :ARG1 (a5 / aggregation)) 
                  :ARG2 (a4 / add-02 
                        :ARG0 (a / and 
                              :op1 (p2 / person 
                                    :name (n3 / name 
                                          :op1 "DiaMed" 
                                          :op2 "Diagnostica")) 
                              :op2 (c3 / country 
                                    :name (n2 / name 
                                          :op1 "Bensheim")) 
                              :op3 (w2 / work-01 
                                    :ARG0 (r2 / reagent) 
                                    :ARG1 (m / mouse) 
                                    :manner (r / reliably)) 
                              :op4 (p / platelet 
                                    :mod (h / human))) 
                        :ARG1 (s / solution 
                              :mod (r3 / ristocetin) 
                              :part (h2 / hand 
                                    :part-of (w / we))) 
                        :op1-of (c4 / C) 
                        :op1-of 250) 
                  :op2-of (a8 / and 
                        :op1 (u / use-01 
                              :ARG1 (p4 / platelet 
                                    :ARG1-of (a9 / adjust-01 
                                          :ARG0 25)) 
                              :ARG2 (a7 / assay))))) 
      :op2 (c2 / country 
            :name (n / name 
                  :op1 "FRG")) 
      :op3 (c / concentrate-02 
            :ARG0 37 
            :ARG1 (a2 / assay)))

# ::snt Each murine assay represents a different animal .
# ::tok Each murine assay represents a different animal .
# ::alignments 6-7|0.1 5-6|0.1.0 3-4|0 2-3|0.0 1-2|0.0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:33.287
(r / represent-01 
      :ARG0 (a2 / assay 
            :mod (m / murine) 
            :mod (e / each)) 
      :ARG1 (a / animal 
            :ARG1-of (d / differ-02)))

# ::snt Analyses of human blood samples were performed as described in the manufacturer 's protocol .
# ::tok Analyses of human blood samples were performed as described in the manufacturer 's protocol .
# ::alignments 13-14|0.0 11-12|0 8-9|0.0.0 6-7|0.0.0.2 4-5|0.0.0.1.0+0.0.0.1 3-4|0.0.0.1.0.0 2-3|0.0.0.1.0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:33.825
(m / manufacture-01 
      :poss-of (p / protocol 
            :time-of (d / describe-01 
                  :ARG0 (a / analyse) 
                  :ARG1 (t / thing 
                        :ARG1-of (s / sample-01 
                              :ARG2 (b / blood 
                                    :mod (h / human)))) 
                  :ARG1-of (p2 / perform-02))))

# ::snt Several repeated measurements were done per human individual to control the reproducibility .
# ::tok Several repeated measurements were done per human individual to control the reproducibility .
# ::alignments 11-12|0.1.1 9-10|0.1 7-8|0.1.0 6-7|0.1.0.0 4-5|0 2-3|0.0 1-2|0.0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:34.256
(d / do-02 
      :ARG1 (m / measure-01 
            :ARG1-of (r2 / repeat-01) 
            :quant (s / several)) 
      :purpose (c / control-01 
            :ARG0 (i / individual 
                  :mod (h / human)) 
            :ARG1 (r / reproducibility)))

# ::snt The acquired aggregation curve data , measured as ascending degree of transmission , were analysed for maximal slope values , while the maximal aggregation amplitude of every single curve was set to 100 % .
# ::tok The acquired aggregation curve data , measured as ascending degree of transmission , were analysed for maximal slope values , while the maximal aggregation amplitude of every single curve was set to 100 % .
# ::alignments 33-34|0.0.1.0.0.0 32-33|0.0.1.0.0.0.0 28-29|0.0.1.0.0.1.0 27-28|0.0.1.0.0.1.0.0 26-27|0.0.1.0.0.1.0.0.0 24-25|0.0.1.0.0.1.0.1 23-24|0.0.1.0.0.1.0.1.1 22-23|0.0.1.0.0.1.0.1.0 18-19|0.0.1.0.0.1 17-18|0.0.1.0.0 16-17|0.0.1.0.0.1.1 11-12|0 9-10|0.0 8-9|0.0.0 6-7|0.0.1 4-5|0.0.1.0 3-4|0.0.1.0.2 2-3|0.0.1.0.2.0 1-2|0.0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:36.188
(t / transmission 
      :mod-of (d / degree 
            :ARG1-of (a3 / ascend-01) 
            :ARG3-of (m3 / measure-01 
                  :ARG1 (d2 / data 
                        :ARG0-of (s2 / slope-01 
                              :ARG1 (p / percentage-entity 
                                    :value 100) 
                              :mod-of (v / value 
                                    :ARG1-of (c / curve-01 
                                          :ARG1-of (s / single-02 
                                                :mod (e / every)) 
                                          :poss-of (a / amplitude 
                                                :mod (m / maximum) 
                                                :mod (a2 / aggregation))) 
                                    :mod (m2 / maximum))) 
                        :ARG1-of (a5 / acquire-01) 
                        :source (c2 / curve-01 
                              :ARG1 (a4 / aggregation))))))

# ::snt In general , all platelet procedures were done at 22 C within four hours after collecting the blood sample .
# ::tok In general , all platelet procedures were done at 22 C within four hours after collecting the blood sample .
# ::alignments 18-19|0.2.0.1 17-18|0.2.0.1.0 15-16|0.2.0 14-15|0.2 13-14|0.2.0.0.1+0.2.0.0 12-13|0.2.0.0.0 10-11|0.1.0.0 9-10|0.1.0 7-8|0 5-6|0.0 4-5|0.0.0 3-4|0.0.1 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:36.718
(d / do-02 
      :ARG1 (p / procedure 
            :mod (p2 / platelet) 
            :quant (a2 / all)) 
      :ARG2 (g / general-02 
            :ARG1 (2 / 22 
                  :era (c2 / C))) 
      :time (a / after 
            :op1 (c / collect-01 
                  :ARG0 (t / temporal-quantity 
                        :quant 4 
                        :unit (h / hour)) 
                  :ARG1 (s / sample-01 
                        :ARG1 (b / blood)))))

# ::snt For standard haematopoetic measurements and cell counts on murine and human blood samples about 300 l of blood were analysed with an ADVIA 120 electronic cell counter ( Bayer ) .
# ::tok For standard haematopoetic measurements and cell counts on murine and human blood samples about 300 l of blood were analysed with an ADVIA 120 electronic cell counter ( Bayer ) .
# ::alignments 28-29|0.0.0.0.1.0.0.0.0+0.0.0.0.1.0.0.0+0.0.0.0.1.0.0 26-27|0.0.0.0.1.0.3 25-26|0.0.0.0.1.0.3.1 24-25|0.0.0.0.1.0.3.1.0 23-24|0.0.0.0.1.0.3.2 22-23|0.0.0.0.1.0.3.0.0.0+0.0.0.0.1.0.3.0.0+0.0.0.0.1.0.3.0 17-18|0.0.0.0.1.0.1.0 15-16|0.0.0.0.1.0.1 14-15|0.0.0.0.1.0.2.0.0 13-14|0.0.0.0.1.0.2.0 12-13|0+0.0 11-12|0.1 10-11|0.1.0 9-10|0.0.0 8-9|0.0.0.1 6-7|0.0.0.0 5-6|0.0.0.0.0 4-5|0.0.0.0.1 3-4|0.0.0.0.1.0 1-2|0.0.0.0.1.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:38.315
(s / sample-01 
      :ARG1 (t / thing 
            :op2-of (a2 / and 
                  :ARG1-of (c3 / count-03 
                        :mod (c4 / cell) 
                        :op2-of (a3 / and 
                              :op1 (m2 / measure-01 
                                    :ARG0 (o / organization 
                                          :name (n / name 
                                                :op1 "Bayer")) 
                                    :ARG1 (l / l 
                                          :mod (b / blood)) 
                                    :ARG1-of (s2 / standard-02 
                                          :ARG0 (a / about 
                                                :op1 300)) 
                                    :ARG2-of (c / counter-01 
                                          :ARG0 (o2 / organization 
                                                :name (n2 / name 
                                                      :op1 "ADVIA")) 
                                          :ARG1 (c2 / cell 
                                                :mod (e / electronic)) 
                                          :quant 120)))) 
                  :op1 (m / murine))) 
      :ARG2 (b2 / blood 
            :mod (h / human)))

# ::snt With this equipment red blood cells and platelets are `` transformed '' into spherical bodies without changing their volume .
# ::tok With this equipment red blood cells and platelets are `` transformed '' into spherical bodies without changing their volume .
# ::alignments 18-19|0.3.0 16-17|0.3 14-15|0.1 13-14|0.1.0 10-11|0 7-8|0.0.1 6-7|0.0 5-6|0.0.0 4-5|0.0.0.0 3-4|0.0.0.1 2-3|0.2 1-2|0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:38.986
(t / transform-01 
      :ARG1 (a / and 
            :op1 (c2 / cell 
                  :mod (b2 / blood) 
                  :mod (r / red)) 
            :op2 (p / platelet)) 
      :ARG2 (b / body 
            :mod (s / spherical)) 
      :ARG3 (e / equipment 
            :mod (t2 / this)) 
      :manner (c / change-01 
            :ARG1 (v / volume)))

# ::snt Therefore number and volume of red blood cells and platelets are not calculated values , but directly measured values .
# ::tok Therefore number and volume of red blood cells and platelets are not calculated values , but directly measured values .
# ::alignments 18-19|0.1.1 17-18|0.1 16-17|0.1.2 15-16|0 13-14|0.0.0 12-13|0.0 11-12|0.0.1 9-10|0.1.0.0.1 8-9|0.1.0.0 7-8|0.1.0.0.0 6-7|0.1.0.0.0.0 5-6|0.1.0.0.0.1 3-4|0.1.0.0.0.2 2-3|0.0.2 1-2|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:43.766
(c / contrast-01 
      :ARG1 (c2 / calculate-01 
            :ARG1 (v2 / value) 
            :polarity - 
            :purpose (a2 / and)) 
      :ARG2 (m / measure-01 
            :ARG0 (n / number 
                  :op1-of (a / and 
                        :op2 (c3 / cell 
                              :mod (b / blood) 
                              :mod (r / red) 
                              :poss-of (v3 / volume)) 
                        :op3 (p / platelet))) 
            :ARG1 (v / value) 
            :ARG1-of (d / direct-02)))

# ::snt The following data were statistically analysed : leucocytes , red blood cells , haemoglobin , haematocrit , mean cellular volume , mean cellular haemoglobin , mean cellular haemoglobin concentration , platelet number , neutrophiles , lymphocytes , monocytes , eosinophiles , basophiles .
# ::tok The following data were statistically analysed : leucocytes , red blood cells , haemoglobin , haematocrit , mean cellular volume , mean cellular haemoglobin , mean cellular haemoglobin concentration , platelet number , neutrophiles , lymphocytes , monocytes , eosinophiles , basophiles .
# ::alignments 41-42|0.2.4 39-40|0.1 37-38|0.2.10 35-36|0.2.3 33-34|0.2.8 31-32|0.2.6.0 30-31|0.2.6 28-29|0.2.11.0 27-28|0.2.11.0.0 26-27|0.2.5 25-26|0.2.11 23-24|0.2.2.0 22-23|0.2.2.0.0 21-22|0.2.2 19-20|0.0 18-19|0.0.0 17-18|0 15-16|0.2.9 13-14|0.2.1 11-12|0.2.7.0 10-11|0.2.7 9-10|0.2.7.0.0 7-8|0.2.0.0.1 5-6|0.2.0.0 4-5|0.2.0.0.0 2-3|0.2.0 1-2|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:47.323
(m4 / mean-01 
      :ARG1 (v / volume 
            :mod (c4 / cell)) 
      :ARG2 (e / eosinophil) 
      :purpose (f / follow-01 
            :ARG1 (d / data 
                  :domain-of (a / analyse 
                        :mod (s / statistics) 
                        :mod-of (l2 / leucocyt))) 
            :ARG3 (h4 / haemoglobin) 
            :manner (m3 / mean-01 
                  :ARG1 (h2 / haemoglobin 
                        :mod (c3 / cell))) 
            :op1-of (l / lymphocyt) 
            :op1-of (b / basophil) 
            :op1-of (c2 / cell) 
            :op1-of (p / platelet 
                  :mod-of (n2 / number)) 
            :op1-of (b2 / blood 
                  :mod-of (c5 / cell 
                        :mod (r / red))) 
            :op1-of (n / neutrophil) 
            :op1-of (h3 / haematocrit) 
            :op1-of (m / monocyt) 
            :purpose-of (m2 / mean-01 
                  :ARG1 (c / concentrate-02 
                        :ARG1 (h / haemoglobin)))))

# ::snt Peptide mass fingerprinting was performed on a Bruker Reflex IV MALDI-TOF mass spectrometer .
# ::tok Peptide mass fingerprinting was performed on a Bruker Reflex IV MALDI-TOF mass spectrometer .
# ::alignments 12-13|0.0.1.0.0 11-12|0.0.1.0 9-11|0.0.1.0.0.0.0.1+0.0.1.0.0.0.0.0+0.0.1.0.0.0.0+0.0.1.0.0.0 8-9|0.0.1.0.0.0.0.1.0 4-5|0.0.0 2-3|0.0 1-2|0.0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:47.757
(p2 / peptide 
      :mod-of (f / fingerprint 
            :ARG1-of (p / perform-02) 
            :mod (m3 / mass 
                  :mod (m / mass 
                        :mod-of (s / spectromet 
                              :mod (t / thing 
                                    :name (n / name 
                                          :op1 (i / IV) 
                                          :op2 (m2 / MALDI-TOF 
                                                :mod (r / reflex)))))))))

# ::snt Recombinant annexin A7 was purified according to [ 27 ] , F-actin-binding of recombinant annexin A7 was done as described [ 28 ] .
# ::tok Recombinant annexin A7 was purified according to [ 27 ] , F-actin-binding of recombinant annexin A7 was done as described [ 28 ] .
# ::alignments 21-22|0.2 19-20|0.1.1.0.0 17-18|0.1.1 13-14|0.0 11-12|0.1.1.0 8-9|0.1.1.0.0.0 5-6|0 4-5|0.1 2-3|0.1.0 1-2|0.1.0.0 0-1|0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:49.940
(s / say-01 
      :ARG0 (r / recombinant) 
      :ARG1 (p / purify-01 
            :ARG1 (a / A7 
                  :mod (a2 / annexin) 
                  :mod (r2 / recombinant)) 
            :ARG2-of (d2 / do-02 
                  :ARG1 (f / f-actin-bind 
                        :ARG1-of (d / describe-01 
                              :ARG0 27)))) 
      :ARG2 28)

# ::snt SDS-PAGE and western blotting were done as described [ 29,30 ] .
# ::tok SDS-PAGE and western blotting were done as described [ 29,30 ] .
# ::alignments 7-8|0.0.0 5-6|0 3-4|0.0.1 2-3|0.0.1.0.1+0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:50.155
(d2 / do-02 
      :ARG1 (a / and 
            :ARG1-of (d / describe-01) 
            :op1 (b / blot-01 
                  :ARG1 (w / world-region 
                        :name (n / name 
                              :op1 "West") 
                        :wiki "Western_world"))))

# ::snt Detection in immunoblots was with enhanced chemiluminescence [ 17 ] .
# ::tok Detection in immunoblots was with enhanced chemiluminescence [ 17 ] .
# ::alignments 8-9|0.0.0.0 6-7|0.0.0.1 5-6|0.0.0 2-3|0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:50.276
(d / detection 
      :location (i / immunoblot 
            :ARG0-of (e / enhance-01 
                  :ARG1 17 
                  :ARG2 (c / chemiluminescence))))

# ::snt Antibodies employed were mab 203 -- 217 directed against mouse annexin A7 core domain [ 5 ] and a polyclonal rabbit anti-sorcin antibody [ 31 ] .
# ::tok Antibodies employed were mab 203 -- 217 directed against mouse annexin A7 core domain [ 5 ] and a polyclonal rabbit anti-sorcin antibody [ 31 ] .
# ::alignments 24-25|0.1.2 22-23|0.0.1.0 20-21|0.0.1 17-18|0 15-16|0.1.0 13-14|0.0.0.0.1 12-13|0.0.0.0 10-11|0.0.0 9-10|0.0.0.0.0 7-8|0.0 1-2|0.1 0-1|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:50.995
(a2 / and 
      :ARG2-of (d2 / direct-01 
            :ARG0 (a3 / annexin 
                  :mod (c / core 
                        :mod-of (m / mouse) 
                        :mod-of (d / domain))) 
            :ARG1 (r / rabbit-01 
                  :ARG1 (a / antibody))) 
      :op1 (e / employ-01 
            :ARG0 5 
            :ARG1 (a4 / antibodi) 
            :ARG2 31))

# ::snt For statistical analyses the following tests were performed : David et al. range test to ensure samples are from a normal distribution , F-test looking for a samples ' homoscedascity , Student 's T-test to judge if samples of different groups have a different mean value and are parts from different normal distributions .
# ::tok For statistical analyses the following tests were performed : David et al. range test to ensure samples are from a normal distribution , F-test looking for a samples ' homoscedascity , Student 's T-test to judge if samples of different groups have a different mean value and are parts from different normal distributions .
# ::alignments 52-53|0.1.0.0.1.0 51-52|0.1.0.0.1.0.0 50-51|0.1.0.0.1 48-49|0.0.1.0.0 46-47|0.0.1.0.3 45-46|0.0.1.0 44-45|0.0.1.0.1 43-44|0.0.1.0.2 40-41|0.0.1.0.3.3 39-40|0.0.1.0.3.3.0 37-38|0.0.1.0.3.2.0+0.0.1.0.3.2 35-36|0.0.1 33-34|0.0.2 31-32|0.0.0+0.0 29-30|0.1.0 27-28|0+0.1 24-25|0.1.0.0 23-24|0.1.0.0.0 21-22|0.0.1.0.3.0 20-21|0.0.1.0.3.0.1 16-17|0.0.1.0.3.0.0.1+0.0.1.0.3.0.0 15-16|0.0.1.0.3.0.0.0 13-14|0.0.1.0.3.0.0.0.0 12-13|0.0.1.0.3.0.0.0.0.0 9-10|0.0.1.0.3.1.2+0.0.1.0.3.1.1.0+0.0.1.0.3.1.1+0.0.1.0.3.1 7-8|0.0.1.0.3.1.0.1 5-6|0.0.1.0.3.1.0 4-5|0.0.1.0.3.1.0.0 2-3|0.0.1.0.3.1.0.1.0 1-2|0.0.1.0.3.1.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:58.842
(s3 / sample-01 
      :ARG0 (p2 / person 
            :ARG0-of (s2 / study-01) 
            :ARG0-of (j / judge-01 
                  :ARG1 (v / value-01 
                        :ARG1 (p / part) 
                        :ARG1-of (m / mean-01) 
                        :ARG1-of (d3 / differ-02) 
                        :op4-of (a / and 
                              :ARG0-of (d5 / distribute-01 
                                    :ARG1 (t4 / thing 
                                          :ARG1-of (e / ensure-01 
                                                :ARG0 (t5 / test-01 
                                                      :ARG1-of (r / range-01))) 
                                          :ARG1-of (s4 / sample-01)) 
                                    :ARG1-of (n2 / normal-02)) 
                              :op1 (p3 / person 
                                    :ARG0-of (t6 / test-01 
                                          :ARG1-of (f2 / follow-01) 
                                          :ARG1-of (p4 / perform-02 
                                                :purpose (a2 / analysis 
                                                      :mod (s5 / statistic)))) 
                                    :name (n3 / name 
                                          :op1 "David") 
                                    :wiki -) 
                              :op2 (t / thing 
                                    :ARG1-of (s / sample-01)) 
                              :op3 (g / group 
                                    :ARG1-of (d4 / differ-02))))) 
            :poss-of (t2 / t-t)) 
      :ARG1 (t3 / thing 
            :poss-of (h / homoscedascity 
                  :ARG1-of (l / look-01 
                        :ARG0 (f / f-t) 
                        :ARG2-of (d2 / differ-02 
                              :ARG1 (d / distribution 
                                    :ARG1-of (n / normal-02)))))))

# ::snt The exact probability values and the significance of an analysis are indicated when the experiments are described .
# ::tok The exact probability values and the significance of an analysis are indicated when the experiments are described .
# ::alignments 16-17|0.0.1.0 14-15|0.0.1.0.0 11-12|0 9-10|0.0.2.0 6-7|0.0.2 4-5|0.0 3-4|0.0.1 2-3|0.0.0 1-2|0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:11:59.412
(i / indicate-01 
      :ARG1 (a2 / and 
            :op1 (p / probability) 
            :op2 (v / value 
                  :ARG1-of (d / describe-01 
                        :ARG2 (e / experiment-01)) 
                  :mod (e2 / exact)) 
            :op3 (s / significant-02 
                  :ARG1 (a / analyze-01))))

# ::snt CH and CSC planned and carried out the experiments with the red blood cells and platelets and the fractionation studies and drafted the manuscript , GL was responsible for platelets , RK gave support on the ADVIA 120 cell counter , evaluated and discussed the results , SMP and BSG gave support on the APACT system , platelet aggregation experiments , and evaluated the results , CZ was responsible for the sorcin studies , MS studied the cytoskeletal activities of the protein , AAN conceived of the studies and participated in its design .
# ::tok CH and CSC planned and carried out the experiments with the red blood cells and platelets and the fractionation studies and drafted the manuscript , GL was responsible for platelets , RK gave support on the ADVIA 120 cell counter , evaluated and discussed the results , SMP and BSG gave support on the APACT system , platelet aggregation experiments , and evaluated the results , CZ was responsible for the sorcin studies , MS studied the cytoskeletal activities of the protein , AAN conceived of the studies and participated in its design .
# ::alignments 92-93|0.0.0.0.1.0.3.0.4.0.0.0 89-90|0.0.0.0.1.0.3.0.4.0.0 88-89|0.0.0.0.1.0.3.0.4.0.0.1 87-88|0.0.0.0.1.0.3.0.4.1 84-85|0.0.0.0.1.0.3.0.4 83-84|0.0.0.0.1.0.3.0.4.0.1.0+0.0.0.0.1.0.3.0.4.0.1+0.0.0.0.1.0.3.0.4.0 81-82|0.0.0.0.1.0.3.0.3.1.0 78-79|0.0.0.0.1.0.3.0.3.1 75-76|0.0.0.0.1.0.3.0.3 74-75|0.0.0.0.1.0.3.0.3.0.0.0+0.0.0.0.1.0.3.0.3.0.0+0.0.0.0.1.0.3.0.3.0 72-73|0.0.0.0.0 71-72|0.0.0.0.0.0 68-69|0.0.0.0.1 66-67|0.0.0.0.2.0+0.0.0.0.2+0.0.0.0 64-65|0+0.0 62-63|0.0.0 61-62|0.0.0.0.1.0 59-60|0.0.0.0.1.0.3.0.0 58-59|0.0.0.0.1.0.3.0.0.0 57-58|0.0.0.0.1.0.3.0.0.1 55-56|0.0.0.0.1.0.3.2 51-52|0.0.0.0.1.0.3.1 50-51|0.0.0.0.1.0.3 49-50|0.0.0.0.1.0.2.0.0+0.0.0.0.1.0.2.0+0.0.0.0.1.0.2 48-49|0.0.0.0.1.0.3.0 47-48|0.0.0.0.1.0.1.0.0+0.0.0.0.1.0.1.0+0.0.0.0.1.0.1 45-46|0.0.0.0.1.0.3.0.2.1.0+0.0.0.0.1.0.3.0.2.1 43-44|0.0.0.0.1.0.3.0.1 42-43|0.0.0.0.1.0.3.0.1.0 41-42|0.0.0.0.1.0.3.0.1.0.0 39-40|0.0.0.0.1.0.3.0.2.2.0 38-39|0.0.0.0.1.0.3.0.2.2.0.1 37-38|0.0.0.0.1.0.3.0.2.2.0.2 36-37|0.0.0.0.1.0.3.0.2.2.0.0.0.0+0.0.0.0.1.0.3.0.2.2.0.0.0+0.0.0.0.1.0.3.0.2.2.0.0 33-34|0.0.0.0.1.0.3.0.2.2 32-33|0.0.0.0.1.0.3.0.2 31-32|0.0.0.0.1.0.3.0.2.0.0.0+0.0.0.0.1.0.3.0.2.0.0+0.0.0.0.1.0.3.0.2.0 29-30|0.0.0.0.1.0.0.1.0 27-28|0.0.0.0.1.0.0.1 23-24|0.0.0.0.1.0.0.0.0.1.0.0.1 21-22|0.0.0.0.1.0.0.0.0.1.0.0 20-21|0.0.0.0.1.0.0.0.0.1.0 19-20|0.0.0.0.1.0.0.0.0.1 18-19|0.0.0.0.1.0.0.0.0.1.0.0.0 16-17|0.0.0.0.1.0.0 15-16|0.0.0.0.1.0.0.0.1.0 14-15|0.0.0.0.1.0.0.0.1 13-14|0.0.0.0.1.0.0.0.0.0.0.0 12-13|0.0.0.0.1.0.0.0.0.0.0.0.0 11-12|0.0.0.0.1.0.0.0.0.0.0.0.1 8-9|0.0.0.0.1.0.0.0.0.0.0 5-6|0.0.0.0.1.0.0.0.0.0 4-5|0.0.0.0.1.0.0.0.2 3-4|0.0.0.0.1.0.0.0 2-3|0.0.0.0.1.0.0.0.2.0.0.0+0.0.0.0.1.0.0.0.2.0.0+0.0.0.0.1.0.0.0.2.0 1-2|0.0.0.0.1.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:12:31.569
(r2 / result-01 
      :ARG2 (t / thing 
            :ARG1-of (e / evaluate-01 
                  :ARG0 (o2 / organization 
                        :ARG0-of (s3 / study-01 
                              :ARG1 (s4 / sorcin)) 
                        :ARG1-of (r / responsible-01 
                              :op5-of (a3 / and 
                                    :op1 (a8 / and 
                                          :op1 (p6 / plan-01 
                                                :ARG0 (a11 / and 
                                                      :op1 (c6 / carry-01 
                                                            :ARG1 (e4 / experiment-01 
                                                                  :ARG1 (c5 / cell 
                                                                        :mod (b / blood) 
                                                                        :mod (r5 / red)))) 
                                                      :op2 (s8 / study-01 
                                                            :op1-of (a7 / and 
                                                                  :op2 (d3 / draft-01 
                                                                        :ARG0 (f / fractionation) 
                                                                        :ARG1 (m / manuscript))))) 
                                                :ARG1 (a9 / and 
                                                      :op1 (p5 / platelet)) 
                                                :op2-of (a10 / and 
                                                      :op1 (o7 / organization 
                                                            :name (n8 / name 
                                                                  :op1 "CSC")))) 
                                          :op2 (r4 / responsible-01 
                                                :ARG1 (p4 / platelet))) 
                                    :op2 (o4 / organization 
                                          :name (n5 / name 
                                                :op1 "SMP")) 
                                    :op3 (o3 / organization 
                                          :name (n4 / name 
                                                :op1 "BSG")) 
                                    :op4 (g / give-01 
                                          :ARG0 (a5 / and 
                                                :ARG0-of (e2 / experiment-01 
                                                      :ARG1 (a4 / aggregation) 
                                                      :mod (p3 / platelet)) 
                                                :ARG1-of (d2 / discuss-01 
                                                      :op2-of (a6 / and 
                                                            :op1 (e3 / evaluate-01))) 
                                                :op1 (g2 / give-01 
                                                      :ARG0 (o6 / organization 
                                                            :name (n7 / name 
                                                                  :op1 "RK")) 
                                                      :ARG1 (t2 / thing 
                                                            :ARG2-of (r3 / result-01)) 
                                                      :ARG2 (s7 / support-01 
                                                            :ARG1 (c3 / counter-01 
                                                                  :ARG0 (o5 / organization 
                                                                        :name (n6 / name 
                                                                              :op1 "ADVIA")) 
                                                                  :ARG1 (c4 / cell) 
                                                                  :quant 120))) 
                                                :op2 (s2 / study-01 
                                                      :ARG0 (c2 / country 
                                                            :name (n2 / name 
                                                                  :op1 "MS")) 
                                                      :ARG1 (a2 / activity-06 
                                                            :ARG1 (p2 / protein) 
                                                            :ARG0 c2)) 
                                                :op3 (c / conceive-01 
                                                      :ARG0 (o / organization 
                                                            :ARG0-of (p / participate-01 
                                                                  :ARG1 (d / design-01) 
                                                                  :op1-of (a / and)) 
                                                            :name (n / name 
                                                                  :op1 "AAN")) 
                                                      :ARG1 (s / study-01))) 
                                          :ARG1 (s6 / support-01) 
                                          :ARG2 (s5 / system)))) 
                        :name (n3 / name 
                              :op1 "CZ")))))

# ::snt All authors read and approved the manuscript .
# ::tok All authors read and approved the manuscript .
# ::alignments 6-7|0.1.0.0 4-5|0.1.0 3-4|0.1 2-3|0 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:12:31.810
(r / read-01 
      :ARG1 (a3 / author-01 
            :mod (a4 / all)) 
      :op1-of (a2 / and 
            :ARG0-of (a / approve-01 
                  :ARG1 (m / manuscript))))

# ::snt We would like to thank M. Heil , B. Hoffmann and R. Merkel for the biophysical experiments , L. Eichinger for discussion , B. Gassen for expert technical assistance and R. Mller for protein purification .
# ::tok We would like to thank M. Heil , B. Hoffmann and R. Merkel for the biophysical experiments , L. Eichinger for discussion , B. Gassen for expert technical assistance and R. Mller for protein purification .
# ::alignments 34-35|0.0 33-34|0 30-32|0.0.0.1.1.2.1.1+0.0.0.1.1.2.1.0+0.0.0.1.1.2.1+0.0.0.1.1.2 29-30|0.0.0.1.1 28-29|0.0.0 27-28|0.0.0.0 26-27|0.0.0.1.1.2.0 23-25|0.0.0.1.0.1+0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 21-22|0.0.0.1.1.0.1.0 18-20|0.0.0.1.1.1.0.1+0.0.0.1.1.1.0.0+0.0.0.1.1.1.0+0.0.0.1.1.1 16-17|0.0.0.1.1.0.1.1.0.1 11-13|0.0.0.1.1.0.1.2.0.1+0.0.0.1.1.0.1.2.0.0+0.0.0.1.1.0.1.2.0+0.0.0.1.1.0.1.2 10-11|0.0.0.1.1.0.1 8-10|0.0.0.1.1.0.0.1+0.0.0.1.1.0.0.0+0.0.0.1.1.0.0+0.0.0.1.1.0 5-7|0.0.0.1.1.0.1.1.1.1+0.0.0.1.1.0.1.1.1.0+0.0.0.1.1.0.1.1.1+0.0.0.1.1.0.1.1 4-5|0.0.0.1.1.0.1.1.0 2-3|0.0.0.1.1.0.1.1.0.2 0-1|0.0.0.1.1.0.1.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:12:36.545
(p2 / protein 
      :mod-of (p / purification 
            :ARG0-of (a2 / assist-01 
                  :ARG2 (t / technical) 
                  :prep-for-of (p4 / person 
                        :name (n2 / name 
                              :op1 "B." 
                              :op2 "Gassen") 
                        :op3-of (a / and 
                              :op1 (p7 / person 
                                    :name (n5 / name 
                                          :op1 "B." 
                                          :op2 "Hoffmann") 
                                    :op2-of (a3 / and 
                                          :ARG0-of (d / discuss-01) 
                                          :op1 (p8 / person 
                                                :ARG1-of (t2 / thank-01 
                                                      :ARG0 (w / we) 
                                                      :ARG1-of (e2 / experiment-01) 
                                                      :ARG1-of (l / like-02 
                                                            :ARG0 w)) 
                                                :name (n6 / name 
                                                      :op1 "M." 
                                                      :op2 "Heil")) 
                                          :op3 (p6 / person 
                                                :name (n4 / name 
                                                      :op1 "R." 
                                                      :op2 "Merkel")))) 
                              :op2 (p5 / person 
                                    :name (n3 / name 
                                          :op1 "L." 
                                          :op2 "Eichinger")) 
                              :op4 (p3 / person 
                                    :ARG1-of (e / expert-01) 
                                    :name (n / name 
                                          :op1 "R." 
                                          :op2 "Mller")))))))

# ::snt Mass spectrometric analysis was performed in the central service facilities of the ZMMK .
# ::tok Mass spectrometric analysis was performed in the central service facilities of the ZMMK .
# ::alignments 12-13|0.1.2.0.0+0.1.2.0+0.1.2 9-10|0.1 8-9|0.1.0 7-8|0.1.1 4-5|0 2-3|0.0 1-2|0.0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:12:37.205
(p / perform-02 
      :ARG1 (a / analyze-01 
            :ARG1 (s2 / spectrometric) 
            :ARG1-of (m / mass-01)) 
      :location (f / facility 
            :mod (s / service) 
            :mod (c / central) 
            :poss (o / organization 
                  :name (n / name 
                        :op1 "ZMMK"))))

# ::snt This worked is supported by a grant from the ZMMK ( Center of Molecular Medicine Cologne ) .
# ::tok This worked is supported by a grant from the ZMMK ( Center of Molecular Medicine Cologne ) .
# ::alignments 11-16|0.1.0.0.4+0.1.0.0.3+0.1.0.0.2+0.1.0.0.1+0.1.0.0.0+0.1.0.0+0.1.0 9-10|0.0.0.0.0+0.0.0.0+0.0.0 6-7|0.0 3-4|0 1-2|0.1 0-1|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-21T21:12:37.376
(s / support-01 
      :ARG0 (g / grant-01 
            :ARG0 (o2 / organization 
                  :name (n2 / name 
                        :op1 "ZMMK"))) 
      :ARG1 (w / work-01 
            :ARG3 (o / organization 
                  :name (n / name 
                        :op1 "Center" 
                        :op2 "of" 
                        :op3 "Molecular" 
                        :op4 "Medicine" 
                        :op5 "Cologne")) 
            :mod (t / this)))

